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ABSTRACT 
Biocatalysts are powerful tools in the synthesis of enantiomerically pure chiral 
compounds. The properties of enzymes can be improved and novel activities 
obtained through the application of directed evolution techniques. A key element in 
this process is the screening technology applied for detection of the desired 
properties. 
This project has focused on amino acid oxidase enzymes with activity towards non-
proteinogenic amino acids. Two sources of amino acid oxidases were investigated. A 
culture collection containing 500 microorganisms was screened for activity towards 
two 13-amino acids. However, no observable oxidase activity was detected towards 
these substrates. In addition, known amino acid oxidase enzymes were subjected to 
both random and single-site saturation mutagenesis with the aim of producing novel 
activity. 
Random mutagenesis libraries were prepared by propagating the Trigonopsis 
variabilis D-amino acid oxidase (TvDAAO) gene in a mutator strain and by 
performing error-prone PCR (epPCR) on the Rhodotorula gracilis D-amino acid 
oxidase (RgDAAO) gene. These libraries were initially screened using a solid-phase 
assay for detection of activity towards 13-amino acids. To overcome reproducibility 
problems, a high-throughput liquid-phase screening method in 96-well plate format 
was developed, evaluated and used to screen the RgDAAO epPCR library. 
In the absence of any detectable activity towards the selected 3-amino acid 
substrates, an alternative strategy, which minimised the variant library size and 
increased the range of substrates, was applied. Single site saturation libraries were 
generated by saturation mutagenesis PCR at the RgDAAO active site residues F58, 
M213, Y238 and R285. The resulting variant libraries were screened in the liquid-
phase for activity towards a range of proteinogenic and non-proteinogenic amino 
acids. 
Saturation mutagenesis at the conserved active site residues Y238 and R285 
produced mainly deleterious exchanges. Reduced oxidase activity was observed 
towards good substrates for the parental enzyme and no novel oxidase activity was 
detected for substrates towards which the parental enzyme is inactive. 
However, saturation at the active site residues F58 and M213 produced a range of 
beneficial and deleterious variants, allowing substrate profiles to be produced for 
each. Evaluation of these profiles permitted the identification of individual variants. 
Although no oxidase activity was observed towards 13-amino acids, improved activity 
was observed in both the F58 and M213 saturation mutagenesis libraries towards 
several proteinogenic and non-proteinogenic substrates. The improved activity 
detected in the assay for the variants F58L and F581 towards (rac)-
tetrahydroisoquinoline-3-carboxylic acid and for F58M towards (R)-pipecolinic acid 
was confirmed by performing whole cell biotransformations and analysing the 
progression of the reactions by HPLC. 
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BSA Bovine Serum Albumin 
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Taq Thermus aquaticus 
TBHBA 2,4,6-tribromo-3-hydroxybenzoic acid 
TEAA Triethyl ammonium acetate buffer 
Tm Melting temperature 
Tris Tris(hydroxymethyl) aminomethane 
Ts transition (nucleotide exchange) 
TS(B) Tryptone soya (broth) 
Tv transversion (nucleotide exchange) 
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INTRODUCTION 
1 INTRODUCTION 
1.1 SYNTHESIS OF CHIRAL AMINO ACIDS 
Amino acids have a large range of industrial applications and some proteinogenic 
amino acids are produced in significant volumes. For example, in 1999 650 000 tons 
of glutamic acid were produced for use in the food industry.' Non-proteinogenic 
amino acids are also important for use as synthetic building blocks for fine chemicals 
and pharmaceutical intermediates. Examples of pharmaceuticals incorporating non-
proteinogenic amino acid moieties are the 13-lactam antibiotic, amoxicillin produced 
by GSK and taltobulin, an antimitotic produced by Wyeth shown in Figure 1.1. 




N  )( NOH HN 	O 
Taltobulin 
Figure 1.1 - Active compounds containing non-proteinogenic amino acids. 
Amino acids are obtained by extraction (proteinogenic amino acids) or by chemical 
or biological synthesis. Where one epimer in an active compound does not confer 
the desired activity, production of enantiomerically pure compounds, rather than 
racemic mixtures is desired. Manufacturers are required to research and characterise 
the physiological activity of each enantiomer in any chiral drug to be marketed as a 
mixture, as the distomer may cause adverse effects. For example, (S)-penicillamine 
has antiarthritic activity while the (R)-enantiomer is toxic. ( 2)  In addition, asymmetric 
production routes reduce cost and waste. There are many chemical methods for the 
asymmetric synthesis of amino acids, for example asymmetric Strecker reaction, a-
alkylation of glycine derivatives and asymmetric hydrogenation. (3,4)  However, as 
biocatalysts offer high chemo-, enantio- and regio-selectivity, catalyse a broad 
spectrum of reactions, are degradable and operate at physiological temperature and 
pH, these present attractive routes to chiral amino acids. 
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1.1.1 Biocatalytic routes to optically pure non-proteinogenic amino acids 
Several enzymes have been investigated for their use in the production of chiral 
amino acids, for example hydantoinases combined with carbamoylases, acylases, 
amidases, lipases, lyases, transaminases and dehydrogenases. Hauer et al. published 
a review in 2004 on industrial production of optically active compounds including 
biocatalytic routes to amino acids' in which several fermentation and 
biotransformation methods are described. An example of a fermentation method used 
industrially is the production of (R)-phenylalanine by Monsanto. ( 5) The 
microorganisms used have been modified such that they produce a racemase, L-
amino acid deaminase and D-amino acid aminotransferase but no D-amino acid 
deaminases. L-phenylalanine is produced endogenously and the L-amino acid amino-
donor group is added to the growth medium. The a-keto acid produced by 







OH OH OH 
L-amino acid D-amino acid 
NH2 
no acid 
/ 	aminotransferase  
L-amino acid 
OH 	deaminase OH OH 
L-phenylalanine o-phenylalanine 
Scheme 1.1 - Fermentation process for the production of D-phenyIaanine using modified 
microorganisms. 
Hauer's review also describes the commercial production of L-aspartic acid by the 
desymmetrisation of fumaric acid using ammonia as nucleophile catalysed by L-
aspartate ammonia lyase (AspA, EC 4.3.1.1). AspA is very substrate specific and no 
useful alternative nucleophiles have been identified. More recently, Feringa et al. 
described the cloning and overexpression of aspartate ammonia lyase (AspB) from 
Bacillus sp.YM55-1. This group found that AspB which, in contrast to AspA can 









Nu = HNOH, MeONH, HNNH2 or MeNH 
Scheme 1.2— AspB catalysed Michael addition of a nucleophile (Nu) to fumarate. Enantiomeric 
excesses> 99 % were achieved with 100 % conversion at 42 mM substrate concentration over 
reaction times ranging from 20 min to 7 days. 
An industrial example which makes use of a dehydrogenase is the Degussa process 
for the production of L-tert-leucine which uses L-leucine dehydrogenase for the 
reductive amination of the corresponding 2-oxocarboxylic acid as shown in Scheme 
This reaction requires a cofactor such as NADH which is regenerated by the 











N H4 HCOO 
Scheme 1.3 - Reductive amination by leucine dehydrogenase.W 
There are many examples of enzymes applied in kinetic resolutions from racemates 
to produce chiral amino acids. For example acylases are used to selectively hydrolyse 
the amide bond in one enantiomer, leaving the other unreacted as shown in Scheme 
1.4. 
R 	 R 
H2N 
+ 
XCO2H 	AcHN' CO2H 
R 7~ 
AcHNCO2H 	 R R 
+ 	
ef 
HN" CO2H 	AcHNCO2H D-acyase 
Scheme 1.4— Acylase-catalysed kinetic resolution of amino acids. 
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A recent example published by Engel et al. describes the kinetic resolution of D-4-
chlorophenylalanine using an engineered L-phenylalanine dehydrogenase. Cofactor 
regeneration is catalysed by diaphorase. The high stereo selectivity of the enzyme 
leaves the D-enantiomer basically unreacted even at high conversions. 









Scheme 1.5— Kinetic resolution of (rac)-4-CI-phenytalanine (5-10 mM). 99 % conversion of the 
(S)-enantiomer after 40 hJ 
A limitation in kinetic resolutions is the 50 % theoretical yield which may be 
obtained. To overcome this limitation strategies such as dynamic kinetic resolution 
or cyclic deracemisation have been applied in some cases. 
A commercial example of a dynamic kinetic resolution used in the production of 
amino acids is the Kanegafuchi synthesis of D-p-hydroxphenylglycine shown in 
Scheme 1 .6.(8)  D-5-(p-hydroxy)-phenylhydantoin is selectively hydrolysed by D-
hydantoinase to N-carbamoyl-p-hydroxy-D-phenylglycine. Under alkaline conditions 
the racemic hydantoin starting material is racemised thus enabling a theoretical yield 
of the carbamoylated D-amino acid of 100 %. Decarbamoylation to the amino acid is 
















H20 	H2N NH 








Scheme 1.6 - Dynamic kinetic resolution of a racemic hydantoin used in the production of D-p-
hydroxyphenyiglycine. 
An alternative strategy researched in the group of Nicholas J. Turner combines an 
enantioselective enzyme-catalysed oxidation reaction with a non-selective, non-




NH2 	 oxidase enzyme 	NH 









Scheme 1.7 - Cyclic deracemisation of amino acids. 
Given ideal conditions, it can be seen that 7 cycles of the above scheme will produce 
a single enantiomer in >99 % e.e. This oxidation-reduction sequence has been 
successfully used within the Turner group for the deracemisation of chiral cc-amino 
acids 	and has been extended to chiral amines'2 . 
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The former method was used in combination with asymmetric hydrogenation to 
access all four diastereomers of a range of 3-methyl-f3-ary1a1anine analogues as 
shown in Scheme 1.8. 10 
Ar
H  

















CO2H NH3:BH3 H2N 	CO2H 
(2S,3R) (2R,3R) 
Scheme 1.8 - Deracemisation of p-methyl-3-ary1aIanine ana1ogues. 10  
It was found that, although, the (2S,3R) and (2R,35) diastereomers were easily 
accessed by asymmetric hydrogenation of didehydroamino acids, this was not the 
case for the (2R,3R) and (2S,3S) diastereomers. Cyclic deracemisation of the (2S,3R) 
diastereomers using L-amino acid oxidase, combined with ammonia borane as 
reducing agent, provided the (2R,3R) diastereomers in yields of between 68-81 % 
and> 99 % de. Deracemisation of the (2R,3S) diastereomers using D-amino acid 
oxidase provided the (2S,35) diastereomers with yields of 80-92 % and> 99 % de. 
13-amino acids are much less abundant than their cc-counterparts but they do occur in 
nature in free form and as substructures of peptides and alkaloids. Naturally 
occurring 13-amino acids include 3-lysine, 13-alanine and f3-tyrosine. '3 13-Alanine, 
for example, is a precursor to pantothenic acid, an intermediate in coenzyme A 
biosynthesis.' Free 13-amino acid and natural products containing 13-amino acids 
have been found to display antibiotic, antifungal, cytotoxic or other pharmacological 
properties. Examples are the antitumor agent paclitaxel, the a-hydroxy 13-amino acid 
side chain of which has been shown to be necessary for activity ( 15)  and the 














Bradykinin B I receptor antagonist 
Figure 1.2 - Structures of the mitotic inhibitor Paclitaxel' and a bradykinin Bi receptor 
antagonist'. 
13-Amino acids are also important as synthetic precursors to 13-lactams, which include 
13-lactamase inhibitors, human leukocyte elastase inhibitors and have been shown to 
posses antibiotic activity and influence cholesterol uptake. 15 Peptidases are unable 
to cleave amide bonds adjacent to a 13-amino acid, thus peptides containing 13-amino 
acids are more stable to enzymatic hydrolysis and can therefore be used in the 
preparation of modified peptides with increased in vivo stability. ( 17),( 18)  
Most biocatalytic routes to enantiomerically pure 13-amino acids involve kinetic 
resolutions using hydrolytic enzymes. Many examples in the literature make use of 
penicillin acylase (PA) from Escherichia coli (E. coli) which is interesting because 
most amidases are substrate specific and 13-amino acids are not the natural 
substrates. 15 An efficient and scaleable example of a lipase catalysed resolution of 









+ 	1 CO2Et 
44% yield, 98 % ee 	40 % yield, 99 % ee 
Scheme 1.9 - A lipase-catalysed resolution of -aryl-i-amino acid esters performed at 200 g U1  
substrate concentration and providing 44 % yield, 98 % e.e. The lipase accepts a variety of 3-
aryl--amino acid ester analogues. (19) 
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A recent paper by Janssen et al. desribes the phenylalanine aminomutase catalysed 
amination of substituted cinnamic acids to produce enantioselectively a— and J3-
phenylalanine derivatives. ( 20)  
0 	 NH2 O 	 0 
H 	NH3 	(AO H + 
D"- 	 phenyIaanine R f  I[ 	 D', 	NH2 aminomutase 
>99%ee 	 >99%ee 
R = H, F, CI, CH3, OCH3, NO2 
Scheme 1.10 - Aminomutase catalysed formation of a- and -phenylalanine derivatives. The 
regioselectivity of the addition reaction is affected by the electronic nature of the aromatic 
substituent. Electron-donating groups promote formation of the n-amino acid. 
Transaminases have been identified for the transamination of both aliphatic and 
aromatic 13-keto acids. An example is the transaminase from Mesorhizobium sp. 
strain LUK which has been cloned and characterised by Kim et al. 21 The 
transamination of benzoylacetic acid is shown in Scheme 1.11. To prevent problems 
caused by the decarboxylation of the 0-keto acid substrate, Kim et al. generated it in 
situ by lipase-catalysed hydrolysis of the t3-keto ester. Inhibition of the transaminase 
by the 0-keto acid product of the amino donor was observed for several donors and 
was overcome by the use of 3-aminobutyric acid, the product of which decomposes 
to acetone and CO2. 




OEt 	 OH OH 
NH2 0 	0 0 	>99%e.e. H20 	 EtOH 	
- OH --0H 	
20 % conversion 
0 
+ 002 




Several biocatalytic routes to both proteinogenic and non-proteinogenic amino acids 
have been described. However, it was hoped that the oxidation-reduction strategy 
used in the Turner group for the deracemisation of a-amino acids could be further 
developed to include new examples of non-proteinogenic a-amino acids and in 
particular J3-amino acids. A suitable enzyme for the enantioselective oxidation of P-
amino acids was therefore required. Possible starting points for this project were A) 
to screen for existing 3-amino acid oxidase activity from a collection of 
microorganisms, B) to screen a-amino acid oxidase enzymes for activity towards 13-
amino acids and C) to assess the ability of monoamine oxidase-N to accept 13-amino 
acid substrates. Activity detected from any of these sources would be further 
developed by directed evolution. 
1.2 D-AMINO ACID OXIDASE 
The cloned D-Amino acid oxidase (DAAO, EC 1.4.3.3) genes from Trigonopsis 
variabilis (TvDAAO) and Rhodotorula gracilis (RgDAAO) were available for this 
project. D-Amino acid oxidase flavoproteins have been known since the 1930s when 
they were discovered by Krebs 22 and these enzymes have been found in both 
prokaryotic and eukaryotic organisms, including mammals 23 . A review of the 
physiological functions of DAAOs was published by Pollegioni in 2007.(24)  The 
functions are wide-ranging and include catabolic, detoxification, biosynthesis and 
regulatory roles. The EC classification 1.4.3.3 describes the oxidoreductase group of 
enzymes which act on CH-NH2 donors and use oxygen as acceptor. As shown in 
Scheme 1.12, the amino acid is enzymatically dehydrogenated to the corresponding 
imino acid. This is coupled to the reduction of the flavin adenine dinucleotide (FAD) 
cofactor which reoxidises spontaneously in the presence of molecular oxygen, with 
the concomitant formation of hydrogen peroxide. FAD reduction and reoxidation is 
shown in Scheme 1.13. The imino acid is non-enzymatically hydrolysed to the keto 
acid and ammonia. Hydrogen peroxide can be detected in colorimetric assays, 







NH 	H20 	0 
RCO2H 	 RCO2H 
+ NH3 










Scheme 1.13 - FAD reduction/oxidation 
The mechanism for the oxidation of D-amino acids by TvDAAO and RgDAAO was 
disputed for some time, however, more recently evidence drawn from structural, 
computational and kinetic isotope studies suggest a direct hydride transfer 




Scheme 1.14 - Proposed hydride transfer mechanism of DAAO. (2  
1.3 DIRECTED EVOLUTION 
A powerful method for the engineering of enzymes is directed evolution, an 
approach which has grown rapidly since the 1990s. Improved mutation and screening 
19 
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methods have been developed, for example, by Arnold and Stemmer 27'28 and 
directed evolution techniques have become a standard tool for biocatalyst 
development. 
Directed evolution is based on the in vitro evolution of biomolecules through 






Figure 1.3 - Simplified schematic of steps involved in directed evolution 
In the case of enzymes improved properties would include substrate specificity, 
stability, enantioselectivity or activity. Given a reliable and high-throughput 
screening/selection process, beneficial mutations can be easily selected and 
deleterious ones discarded. Significant advantages of this approach over rational 
design are that a detailed knowledge of the enzyme active site and of the reaction 
mechanism are not required. 
A good example of the improvement which can be obtained by this method is the 
evolution of an aspartate transaminase with 2.6 x 106  -fold  higher activity towards the 
non-native substrate valine. This was achieved through the cumulative effects of 
mutations distributed over much of the enzyme structure. In this case, the majority of 
the substituted amino acids are not in contact with the substrate or cofactor. This 
highlights the advantage of directed evolution over rational design which relies on 
the ability to predict useful mutations and will mainly concentrate on active site 
residues. (29)  
20 
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The parental gene which codes for the enzyme in question is subjected to random 
mutagenesis and a mutant library is generated. The mutant genes are then 
transformed into a host, often E. coli, for gene expression and screening. Colonies 
identified as showing improved activity during the screening process are selected and 
subjected to another round of mutagenesis in an iterative process towards the 
optimised variant (Figure 1.4). 
wild-type enzyme 
performing natural 










I wild type enzyme 
10 	 performing new function 
number of mutations 
Figure 1.4 - Increase in performance during iterative process 
1.3.1 Random Variant Libraries and Bias 
In an ideal random library of mutants, each possible mutation should be as likely to 
occur as any other. This is usually not the case and instead some mutants will be 
significantly more represented than others and some might not occur at all. The 
library will therefore demonstrate bias in favour of certain mutants. Numerous 
methods for producing libraries have been developed, often with the aim of reducing 
this bias, and the advantages and disadvantages of these will be discussed. First the 
inherent bias of key methods such as error-prone PCR (epPCR) and the use of 
mutator strains, which introduce single point mutations, are described. 
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One significant reason for bias in a library with single-point mutations arises from 
the nature of nucleotide exchanges. Two types of single base-pair exchanges can 
occur, transitions and transversions. Transitions are purine to purine (A+-*G) or 
pyrimidine to pyrimidine (T-*C) exchanges. Transversions are purine to pyrimidine 
(A or G -* T or C) or pyrimidine to purine (T or C -), A or G) exchanges. The DNA 
bases are shown in Figure 1.5 and it can be seen that there are twice as many possible 
transversions as transitions. For example, the three possible exchanges of the 
nucleotide A result in one transition (A to G) and two transversions (A to T or Q. 
However, transitions naturally occur more frequently than transversions. 30 The 
molecular cause of point mutations can be found in tautomerisation, oxidative 
deamination or oxidation of the bases, and these most often result in a transition. An 
example is the amino-imino tautomerisation of adenine shown in Figure 1.6 along 
with the resulting non-complementary base-pairing which arises due to the altered 
position of favourable hydrogen bonds. Figure 1.7 shows the outcome of the 
alternative base-pairing, that is, an A--),G transition in one strand and a T—*C 
transition in the other. 
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Figure 1.5 - Purine bases adenine (A) and guanine (G) are shown to the left of the central red 
line and pyrimidine bases thyamine (T) and Cytosine (C) to the right. A purine to purine 
exchange or a pyrimidine to pyrimidine exchange is called a transition. An exchange of a purine 
base for a pyrimidine base or vice versa is called a transversion. 
A* 	 A* 	 C 
N H 
</ 
 NH 	N 	
(K=1 O 4) 
H H 
N 	N ----- H—_N" 
NHJ/ 
~





Figure 1.6 - Relationship between adenine (A) and its imino tautomer (A*) and the resulting 





A- - - -T 	
A- - - -T 
A----T 
A*-----C 
Figure 1.7— Tautomerism in the adenine base leads to an A--+G transition in one strand and a 
T—*C transition in the other. (31) (A* = tautomer of adenine.) 
In addition to the higher frequency of transitional exchanges over transversional 
exchanges, the degeneracy in the genetic code (Table 1.1) means that some amino 
acid exchanges are more likely to occur than others. For example, 6 codons encode a 
leucine residue while only one encodes a methionine residue. The table also shows 
that an exchange at the 3rd position of a codon often does not result in a change to 
the encoded amino acid (synonymous exchange). This is particularly true for 
transitions at the 3rd position where only ATA-*ATG and TGA(Ter)-->TGG result 
in a change to the amino acid encoded. 
Further, transitions occurring at the first codon position are likely to result in a 
chemically similar amino acid residue. (32)  The chemical groupings are shown by 
colour code in Table 1.1. These are aromatic (F, W, Y); aliphatic (G, A, V, L, I); 
neutral (C, M, P, S, T, N, Q); and charged (D, E, H, K, R). For example, the codons 
of the hydrophobic amino acids A, V, L or I cannot be mutated by a single nucleotide 
exchange to codons of the charged amino acids D, E, K or R. 32 It is statistically 
unlikely that more than one nucleotide per codon will be exchanged and, therefore, 
even under the assumption that each nucleotide exchange at each codon position is 
equally likely, the possible exchanges for a given amino acid residue drop from 19 to 
an average of 75(32)  In natural evolution degeneracy minimises the consequences of 




Table 1.1 - The genetic code. The colour codes represent the chemical group of the encoded 
amino acid. Pink = aromatic, green = a1filatic, blue = neutral, red = charged. The one letter 
amino acid codes are given in the Appendix. Ter = terminator codon. 
"\Pos 2 
T C A G 
Pos" 1 
iTT F TCT S TAT Y TGT C 
TTC F TCC S TAC Y TGC C 
T TTA L TCA S TAA Ter TGA Ter 
TIG L TCG S TAG Ter TGG W 
CTT L CCT P CAT H CGT R 
CTC L CCC P CAC H CGC R 
CTA L CCA P CAA Q CGA R 
CTG F CCG P CAG Q CGG R 
"TT ACT T AAT N AGT S 
ATC ACC T AAC N AGC S 
A ATA 1 ACA T AAA K AGA R 
ATG M ACG T AAG 
V 
K AGG R 
GTT 'CT A GAT D GGT C 
GTC V CCC A GAC D GGC C 
G 
GTA V OCA A GAA E GGA C 
GTG \i CCG A I 	GAG E GGG C 
Mutator Strains 
The gene of interest is cloned and propagated in a host strain engineered to cause 
faults in DNA replication and repair. One example is the E. coli host XL 1-Red which 
contains three mutations, mutS, mutD and muff, affecting the DNA repair 
pathways. (33)  This generates a mutation rate approximately 5000-fold greater than 
wild-type and results in approximately 1 nucleotide mutations/kb. The main 
advantage of this method is the lack of a sub-cloning step. However, mutations are 
not restricted to the gene of interest but can occur elsewhere in the plasmid, for 
example mutations in the promoter region may lead to expression variants. In 
addition, the process is time consuming and yields a low mutation rate. Only single 




Error-crone Polvmerase Chain Reaction (eDPCR 
By changing the standard PCR reaction components and conditions, for example, the 
use of Thermus aquaticus (Taq) polymerase which has a naturally high error rate, 
increased Mg2 concentration, addition of Mn 2+ and altering the balance of dNTPs 
added, the fidelity of the reaction is decreased so as to cause one or more amino acid 
substitutions in the encoded protein. (34)  The mutation frequency can be adjusted and 
rates of 1-10 nucleotides per kb can be obtained. An additional advantage is that the 
mutations generated are contained within the gene of interest. However, epPCR is 
susceptible to the mutational bias discussed above. Another disadvantage is that a 
sub-cloning step must be included. In addition, Taq polymerase is 4 times more 
likely to mutate As and Ts. 
1.3.2 Assessment of random libraries 
Schwaneberg et al. (35)  make the point that the traditional method of assessing the 
quality of a random library, that is by taking the Ts/Tv ratio and the ratio of 
AT—>GC/GC—AT transitions, is limited. An ideal mutational method would 
produce values of 0.5 and 1 for the above ratios respectively, with the value of 0.5 
arising for Ts/Tv because there are 4 possible transitions and 8 possible 
transversions. However, the degeneracy in the genetic code and the low probability 
of exchanging more than one nucleotide per codon mean that, a library displaying 
these ideal ratios will not show ideal diversity in the amino acid sequences encoded. 
For the above reasons, three alternative indicators of the quality of a random 
mutagenesis library were suggested. 
An amino acid diversity indicator to assess the average number of amino acid 
substitutions per residue and the probability of producing variants with 
preserved amino acid sequences. 
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A chemical diversity indicator to analyse the substituted amino acid residues 
according to the groupings aliphatic, aromatic, charged and neutral. 
Finally, a protein structure indicator to indicate the statistical likelihood of 
generating stop, glycine or proline producing codons. Glycine and proline 
residues destabilise helical structures while stop codons produce truncated 
proteins and all may result in inactive variants. 
This group have produced an analysis tool, named MAP (36)  which takes an input 
gene sequence and, based on these 3 factors and the mutational spectra of 19 
different mutational methods (including enzymatic, chemical and whole cell), 
provides a prediction of the library composition. In assessing the random single 
nucleotide exchange libraries of 4 genes from different organisms (to account for 
codon usage) they provide a predicted spectrum for a non-biased library (non-biased 
mutational spectrum with each nucleotide equally targeted). This would produce 21-
25.8 % preserved amino acids, an average of 7 possible amino acid substitutions per 
residue (instead of the full 19), 55.5 % amino acids with chemically different side 
chains, 2.9-4.7% stop codons and 11.1-16.0% glycine/proline residues. 
1.3.3 Activity Screening 
Horseradish Peroxidase Colorimetric Assay 
A coupled colorimetric screen was used to detect turnover of amino acids by D-
amino acid oxidase. Scheme 1.15 shows the DAAO catalysed oxidation of an amino 
acid to the corresponding imino acid and the resulting reduction of the flavin 
cofactor. The cofactor is reoxidised by molecular oxygen to form hydrogen peroxide, 
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Scheme 1.15 - The principle of the HRP coupled colorimetric assay for detection of DAAO 
activity. The flavin cofactor is reduced upon oxidation of amino acids by DAAO. Recycling of 
the cofactor by molecular oxygen produces hydrogen peroxide which is detected using an HRP 
based screen. 
HRP catalyses the reduction of hydrogen peroxide to water. This involves a two 
electron oxidation of HRP by hydrogen peroxide, followed by two one electron 
reductions of the enzyme by electron donors, such as aromatic amines or phenolic 
compounds, to return the enzyme to its resting state. ( 37) The reaction cycle is shown 
in Scheme 1.16. 
H20, 	 H20 
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Scheme 1.16 - HRP reaction cycle. 3 First, a two electron oxidation of HRP by hydrogen 
peroxide to HRP-1 (Porph = porphyrin). This is followed by two one electron reductions of the 




To enable detection of H202 formation, chromogenic electron donors are selected 
which form a coloured product after coupling of their oxidised radical forms. The 
electron donor substrate in the solid-phase assay is 3,3'-diaminobenzidine (3,3'-

















insoluble brown oxidation product 
Scheme 1.17— Peroxidase catalysed oxidation of 3,3'-DAB in the solid-phase produces a brown-
coloured oxidation product within the colonies. The qualitative solid-phase assay is a high-
throughput method which was used in this work to screen epPCR RgDAAO libraries for 
improved activity towards non-proteinogenic amino acids. (38) 
The colour-forming substrates in the HRP-coupled solution phase assay are 
4-aminoantipyrine (4-AAP) and 2,4,6-tribromohydrobenzoic acid (TBHBA). These 
combine to give a soluble, red quinoneimine dye (Scheme 1.18) which is detected 
using light with a wavelength of 510 nm. 
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/ 	 Br 	OH 
+ HO2C* Br / 
0 NH2 	 Br 
H RP 
H202 	F 
+ 2H20 + HBr 
4-AAP 	 TBHBA 	 quinoneimine dye 
Scheme 1.18 - Peroxidase catalysed formation of quinoneimine dye in the liquid-phase assay was 
performed in 96-well microtitre plates. The quantitative liquid-phase assay employing 4-AAP 
and TBHBA as dye components was used in this work to screen epPCR RgDAAO libraries for 
improved activity towards non-proteinogenic amino acids. Colour formation was followed at 
510 nm. 
1.4 SUMMARY AND AIMS 
Biocatalysts are attractive for the asymmetric synthesis of chiral compounds due to 
their potential chemo-, regio- and stereo-selectivity as well as the mild reaction 
conditions they require. There are a number of biocatalytic methods for the synthesis 
of optically pure proteinogenic and non-proteinogenic amino acids. The aim of this 
project was to develop an enzyme for the oxidation of non-proteinogenic amino acids 
which could be used in future deracemisation reactions to provide a theoretical 
100 % yield of the desired enantiomer. The substrates investigated were therein non-
proteinogenic a-amino acids and 13-amino acids. Methods employed to reach this 
goal included screening of microbial libraries and random mutagenesis as well as site 
directed mutagenesis of DAAO. 
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2 	RESULTS AND DISCUSSION 
2.1 	SCREENING MICROORGANISMS FOR ACTIVITY TOWARDS 13- 
AMINO ACIDS 
With the aim of detecting any existing 13-amino acid oxidase activity, a culture 
collection containing 535 microorganisms (see Appendix 5.8) was screened using the 
HRP-coupled liquid phase assay described in Section 1.3.3. The culture collection 
was obtained in the form of lyophilised powder in 15 x 96-well storage plates, with 
each microorganism present in duplicate on a single plate. 
A Tecan Genesis Workstation 150, comprising a robotic arm, liquid handler, plate 
reader and storage carousel was programmed to perform the following protocol:- 
Suspend the lyophilised microorganisms in buffer. 
Transfer cell suspension, assay mix (HRP, 4-AAP and TBHBA) and substrate 
to black polystyrene, 96-well assay plates. 
Measure absorbance at 510 nm in an integrated plate reader (time = 0). 
Lid assay plate 1 and move to a storage carousel for room temperature 
incubation. 
Remeasure absorbance at 510 nm (time = 2 and 20 h). 
Two 13-amino acid substrates were assayed against the culture collection: (rac)- I3-
phenylalanine and (rac)-13-homophenylalanine (see Figure 2.1). An additional assay 







Figure 2.1 - f3-Phenylalanine and 3-homophenyIaIanine. 
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It was anticipated that any 13-amino acid oxidase activity would be present at very 
low levels and therefore endpoint absorbance measurements were taken at 2 and 
20 h. However, a number of wells on some plates responded to the assay with rapid 
colour formation both in the presence and in the absence of substrate. The results 
obtained from the assay of one plate of microorganisms against (rac)-13-
homophenylalanine are shown in Figure 2.2. 
11 
Figure 2.2 - The results produced from the assay of one plate of microorganisms against (rac)-J3-
homophenylalanine following a 2 h room temperature incubation. The microorganisms have 
been plated such that the left hand side of the plate, Alto 146, is identical to the right hand side 
of the plate, A7 to 1112. 
The absorbances measured at 2 and at 20 h were corrected by subtracting the 
absorbance recorded at time = 0. The data for each substrate were compared with the 
negative control data. All the wells containing microorganisms which showed an 
increase in absorbance at 510 nm in response to the assay mixture with substrate also 
produced an increase in absorbance in response to the negative control assay mixture 
where substrate had been replaced with water. This false positive response was 
observed for prokaryotic and eukaryotic microorganisms alike. The oxidation of the 
dye precursors TBHBA and 4-AAP could be caused by other enzymatic sources of 
hydrogen peroxide in these particular microorganisms but could otherwise be due to 
alternative oxidising systems which result in the oxidation of the dye precursors to 
the quinoneimine dye. 
No 13-amino acid oxidase activity was detected within the microorganism collection 
by the HRP-coupled liquid-phase assay. The method could be improved by 
measuring the initial rate, rather than endpoint absorbance. In view of the fact that 
32 
RESULTS AND DISCUSSION 
some microorganisms respond to the TBHBA, 4-AAP, HRP assay mixture in the 
absence of an externally added substrate, an alternative detection system would be 
preferable. Consumption of 3-amino acid could be detected by HPLC analysis, 
although this would reduce screening throughput. 
A broader substrate spectrum of J3-amino acids screened could have allowed 
detection of 3-amino acid oxidase activity. This could be done by applying a 
substrate cocktail containing various p-amino acid substrates and subsequent 
identification of the substrate responsible for any oxidase activity identified. 
Due to the lack of detectable 13-amino acid oxidase activity in the microorganisms 
screened, it was decided to subject known amino acid oxidase enzymes to directed 
evolution with the aim of producing novel oxidase activity towards 13-amino acids. 
33 
RESULTS AND DISCUSSION 
2.2 CHARACTERISATION OF PARENTAL OXIDASE ENZYMES 
2.2.1 Confirmation of parental gene sequences 
The following two D-amino acid oxidase (DAAO) enzymes were used in this work. 
Rhodotorula gracilis DAAO (RgDAAO) and Trigonopsis variab ills DAAO 
(TvDAAO). The corresponding genes were obtained as cloned plasmids; RgDAAO 
in pPOT3 from Ingenza, Edinburgh and TvDAAO in pJLM402 from Dr Jemma 
Morgan. (39) The plasmid maps and parental gene sequences are shown in the 
Appendix (Section 5.3). 
The parental sequences of both genes were sequenced and the nucleotide sequences 
thus obtained were compared with published sequences. 
RgDAAO 
The parental RgDAAO sequence consists of 1107 bp and differs from the published 
nucleotide sequence (Pollegioni et al. (40),  GenBank!EMBL accession number 
U60066) at 4 nucleotide positions: 217T>C, 597G>C, 882T>C and 1006G>A. Two 
of these nucleotide differences 597G>C and 882T>C, result in no change to the 
amino acid sequence, whereas 21 7T>C gives rise to proline in place of serine 73 
(S73P) and 1006G>A to threonine in place of alanine 336 (A336T). Residue 73 is 
located on the outer surface of the enzyme, while residue 336 is located in the active 
site (it has been reported that serine 335 is involved in hydrogen bonding to the (X-
amino group of amino acid substrates (41)). 
TflA Afl 
The nucleotide sequence of the TvDAAO gene provided consists of 1071 bp and is 
identical to that published by Alonso, 42 GenBank/EMBL accession number Z80895. 
2.2.2 Comparison of the RgDAAO and TvDAAO amino acid sequences 
The RgDAAO and TvDAAO amino acid sequences resulting from the genes used 
were aligned using the BLOSUM62 matrix and are compared in Figure 2.3. 
Similarities in the amino acid residue sequences of various DAAO enzymes have 
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been discussed by, for example, Faotto 43 and Pilone 23 and regions common to 
many DAAO enzymes are highlighted (numbered I to VI) in Figure 2.3. The 3 
conserved active site residues discussed by Pilone(23) are marked with a red star. In 
RgDAAO these are Y223, Y238 and R285, corresponding to Y243, F258 and R301 
in TvDAAO. The alignment of the two amino acid sequences yielded 29.8 % identity 
(yellow) and 46.0 % identity or similarity (blue). 
RgDAAO 1 MHSQKR 	G GVIGL LILARKG SVHIRDLPED SSQT SPWAGANWTPF T 
TvDAAO 1 MA K G GVAGL LQLLRK EVTI EFTPHD SI- TSPWAGANW--- T 
RgDAAO 61 LTDGP QA 	--E-PTF 	VELVP-TG 	ML --- T-RRF NEDC L.: ------W 
TvDAAO 54 FYDG LAD VSYPIL LARSSPEAGIR I RSHVLKRDLP LET SAICQ PM 
RgDAAO 109 	ITP RP PS-SECPP 	--VT D S HAPKYCQ LAR LQKLGATFE RTVTS 
TvDAAO 114 TVD El EDRSRIVHDD YLVE 	C MT VYLJLMSjCLSLGATVVMRRVNH 
II 
RgDAAO 165 MQA----FD--D N GL S G D EPIRGQTVL PCKRCTMDSSDP 
TvDAAO 174 DANLLHSS RPD NC GLF F 	D KMYPIRGQVVL SLPFMASFSSTP 
* 	 111* 
RgDAAO 219 A-- P --- AYI1PRP.GEVICGGTj VIIWDLSVPETVQRILKHCLRLDPTESDGT 
TvDAAO 234 EKEIEDEALYIITRFDGTSIIGGCIQPNIWSSEP IPSLTHRILSRALDRFPE KDGP 
* 	Iv 	 V 
77 RgDAAO 274 lIERHNVGLRPARRGGPRVEAE IVLPLDRTKSPLSL(RGSARAAKEKEVT HAYGF
TvDAAO 293 --- RECVGHRP REGGPRVELE I --------- P ----- GV -------F- HNYGA 




329 AGYQSS GMANAVSYVIRALTR 	PNL* 
Figure 2.3 - Alignment of the amino acid residue sequences of RgDAAO and TvDAAO. The 
alignment was performed using the BLOSUM62 matrix which yields 29.8 % identity (yellow) 
and 46.0 % identity or similarity (blue) between the two sequences. Regions I and III are 
involved in FAD binding, with I showing the typical motif, GxGxxG. Regions II, IV and V are 
DAAO active site regions. Region VI in RgDAAO shows the type 1 peroxisomal targeting signal 
SK/HL, which is not present in TvDAAO. Red stars mark conserved residues as proposed by 
Pilone(23). 
2.2.3 Parental oxidase activity towards proteinogenic and non-proteinogenic 
amino acids 
The HRP-coupled solid- and liquid-phase colorimetric assays described in Section 
1.3.3 were used for the detection of parental oxidase activity. 
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Liquid-phase assay substrate screen 
The liquid-phase assay was performed in 96-well microtitre plates using cell free 
extract (CFE) obtained from cells expressing TvDAAO or RgDAAO. The HRP 
substrates were 4-aminoantipyrine (4-AAP) and tribromohydroxybenzoic acid 
(TBHBA). The increase in absorbance at 510 nm was monitored over time using a 
plate reader. A panel of proteinogenic and non-proteinogenic substrates was 
monitored against TvDAAO and RgDAAO. Figure 2.4 shows the parental activity 
spectra for both enzymes. Substrates towards which both enzymes proved inactive 
are listed in Table 2.1. As both DAAOs showed good activity towards (R)-
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Figure 2.4 - Recorded activity rates for the TvDAAO and RgDAAO liquid-phase assays against 
a panel of substrates. Rates are given relative to that obtained for (R)-methionine (100 % = 
1.9 x 101  and 1.6 mAU s for TvDAAO and RgDAAO respectively). The assays were performed 
in 96 well microtitre plates with each well containing buffer, HRP, TBHBA, 4-AAP, substrate 
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(20 mM racemate or 10 mM single enantiomer) and CFE obtained from cells expressing either 
RgDAAO or TvDAAO. The rate of increase in absorbance at 510 nm was measured for 55 mm. 
Both assays were performed in triplicate and the results are shown ± one standard deviation. 
Table 2.1 - Substrates towards which RgDAAO and TvDAAO showed no activity. * = TvDAAO 
activity was not measured. ** = 13-amino acid 
y-amino-n-butyric acid (S)-cysteine (D-cysteine) 
13-glutamic acid**  (S)-azetidine-2-carboxylic acid* 
13 aIanine** (S)-aspartic acid 
glycine (S-arginine 
ethyl-4-aminobutyrate (S)-2-aminobutyric acid 
(rac)-cis-2-Aminocyclopentanecarboxylic acid * * (rac)13homophenyla1anine* * 
(rac)-cis-2-Aminocyclohexanecarboxylic acid * * (rac)13hornoleucine* * 













(S)-serine (rac)-nipecotic acid** 
(S)-proline (rac)-ethylpipecolinate 
(S)-pipecolinic acid* (rac) ethyl3_aminobutyrate* 
(S)-phenylalanine (rac)-cysteine 
(5)-ornithine (rac)-3-aminobutyric acid** 
(S)-lysine 
(rac)-3-amino-3-phenyl propionic acid (13-
phenylalanine)* * 




(S)-histidine (R) amethyIbenzylamine* 
(S)-glutamiiie (R)-glutamic acid 
(S)-glutamic acid (R)-2-amino- 1 propanol* 
In accordance with literature data(26,44), hydrophobic a-amino acids are the best 
substrates for both TvDAAO and RgDAAO. However, some discrepancies appear in 
Figure 2.4 compared with literature values. The most conspicuous of these is the 
observation of 60 % relative activity of RgDAAO towards (S)-alanine. The literature 
explicitly states that L-amino acids, such as (S)-alanine, are not substrates for 
DAAOs(26). Due to the high stereo selectivity of RgDAAO, it has been developed as 
a biosensor for the detection of D-amino acids, including (R)-alanine, in food.'45 No 
RgDAAO activity was expected towards (5)-alanine or, additionally, (5)-methionine 
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for which relative rates of 9 and 12 % were obtained for TvDAAO and RgDAAO 
respectively. The observed colour formation may be due to racemisation of these 
substrates in the presence of CFE or perhaps to a change in enantioselectivity of 
RgDAAO caused by the T336A mutation described in Section 2.2.1. No analysis to 
assess the enantiopurity of the substrates was undertaken. No activity was shown 
towards other L-amino acids tested (see Table 2.1). 
Tishkov presents a comparison of the relative rates from literature for various 
DAAOs. 44 When these values are compared with the data presented here, the 
significant differences are relative rates observed in this work for TvDAAO towards 
(R)-alanine, (R)-phenylalanine and (R)-glutamine of 20 %, 160 % and 30 % 
respectively compared with literature values of 120 %, 50 % and 100 % respectively. 
In addition, a relative rate of 37 % was obtained for RgDAAO towards (R)-arginine 
in this work but is reported as 2 % in the literature. Tishkov advises that 
discrepancies in relative rates reported in the literature are due to the use of different 
assay procedures under different experimental conditions. Additionally, results can 
be influenced by the presence of catalase in cell preparations and by the fact that the 
concentration of oxygen in water under normal experimental conditions can be lower 
than its Km value for some of the enzymes. For example, the concentration of oxygen 
in water at atmospheric pressure of air is 0.21 mM at pH 8.0 and 37°C under 
equilibrium conditions and the Km value of oxygen for TvDAAO is 0.72 mM. 44 
The data presented here show that both TvDAAO and RgDAAO are active towards 
(R)-phenylalanine but show poor activity towards (rac)-phenylglycine. Several 13-
analogues of phenylalanine, for example, (rac)-13-phenylalanine and (rac)-13-
homophenylalanine (Figure 2. 1), were included in the screen but no activity was 
shown by either enzyme towards these substrates. 
(R)-Serine is a substrate for RgDAAO but not for TvDAAO, whereas both enzymes 
show poor activity towards (R)-threonine. 
RESULTS AND DISCUSSION 
Neither DAAO demonstrated activity towards any of the 3-amino acids tested 
(marked ** in Table 2.1). Additionally, no oxidase activity was observed towards y-
amino-n-butyric acid, (R)-2-amino- 1 -propanol or (R)-c-methylbenzylamine. 
Anthranilic acid is known to be a competitive inhibitor of RgDAAO(41) and has the 
structure 	shown 	in 	Figure 	2.5. 	The 	substrates 	(rac)-cis-2- 
aminocyclohexanecarboxylic acid, (rac)-cis-2-aminocyclohex-3 -enecarboxylic acid 
and (rac)-cis-2-aminocyclopentanecarboxylic acid were added to the substrate panel. 
No activity was observed towards these substrates. 
cc02H C~ CO2H 	C~CO2H Cc02H 
Figure 2.5 - Cyclic 3-amino acids included in the screen against RgDAAO and TvDAAO. 
Anthranilic acid, (rac)-cis-2-aminocyclohexanecarboxylic acid, (rac)-cis-2-aminocyclohex-3-
enecarboxylic acid and (rac)-cis-2-aminocyclopentanecarboxylic acid. 
RgDAAO displayed 80 % relative activity towards (R)-proline and 8 % relative 
activity towards the 6-membered ring homologue, (rac)-pipecolinic acid. However, 
no oxidase activity was observed towards the n-analogue of (rac)-pipecolinic acid, 
(rac)-nipecotic acid, nor towards the ethyl ester of (rac)-pipecolinic acid (Figure 
2.6). In a second round of substrate screening (see Figure 2.7), RgDAAO showed 
4 % relative activity towards (rac)-tetrahydroisoquinoline-3-carboxylic acid. 
	
HO H: 	HO 0 Ho 
Figure 2.6 - Heterocyclic amino acids screened against RgDAAO. (rac)-Pipecolinic acid, (rac)-
nipecotic acid and (rac)-tetrahydroisoquinoline-3-carboxylic acid. 
The second substrate panel was assessed against RgDAAO only and the data are 
shown in Figure 2.7. These substrates were measured in duplicate and the rates 
obtained are again given relative to (R)-methionine. 
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Figure 2.7 - Results of the RgDAAO liquid-phase assay against a secondary panel of substrates. 
The assays were performed in 96 well microtitre plates with each well containing buffer, HRP, 
TBHBA, 4-AAP, substrate (20 mM racemate or 10 mM single enantiomer; (rac)-
tetrahydroisoquinoline-3-carboxylic acid = 10 mM) and CFE obtained from cells expressing 
RgDAAO. The rate of increase in absorbance at 510 nm was measured for 55 mm. Rates are 
given relative to that obtained for (R)-methionine (100 % = 1.6 mAU s'). The data were 
measured in duplicate and are shown ± one standard deviation. Tiq = tetrahydroisoquinoline-3-
carboxylic acid. 
A relative activity of 49 % was observed for RgDAAO towards (R)-valine. This 
increased to 120 % for the straight-chain aliphatic amino acid (R)-norvaline, whereas 
the relative rate obtained towards (rac)-3 -hydroxynorvaline was just 8 %. The 
relative activities demonstrated by RgDAAO towards the leucine series were: (R)-
leucine 104 %; (R)-norleucine 103 %; (R)-isoleucine 70 % but the enzyme was 
inactive towards (rac)-tert-leucine and 13 -homoleucine. (Rac)-allo-tbreonine was 
oxidised considerably faster (64 % relative rate) than (rac)-threonine (3 % relative 
rate). 
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Solid-phase assays 
The solid-phase assay discussed in Section 1.3.3 was used to screen TvDAAO and 
RgDAAO for activity towards the 13-amino acids: (rac)-J3-phenylalanine, (rac)-13-
homophenylalanine, 13-homoleucine and 13-homomethionine. Cells expressing 
RgDAAO, TvDAAO or containing plasmid with no gene insert (empty vector) were 
grown and induced on nitrocellulose membranes and sections of these membranes 
were transferred to assay plates containing a filter paper soaked with HRP-assay 
mixture and substrate, as shown in Figure 2.8. This figure shows the results of the 
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Figure 2.8 - DAAO solid-phase assay. Each assay plate contained a filter paper soaked in assay 
mix consisting of buffer, substrate (20 mM racemate or 10 mM single enantiomer), HRP and 
3,3'-DAB. Substrate A = (rac)-f3-homo-leucine and substrate B = (R)-alanine. Colonies were 
grown on nitrocellulose membranes which were cut into sections and placed in the assay plates. 
Membranes numbered 1 held TvDAAO expressing colonies, 2 held RgDAAO expressing 
colonies and 3 held colonies containing empty vector. 
Figure 2.8 B) shows that, as expected, colonies expressing TvDAAO (membrane 1) 
or RgDAAO (membrane 2) turn a red/brown colour as the hydrogen peroxide 
produced in the reoxidation of the cofactor of DAAO leads to the oxidation of 3,3'-
DAB in a HRP-catalysed reaction. The empty vector colonies (membrane 3) remain 
uncoloured as there is no DAAO present to oxidise (R)-alanine and therefore no 
H202 produced. The substrate in Figure 2.8 A) is (rac)-13-homoleucine and lack of 
colour formation in the colonies on all three membrane sections indicates that (rac)- 
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13-homoleucine is not a substrate for either RgDAAO or TvDAAO, as confirmed in 
the liquid-phase assay discussed above. This assay was repeated using (rac)-13-
phenylalanine, (rac)-3-homophenylalanine, and 13-homomethionine with no 
indication of oxidation by either TvDAAO or RgDAAO. 
The solid-phase assay was also used to assess the potential of a variant monoamine 
oxidase-N from Aspergillus niger (MAO-N, variant D5 46 ) which oxidises amines, 
for activity towards these four n-amino acid substrates. The assay was performed 
using an identical protocol to that described above but the positive control substrate 
in this case was (rac)-x-methylbenzylamine ((rac)-(-MBA). The results of the solid-
phase assay towards (rac)-t3-homoleucine  and (rac)-a-MBA are shown in Figure 2.9 
A) and B) respectively. 
Figure 2.9 - MAO-N solid-phase assay. These assay plates were prepared as for the assay shown 
in Figure 2.8. Substrate A = (rac)--homo-Ieucine and substrate B = (rac)-a-MBA. Membranes 
numbered 1 contained MAO-N expressing colonies and membranes numbered 2 contained 
empty vector colonies. 
Figure 2.9 B) shows that MAO-N producing colonies on membrane 1 lead, when 
exposed to (rac)-a-MBA and assay mix, to colour formation, while the empty vector 
colonies showed no colour formation. In Figure 2.9 A), neither the MAO-N 
producing colonies on membrane 1 nor the empty vector colonies on membrane 2 
coloured up during incubation with (rac)-3-homoleucine and assay mix, indicating 
that 3-homoleucine is not a substrate for MAO-N. This assay was repeated using 
(rac)-3-phenylalanine, (rac)-J3-homophenylalanine and -homometMothne as 
substrates and no colour formation was observed. 
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2.2.4 Conclusions 
The gene sequences of TvDAAO and RgDAAO were obtained and their amino acid 
sequences aligned and compared. Regions of the two sequences which are conserved 
in DAAOs were highlighted. 
A panel of substrates was assayed in the liquid-phase to give an overview of the 
parental activity profiles of both TvDAAO and RgDAAO and these were compared 
with relative rates presented in the literature. Although some discrepancies appeared 
between the data presented here and literature values, it was confirmed that amino 
acids with hydrophobic side chains are the best substrates for both enzymes. No 
oxidase activity was detected towards 3-amino acids or towards other amino-
containing compounds without a carboxylic acid functionality at the a-carbon. Some 
activity was observed towards the non-proteinogenic a-amino acids (rac)-pipecolinic 
acid and (rac)- 1,2,3 ,4-tetrahydroisoquinoline-3 -carboxylic acid. 
In accordance, a solid-phase screen showed no RgDAAO or TvDAAO activity 
towards the -amino acids (rac)-f3-phenylalanine, (rac)-3-homopheny1alanine, (rac)- 
-homoleucine or (rac)-13-homomethionine.  Additionally, solid-phase screening of a 
MAO-N variant against the same 13-amino acid substrates showed no observable 
oxidase activity. 
It was expected that directed evolution of the TvDAAO or RgDAAO genes would 
produce variant enzymes acting as 13-amino acid oxidases which could be detected 
using a solid-phase assay against the 13-amino acid, (rac)-13-homophenylalanine. 
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2.3 DIRECTED EVOLUTION OF D-AAO 
2.3.1 Mutator strain library TvDAAO 
The starting point for directed evolution in this project was to generate a TvDAAO 
random library through the use of the mutator strain XL 1-Red as discussed in Section 
1.3.1. Fresh plasmid DNA was isolated from a single TOP 10 E. coil colony and used 
to transform XL1-Red E. coii cells which were grown as described in Experimental 
Sections 3.2.2 and 3.2.3 to generate a library of variants. 
Verification of Mutator Strain Library 
Plasmid DNA extracted from the mutator strain library was used to transform E. coli 
BL21(DE3) cells which were grown on LB agar plates containing antibiotic. Twenty 
of the resulting colonies were selected and cultured overnight. The plasmid DNA 
was extracted and sequenced as described in Section 3.2.1. Full sequences were 
obtained for 14 genes and more than 50 % of each of the remaining genes was 
captured. The nucleotide mutation 3G>T was observed in 18 of the 20 TvDAAO 
nucleotide sequences and the other two genes were not sequenced in this region. This 
nucleotide exchange results in the exchange of the start codon, methionine (ATG), 
for an isoleucine (ATT). The absence of the start codon means that the TvDAAO 
enzyme will not be expressed by the cell. No other mutations were observed in any 
of the sequenced genes. The original plasmid DNA used to transform the XL 1-Red 
cells was checked by sequencing and found to contain the start codon ATG. It was 
therefore assumed that the mutation to ATT was generated early during the 
propagation cycles and became dominant in the culture. 
A repeat of the mutator strain experiment was considered but, as a result of the very 
low mutation rates achieved, it was decided to perform epPCR with the aim of 
producing a higher mutation rate. 
In the meantime, the RgDAAO gene cloned into the vector pPOT3 was obtained 
from Dr Annette Turner of Ingenza, Edinburgh. As a crystal structure is available for 
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Knowledge of the structure would allow a more detailed analysis of any mutants 
which displayed improved activities towards unnatural amino acids. 
2.3.2 epPCR library RgDAAO 
An epPCR was performed with the aim of producing an RgDAAO variant library 
with a mutation rate of 2-3 nucleotide exchanges per gene for subsequent screening 
against a range of 13-amino acids. Fresh RgDAAO plasmid was prepared from 
TOP1O cells and an epPCR was performed using this as template at four different 
annealing temperatures (50.0, 56.1, 60.2 and 65.5 °C). The gene was successfully 
amplified in all cases as shown in Figure 2.10. 
Figure 2.10 - epPCR products (1107 bp) following agarose gel electrophoresis. Lane 1 DNA 
ladder, lanes 2 to 5 ep products from 50.0, 56.1, 60.2 and 65.6 °C epPCRs respectively. 
The products were combined and used as megaprimers in a PCR with parental 
RgDAAO/pPOT3 as template to subclone the library into the pPOT3 vector. The 
PCR was carried out with mass ratios (ng tL' reaction volume) of 0.5, 1 and 2 times 
megaprimer to template DNA. The products of these PCRs were digested with the 
restriction enzyme DpnI to remove methylated parental DNA as explained in Section 
3.2.1. The digested products were used to transform highly competent XL1-Blue 
cells which repair the nicked DNA produced in the PCR reaction. The transformants 
were grown on LB or TSB agar plates treated with chioramphenicol (CAP). As the 
plasmid confers CAP resistance to the cells, only cells successfully transformed with 
plasmid DNA grew. Figure 2.11 shows the number of XL1-Blue colonies produced 
per 100 tL transformation mixture in each case (in duplicate). A ratio of megaprimer 
to template DNA of 1-2 to 1 by mass produced good results. 
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Figure 2.11 - XL1-Blue transformation efficiency by mass ratio of megaprimer to DNA template 
used for whole plasmid extension. Data points represent the mean values ± standard deviation 
obtained from duplicate plates. 
Verification of epPCR Library 
The library was analysed for the number and diversity of mutations it contained. 
Twenty XL 1-Blue colonies were selected and cultured overnight. The plasmid DNA 
was extracted and sequenced as described in Section 3.2.1. The primers used for the 
amplification captured approximately 85 % of each of the sequenced genes. Eighteen 
of the sequenced samples contained the DAAO gene and two were circular plasmid 
with no gene insert. The number of nucleotide exchanges per gene in the sample 
were calculated and resulted in an average number of nucleotide mutations per gene 
of 2.7 as shown in Figure 2.12. 
0 	1 	2 	3 	4 	5 	6 
':4 
RESULTS AND DISCUSSION 
Number of nucleotide mutations 
Figure 2.12 - Number of nucleotide mutations per gene observed in a sample of 20 sequenced 
variants from the RgDAAO epPCR library. Average number of mutations per gene = (7x1 + 2x2 
+ 3x3 + 3x4 + 2x5 + 1x6)/18 = 2.7. 
A summary of the observed nucleotide mutations in 18 randomly picked samples are 
shown in Table 2.2. Point insertions and deletions are normally not beneficial as they 
cause a shift in the reading frame of the sequence and are likely to generate inactive 
variant enzymes. No insertions were detected but the tested samples contained 3 
point deletions over 2 genes. 
Table 2.2- Analysis of mutations in sample of RgDAAO epPCR library. (Sample size = 18 
variants.) 
Type of mutation Number Percentage of total mutations 
nucleotide exchanges 45 94% 
nucleotide deletions 3 6% 
nucleotide insertions 0 0% 
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A common method of assessing diversity in a random library is to take the transition 
to transversion (Ts/Tv) and AT-*GC/GC-+AT transition ratios. Transitions are 
purine to purine (A+-).G) or pyrimidine to pyrimidine (T4-*C) exchanges. 
Transversions are purine to pyrimidine (A or G -f T or C) or pyrimidine to purine (T 
or C -), A or G) exchanges. In this context, a library is considered to be free from 
bias when each type of nucleotide exchange occurs with an equal frequency. As there 
are twice as many possible transversions as transitions, the Ts/Tv ratio should be 0.5. 
The number of AT-GC transitions should equal the number of GC-*AT transitions 
and the ratio should be 1. The values observed in the RgDAAO library and the non-
biased values produced by a similar method were compared. Schwaneberg et 
compared the Ts/Tv and AT-*GC/GC---+AT ratios generated by a range of 
mutagenesis protocols. Of these, the most similar to that used in this work was an 
epPCR method presented by Shafikhani et al., (48)  which includes a Thermus 
aquaticus (Taq) PCR in the presence of Mn 2+  and dNTPs with the balance 
dGTP=dATP<dCTP=dTTP. However, 1.25-fold more of each primer and 10-fold 
more MnC12 were used than in this work which was adapted from a procedure taken 
from Escalettes and Turner. (49) The values obtained for Ts/Tv and AT-GC/GC—AT 
ratios by each method are shown in Table 2.3. 
Table 2.3 - Quality of RgDAAO library expressed by nucleotide exchange ratios. (Sample size = 
18 variants.) 
Non-biased Comparison epPCR 1 RgDAAO epPCR 
Ts/Tv 0.5 0.8 2.5 
AT—GC/GC--*AT 1.0 2.0 2.2 
[a] see reference (35) 
It can be seen that the comparison epPCR results and the experimental results deviate 
from the ideal, with both showing higher Ts/Tv and AT—GC/GC—AT ratios. In 
relation to the comparison method, the RgDAAO epPCR library produced here 
generated a similar AT-*GC/GC-*AT ratio but a 3-fold higher Ts/Tv ratio. This was 
investigated further by comparing each exchange type as shown in Table 2.4. There 
were 2.3 times fewer A--+T and T--+A transversions and approximately 1.7 times 
more A---*G and T--).0 transitions produced in this library than by the comparison 
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method. The effect of manganese concentration was considered. The comparison 
epPCR method used 500 LM Mn2 , whereas the method employed here used only 
50 p.M. At 50 p.M Mn 2+'  the mechanism of manganese-induced mutagenesis involves 
Mn 2+  binding to the DNA template which causes misinsertions to occur. (50)  
Additional mechanisms begin to feature at concentrations of Mn 2+  above 500 p.M 
(Mn 2+  association with either single stranded regions of DNA or with the 
po1ymerase) 50 and it is possible that these have some influence on the mutagenic 
profile of the comparison epPCR. 
Table 2.4 shows that neither the comparison epPCR method, nor the epPCR method 
used here, produced unbiased nucleotide exchange libraries. The impact of this bias 
was assessed by studying the amino acid sequences encoded. 
Table 2.4 - Detailed analysis of nucleotide exchanges in RgDAAO epPCR library (sample size = 
18 variants). 





AtoG 8 14 22 
TtoC 8 14 27 
GtoA 8 7 9 
CtoT 8 7 13 
transversions 
AtoT 8 21 9 
TtoA 8 21 9 
AtoC 8 4 2 
TtoG 8 4 2 
G to C 8 1 2 
CtoG 8 1 0 
GtoT 8 2 2 
CtoA 8 2 2 
Total 96 98 99 
[a] see reference (35) 
The distribution of amino acid substitutions among the variants selected for 
sequencing is shown in Figure 2.13. The average number of amino acid substitutions 
per variant is 1.4 (from 2.7 nucleotide exchanges per gene). This moderate mutation 
rate is a useful starting point for investigating the effects of mutating RgDAAO on its 
ability to oxidise unnatural amino acids. However, 4 of the 18 variants contained 
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synonymous nucleotide mutations with no change occurring in the amino acid 
sequence. This had to be taken into account when the number of colonies which must 
be screened to cover the majority of sequences present in the library is considered. 
The number of colonies to be screened will be discussed in more detail later in this 
Section. 
Number of amino acid exchanges 
Figure 2.13 - Distribution of amino acid exchanges in RgDAAO epPCR library. Sample size = 18 
variants with an average amino acid exchange per gene of 1.4 (6x1+ 5x2 + 20 + 1x4)/18. 
It is useful to discuss the range of amino acid exchanges observed in the context of a 
set of diversity indicators proposed by Schwaneberg et al. (35)  as these provide an 
overview of the library composition which can then be compared to the ideal library 
composition. Schwaneberg also analysed a range of mutagenic methods and 
produced a statistical tool (MAP) which predicts the mutagenic profile (amino acid 
exchanges) for a particular gene when subjected to each of these methods. The 
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method most similar to that used to create the RgDAAO epPCR library is the 
Shafikhani et al. epPCR method discussed above. Despite the difference in 
manganese concentrations used, the results of a MAP prediction of the mutagenic 
profile of the RgDAAO gene using the Shafikhani epPCR method are also compared 
with the ideal and observed results. In addition, the mutagenic profile predicted by 
MAP for a non-biased nucleotide library of the RgDAAO gene is included in the 
comparison. The data from the two RgDAAO MAP analyses are referred to as the 
'predicted' and 'non-biased' results, respectively, in the discussion below. The three 
diversity indicators are chemical diversity indicator, protein structure indicator and 
amino acid diversity indicator. 
- Chemical diversity indicator: 
The "ideal chemical distribution" of amino acid substitutions is shown in 
Table 2.5 and is simply based on the number of amino acids in each chemical 
category: 25 % charged (D, E, H, K, R), 35 % neutral (C, M, P, S, T, N, Q), 15 % 
aromatic (F, Y, W) and 25 % aliphatic (G, A, V, L, I). This distribution describes a 
situation where each category of amino acid is targeted with the appropriate 
frequency, for example 25 % of the newly substituted residues will be charged. The 
category of the residue displaced is not considered. 
The ideal figures (Table 2.5) are compared with the distribution which would have 
been obtained had a non-biased nucleotide exchange library of this gene been 
produced and with the predicted and observed distributions. It can be seen that a non-
biased nucleotide exchange library cannot access each amino acid exchange equally. 
As discussed in the Introduction, this is due to the degeneracy of the genetic code 
and the fact that it is statistically unlikely to exchange more than one nucleotide per 
codon. The observed amino acid exchanges reasonably match the ideal chemical 
distribution but with a loss of aromatic substitutions in favour of aliphatic 
substitutions. The percentage of aromatic substitutions in the library generated is also 
lower than in the predicted library. This observation could be due to the small sample 
size (26 amino acid exchanges from 18 sequenced variants) giving a non- 
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representative reflection of the data or to the increased manganese concentration in 
the method used for prediction purposes. 
In summary, in comparison with the ideal chemical distribution of the replacement 
amino acid residues the RgDAAO epPCR library contains 2 percentage points fewer 
charged substitutions, 4 percentage points fewer neutral substitutions and 
11 percentage points fewer aromatic substitutions. In contrast, there are 
14 percentage points more aliphatic substitutions and 4 percentage points more stop 
codons than would be shown by an ideal distribution. 
Table 2.5 - The ideal chemical diversity of substituted amino acids in a random library and 
values produced from MAP analyses for 'non-biased' and 'predicted' RgDAAO libraries 
compared with the observed diversity in the RgDAAO epPCR library. 
Charged Neutral Aromatic Aliphatic 
Ideal chemical distribution 25 35 15 25 
Non-biased 23 32 6 35 
Predicted 22 32 7 34 
Observed (18 sequenced variants) 23 31 4 38 
- Protein structure indicator: 
This investigates mutated codons which are likely to introduce structural changes in 
the protein and may lead to inactive variants, for example stop codons or those 
encoding glycine or proline residues which destabilise helical structures. Ideally, no 
stop codons would be introduced to the gene. However, 4 % of the amino acid 
exchanges in the sequenced samples yield stop codons as shown in Table 2.6. This 
value is consistent with the MAP analyses for the 'predicted' and 'non-biased' 
RgDAAO libraries. In the case of Gly and Pro residues, the observed value of 23 % 
is higher than both the predicted and non-biased values (13 and 14 % respectively). 
However, Gly and Pro residues will only destabilise the protein structure when they 
occur within a helical region. A cartoon representation (generated using PyMOL) of 
the RgDAAO monomer(47)  is shown in Figure 2.14 with helices coloured blue and 
strands coloured red. The Protein Data Bank (PDB) entry (1COP) shows that 
RgDAAO contains 36 % helical structures. This means that any Gly and Pro residues 
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introduced have approximately 36 % likelihood of causing destabilisation. This 
reduces both predicted values of potentially destabilising mutations to 9 % (4 % stop 
and 5 % Pro/Gly) and the observed value to 12 % (4 % stop and 8 % Pro/Gly). 
Table 2.6 - Exchanges with potential to adversely affect protein secondary structure. 
Stop Gly/Pro 
Ideal chemical distribution 0 10 
Non-biased 4 14 
Predicted 	 j 4 j 	13 
Observed (18 sequenced variants) 	 1 4 1 23 
Figure 2.14 - PyMOL cartoon representation of the RgDAAO monomer. 4 PDB ID code IcOp. 
Helices are shown in blue and strands are shown in red. The monomer contains 36 % helical 
structures and exchanges to Pro or Gly residues in these regions may cause structural 
destabilisations which result in inactive enzymes. 
- Amino acid diversity indicator: 
The amino acid diversity indicator assesses the number of variants with synonymous 
nucleotide exchanges and the average possible amino acid substitutions per residue 
(assuming a single nucleotide exchange within each codon). The MAP analysis 
predicted 23 % synonymous exchanges but only 9 % were observed. The analysis 
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also showed that the average possible amino acid substitutions available per residue 
when mutating the RgDAAO gene using the most similar epPCR conditions is 7.5. 
The minimum predicted for this gene using any of the seven Taq-based epPCR 
methods described in the MAP analysis programme is 5.5 and it would therefore be 
expected that the actual number lies within this range. The maximum possible 
average diversity per residue achievable by any of the single point mutational 
methods is 7.5 (with the exception of those methods which actively increase the 
likelihood of yielding more than one exchange per codon). The limitations are again 
due to the degeneracy of the genetic code and the statistical likelihood that only one 
nucleotide per codon will be exchanged. 
Overall, the generated RgDAAO epPCR library contained an average of 1.4 amino 
acid substitutions per variant. Amino acid exchanges to all chemical groupings were 
observed and the mutational profile compared well with the ideal chemical 
distribution with the exception of a reduced percentage of exchanges to aromatic 
residues. A MAP analysis of the gene showed that the library is likely to target an 
average of between 5.5 and 7.5 amino acids per residue (28.9 - 39.5 % of the natural 
diversity). The number of amino acid exchanges which may lead to enzyme 
inactivity for structural reasons was estimated to be 12 % which is reasonably close 
to both the 'predicted' and 'non-biased' values. Any single nucleotide exchange 
method of mutagenesis will introduce some form of bias to the library generated and 
although the limitations of the RgDAAO epPCR library must be considered, the 
library is appropriate for screening for variant DAAO activity towards new 
substrates. 
2.3.3 Screening the RgDAAO epPCR library 
Using the equations described by Patrick et al., 51 the number of variants which 
should be selected in order to have a 95 % likelihood of screening 100 % of the 
possible sequences is given by Equation 1. L is the number of variants to be 
screened, the probability (Pa) is 0.95 and V is the total number of possible sequences. 
V is determined from the number of possible codons (64) and the average number of 
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nucleotide exchanges/gene (2.7). In the case of this epPCR library, V has a value of 
642.7 or 75 28 1, resulting in the number of colonies to be screened (L) of -i 069 000. 
L = -Vln(-lnP/V) 
Equation 1 - L = number of variants to be screened, P, = probability, V = total number of 
possible sequences. 
This calculated figure includes the deletions observed in the sequenced sample but 
not the 2 sequences in which empty plasmids were observed. As these account for 
10 % of the sample, the screening efforts should be increased accordingly to 
-1 176 000. With these numbers, the screen to be used for the detection of improved 
variants in random libraries must be robust and high-throughput. 
Solid-phase screen and limitations 
Initially the RgDAAO epPCR library was screened for novel activity using the HRP-
coupled solid-phase assay described in Section 1.3.3. A solid-phase screen has been 
successfully used in the Turner and other groups for detecting desired improvements 
in oxidases towards substrates of interest. (49,12)  Figure 2.15 shows an example of the 
detection of MAO-N variants with improved activity towards chiral amines. (53)  
Figure 2.15 - Detection of improved oxidase activity by solid-phase HIRP-coupled screen(53). 
The brown coloured colonies indicate oxidase activity towards the substrate screened. 
Approximately 50 000 RgDAAO epPCR variants were screened on solid-phase 
against 3-amino acid substrates. No activity was detected. This was not conclusive 
because it became evident that the solid-phase screen was not consistent or robust 
enough to screen the large numbers of colonies required. To demonstrate the problem 
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two transformations of E. coli BL21(DE3) cells were carried out, one using the 
parental RgDAAO/pPOT3 and the other using MAO-N variant/pET16b. 54 The 
transformants were grown on nitrocellulose membranes and are shown in Figure 
2.16. Membrane A contains colonies expressing RgDAAO and membrane B contains 
colonies expressing MAO-N. Both membranes were treated with an HRP assay 
mixture containing active substrate ((R)-alanine for RgDAAO and (X-methyl 
benzylamine for MAO-N). The colonies on each membrane should have developed 
colour under these conditions. All MAO-N producing colonies on membrane B 
coloured as expected. However, on membrane A many of the parental RgDAAO 
producing colonies showed no colour formation, although this should have been 
observed. This was a recurring problem with RgDAAO producing colonies in the 
solid-phase assay. Given the number of colonies required for full screening of the 
library, it was decided that this solid-phase assay was not a useful method for 
RgDAAO screening. Therefore, a new assay method was required. 
Figure 2.16 - Solid-phase HRP coupled assay. A = Transformants expressing RgDAAO, treated 
with HRP, 3,3'-DAB and (R)-alanine, B = transformants expressing MAO-N (D5) treated with 
HRP, 3,3'-DAB and a-MBA. Not all identical colonies on membrane A showed colour 
formation as observed on membrane B. 
Liquid-phase assay and validation 
Solid-phase assays only allow a qualitative evaluation of activity. In contrast, 
screening in liquid-phase is more quantifiable as colour formation is measured 
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spectrophotometrically and does not rely on detection by eye. The sensitivity, 
reproducibility, accuracy and robustness of the assay can be easily evaluated. 
As described in Section 2.1 some microorganisms cause the oxidation of the dye 
precursors 4-AAP and TBHBA in the HRP-coupled liquid phase assay in the absence 
of an externally added amino acid, which made controls impossible. Figure 2.17 
shows an example of the positive and negative controls used for liquid-phase 
screening of the RgDAAO epPCR library. The positive controls in wells 1 to 3 
contain cells transformed with RgDAAO/pPOT3 and the negative controls in wells 4 
to 6 cells contain cells transformed with pPOT3 (empty vector). All the wells contain 
HRP, 4-AAP, TBHBA and (R)-alanine. No colour formation is observed in the 
negative control wells in contrast to the positive controls. 
5 6 
Figure 2.17 - Liquid-phase HRP coupled assay. Wells 1-3 are positive controls which contain 
cells producing RgDAAO, HRP, 4-AAP, TBHBA and (R)-alanine. Wells 4-6 contain empty 
vector cells, HRP, 4-AAP, TBHBA and (R)-alanine. 
Determination of total protein concentration in cell free extracts 
In the liquid-phase assay, RgDAAO was used either as whole cells or in the form of 
CFE. Total protein concentration of CFE from different cell growths and extractions 
was estimated and compared. The methods used for determination of the total protein 
concentration of the prepared samples were UV absorbance at 260 and 280 nm and 
bicinchoninic acid (BCA) assay. The principles of these two methods are described 
in Section 3.2.4. An example of the standard curve produced when using the BCA 
assay is shown in Figure 2.18. 
57 











0 	 500 	1000 	1500 	2000 
Protein concentration (tg mL1) 
Figure 2.18 - BCA standard curve for determination of total protein concentration of CFE 
produced using BSA of known concentration. Each sample and standard was measured in 
triplicate and data points represent the mean values ± standard deviation. Background was 
removed by subtracting a control which contained no BSA. 
The values for total protein content in cell free extracts by UV spectrophotometry 
and by BCA assay were compared. Protein concentrations from various E. coli 
BL21(DE3) fermentations were determined. The results are shown in Table 2.7. 
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Table 2.7 - Comparison of total protein concentration obtained from cells containing different 
plasmids. Empty vector = pPOT3 piasmid with no gene insert. (1) and (2) represent extracts 
from different cell growths. UV absorbance was measured using a 1 in 20 dilution of the CFEs 
to measure within the linear detection range. CFE used in the BCA assay was diluted 1 in 5 to 
measure within the range of the standards 
Concentration 
UV absorbance approximation 




Empty vector (pPOT3) (1) 5.1 4.2 
Empty vector (pPOT3) (2) n/rn 4.7 
TvDAA0/pP0T3 (1) 5.7 4.9 
TvDAAO/pPOT3 (2) n/rn 4.7 
RgDAA0/pP0T3 (1) 5.3 3.9 
RgDAAO/pPOT3 (2) 5.2 4.2 
Estimating the protein concentration using UV absorbance gives higher values than 
by BCA assay. However, similar concentrations are obtained within each of the 
individual methods. 
Robustness of the liquid-phase assay 
An easily calculated parameter is the Z factor, Z'. This is a "screening window 
coefficient" described by Zhang et al. (55)  which is calculated using the average 
positive control (.t+), average negative control (.t) and the standard deviations 
obtained for each (+ and i respectively) in Equation: 
(3+ + 
Z' = 1 - 
Itc+ - 
Equation 2 - Z' = screening window coefficient, t+ and 	= averages of the positive and 
negative controls respectively, + and c = standard deviations of the positive and negative 
controls respectively. 
The Z' factor describes the separation of the distributions of the positive and negative 
controls. A Z' value of between 0.5 and 1 means that the separation band is large and 
indicates that the assay will be useful for screening. Assays showing lower Z' values 
have to be examined more carefully but can still produce meaningful results. Figure 
2.19 shows Z' calculated over the time-course of an HRP-coupled liquid-phase assay 
detecting parental RgDAAO activity against (R)-alanine as the positive control. The 
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assay was performed using CFE. Two different negative controls were used for the 
calculation, absence of substrate (blue line) or absence of enzyme (pink line). Both 
sets of data give values close to 1, confirming that the assay will be useful for 
screening purposes and that either negative control can be used. With increasing 
colour formation the Z' value improves rapidly. 
Z (no substrate) 
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Figure 2.19 - Z' calculated for an HRP-coupled assay detecting parental RgDAAO cell free 
extract (cfe) activity against (R)-alanine as the positive control. Two different negative controls 
are compared, absence of substrate (red line) and absence of enzyme (blue line). 
Light Sensitivity of Liquid-phase Assay 
The HRP substrate, 4-A-AP, used in the liquid-phase assay is light sensitive and a 
solution containing 4-AAP, TBHBA and HRP will colour pink over time when 
exposed to light. This causes an increase in the recorded absorption which must be 
subtracted as background. The wells around the edge of a 96-well plate are more 
likely to be exposed to light than those at the centre and the background response is 
not identical for each well. In addition, as the project was concerned with detecting 
novel and potentially very low activities, it was useful to allow long-term 
Ell 
RESULTS AND DISCUSSION 
development of the assay. This timescale increased the impact of background colour 
formation on the assay results. 
Three HRP-coupled assays were performed under different conditions over 15 h to 
assess the background colour formation. Three microtitre plates were prepared with 
triplicate positive (+) and negative (-) controls. The positive controls were whole 
cells expressing RgDAAO assayed against (R)-alanine and the negative controls 
were whole cells transformed with empty plasmid also assayed against (R)-alanine. 
Plate A was a normal transparent polystyrene microtitre plate which was covered 
with a transparent lid between measurements. Plate B was an identical transparent 
plate which was covered with foil while not being measured. Plate C was a black 
polystyrene microtitre plate (with transparent base to allow absorbance 
measurement) which was covered with a black polystyrene lid while not being 
measured. The absorbance at 510 nm was measured after 1, 3 and 15 hours and the 
results from each triplicate averaged. A plot of the results is shown in Figure 2.20. 
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Figure 2.20 - Light sensitivity of liquid-phase assay. Plate A = transparent plate, plate B = foil-
covered transparent plate, C = black polystyrene plate with black lid. Squares show the 
averaged absorbance of positive controls and triangles the averaged absorbance of negative 
controls. All points are shown ± 1 standard deviation. 
As expected, the positive controls all show a significantly better response than their 
respective negative controls. The standard deviation (shown by the error bars) in the 
data from the plate left open to light were much greater than in plates B and C for 
both the positive and negative controls. The increase in absorbance due to the 
influence of light was investigated by comparing the rate obtained for each negative 
control. 
The results are shown in Table 2.8 and demonstrate that the smallest background 
colour formation is given when using a black microtitre plate covered with a lid with 
a rate ofl.4x 10 3 AU.h 1 . 
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Table 2.8 - slope of the negative control response over 15 hours for plates A, B and C. Plate A = 
transparent plate, plate B = foil-covered transparent plate, C = black polystyrene plate with 
black lid. 
Plate A B I C 
AU.h' 3.2x10 3 ±2.7x10 4 2.8x10 3 ±2.2x104  11.4x10 3 ±1.5x10 4 
The Z factor was used to further investigate the impact of light exposure on the 
assay. Z' values were calculated for each of the three plates and are shown plotted 
against time in Figure 2.21. Given that Z' values above 0.5 indicate a good screening 
assay, it is clear that an uncovered transparent plate (A) is an unsuitable method for 
screening, while either a black plate and lid (C) or a foil-covered plate (B) give good 
separation of the positive and negative controls with Z' values of between 0.65 and 
0.90. This experiment also demonstrates that assays using whole cells give 
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Figure 2.21 - Sensitivity of liquid-phase assay towards light expressed by V. (A) = transparent 
plate left open to light, (B) = transparent plate covered from light and (C) = black plate with lid. 
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Linearity and detection limit of the liquid-phase assay 
The sensitivity of the HRP assay was assessed by performing a serial dilution of 
hydrogen peroxide in a microtitre plate. This assay used HRP, 4-AAP, TBHBA and 
H202, with no RgDAAO or substrate present. 
The concentration of an approximately 30 % w/v solution of H202 was determined 
by titration against KMn04 and was found to be 5.30 M (18.0 % wlw), according to 
Equation 3. 
2 Mn04 + 5 H202 + 6 H 	 2 Mn 2+ + 5 02 + 8 H20 
Equation 3 
The maximum concentration of H202 was 25 .iM which was reduced in a series of 1 
in 2 dilutions as shown in Table 2.9. The assay was repeated 8 times and the data for 
each dilution averaged. The absorbance obtained for the well containing no H202 was 
used to blank the other results which are plotted as absorbance against H202 
concentration in Figure 2.22. The plot marked (A) in this figure shows the full range 
of dilutions measured, while the plot marked (B) shows only the lowest 
concentrations. 
Table 2.9 - A serial dilution of H202 was performed to determine the detection limits of the 
cotorimetric assay. 
Position 1 23 4 5 6 7 8 9 10 11 
H202 
25.00 12.50 6.25 3.13 1.56 0.78 0.39 0.20 0.10 0.05 0.00 
(AM) 
The maximum reading on the plate reader used (Fluostar Optima) was 4.5 AU at 
510 run). Figure 2.22 (A) shows that detection of colour formation is linear up to this 
maximum which occurs at a concentration of 25 .tM H202. An R2 value (see Section 
5.7) of 1.00 was obtained for the linear regression. Figure 2.22 (B) shows only the 
data for the five lowest H202 concentrations. The linear dependence of colour 
formation on H202 concentration is maintained, with an R2 value of 0.92, and 
concentrations as low as 0.05 iM can be detected by the HRP-dye system. This 
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Figure 2.22 - Plots of averaged endpoint absorbance (minus blank) against H202 concentration 
for an assay also containing HRP, 4-AAP and TBHBA. (A) shows the full range of dilutions 
measured and (B) shows only the lowest concentrations. All data points represent mean values 
from reactions repeated 8 times and are given ± one standard deviation. 
The HRP-coupled liquid-phase assay was assessed further by performing a series of 
dilutions of both substrate ((R)-alanine) and cell free extract (from cells expressing 
RgDAAO). A liquid-handler was used to perform the dilutions. The total volume of 
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the wells was 200 p.L, the maximum concentration of CFE added was 50 % v/v (Al-
Al2) and the maximum concentration of (R)-alanine was 10 mM (Al-Hi). Figure 
2.23 shows the layout of the 96-well plate with increasing substrate concentration 
towards the top of the plate and increasing CFE volume to the right. All wells 
contained HRP, 4-AAP, TBHBA and dilutions of RgDAAO CFE and (R)-alanine 
with the exceptions of Hi-H12 (no RgDAAO CFE) and Al2-H12 (no (R)-alanine). 
Table 2.10 gives the concentrations of CFE and (R)-alanine in each well. 
[5] 
[CFE] 
Figure 2.23 - Layout of serial dilution plate used to estimate the detection limit of HRP-coupled 
liquid-phase assay. All wells contain RgDAAO CFE, HRP, 4-AA-P, TBHBA and (R)-alanine with 
the exceptions of H1-H12 (no RgDAAO CFE) and Al2-H12 (no (R)-alanine). The well numbers 
are labelled in blue. Total well volume = 200 ILL. 
Table 2.10 - Concentrations of RgDAAO CFE and (R)-alanine used in serial dilutions assay. 







A 50.0 1 10.00 
B 25.0 2 5.00 
C 12.5 3 2.50 
D 6.3 4 1.25 
E 3.1 5 0.63 
F 1.6 6 0.31 
G 0.8 7 0.16 
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The assay was performed in triplicate and measured over 50 minutes. The rate of 
change in absorbance (mAU 1)  was calculated for each well. The data were 
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averaged and are shown in Figure 2.24 as rate against the substrate concentration. 
Error bars (± one standard deviation) are shown only for 1.6 and 50 % v/v CFE. This 
figure shows that the increase in rate due to substrate concentration is approximately 
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Figure 2.24 - Liquid-phase serial dilutions assay. Data points represent mean values from 
triplicate reactions. Plot of maximum rate of change in absorbance against substrate 
concentration for various concentrations of RgDAAO CFE. (A) shows the full range of data 
68 
RESULTS AND DISCUSSION 
collected while (B) shows only the rates obtained for substrate concentrations up to 0.63 mM. 
The curves produced for 1.6 and 50 % v/v CFE are shown ± one standard deviation. CFE serial 
dilutions were made by manual pipetting and substrate dilutions by means of a liquid handler 
(Tecan Genesis). Assay mix was also added by the liquid handler. The order of addition was: 
CFE, assay mix, (R)-alanine. 
The data were also plotted in the alternative representation shown in Figure 2.25 with 
the rate plotted against CFE concentration. Error bars (± one standard deviation) are 
shown for 10.0 and 0.01 mM substrate. This figure indicates a high degree of 
inaccuracy at low CFE and high substrate concentrations within the chosen 
experimental setup. The increase in rate due to CFE concentration is linear until a 
steep decrease at around 1.6 % v/v CFE. Vm (AU 1)  should increase with 
increasing CFE concentrations. However the opposite trend was observed for 
concentrations of CFE higher than 1.6 % v/v. The highest values for V,,ax  were given 
by 0.8 to 1.6 % v/v CFE and the lowest by 50 % v/v. It was assumed that this 
decrease was caused by either protein precipitation or other CFE enzymes affecting 
either the RgDAAO system or the HRP system. Future assays were carried out with 
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Figure 2.25 - Liquid-phase serial dilutions assay. Data points represent mean values from 
triplicate reactions. Plot of maximum rate against CFE concentration for various concentrations 
of substrate. (A) shows the full range of data collected while (B) shows only the rates obtained 
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for CFE concentrations up to 3.1 %v/v. The curves produced for 10.0 and 0.01 mM (R)-alanine 
are shown ± one standard deviation. CFE serial dilutions were made by manual pipetting and 
substrate dilutions by means of a liquid handler (Tecan Genesis). Assay mix was also added by 
the liquid handler. The order of addition was: CFE, assay mix, (R)-alanine. 
The Michaelis constant (Km) is the substrate concentration at half the maximum 
velocity and should remain constant at all enzyme concentrations. Km values can be 
calculated either from Michaelis-Menten plots such as those shown in Figure 2.24 or 
from double-reciprocal (Lineweaver-Burk) plots such as those shown in Figure 2.26 
where IN has been plotted against 1/[S]. These double-reciprocal plots should 
produce a linear relationship from which Km can be determined via extrapolation to 
the intercept on the x-axis. Figure 2.26 (A) shows the double-reciprocal plot obtained 
using 50 % v/v CFE and (B), for comparison, shows that obtained using 0.8 % v/v 
CFE. 
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Figure 2.26 - Lineweaver-Burk plots for (A) 50 %vlv CFE and (B) 0.8 %v!v CFE. The inverse 
of the maximum rates (1IV, s AU-) are plotted against the inverse of substrate concentration 
(1/ISI, mM 1 ). Km can be extracted by extrapolation of the linear regression to the point where it 
intercepts the x-axis (at 1/Km). 
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The programme OriginPro 8 was used to calculate the values obtained for Km and 
Vmax from both the Michaelis-Menten and the Lineweaver-Burk plots. This was done 
for each enzyme concentration and the results of these calculations are shown in 
Table 2.11. 
Table 2.11 - Vmax and Km values calculated for various concentrations of RgDAAO against 
(R)-alanine (pH 7.6, 25 °C) using both Michaelis-Menten and Lineweaver-Burk plots. 
Michaelis-Menten Lineweaver-Burk 
ICF'El (%v/v) Vmax (mAU s) Km (mM) Vmax (mAU s') Km  (mM) 
50.00 3.30±0.32 0.10±0.03 3.44±0.11 0.10±0.01 
25.00 4.20+0.30 0.12+0.04 4.16+0.23 0.09+0.02 
12.50 5.07+0.19 0.10+0.02 4.75 +0.15 0.07+0.01 
6.25 7.58+1.46 0.22±0.16 6.22±0.32 0.11 ±0.01 
3.13 10.76±3.16 0.72±0.81 6.90±0.64 0.11 ±0.02 
1.56 9.67±4.40 0.59±0.92 6.74±0.78 0.11 ±0.02 
0.78 8.49±0.85 0.85±0.81 7.02±0.91 0.19±0.04 
As discussed, the values obtained for Vmax peak at CFE concentrations of 
approximately 1.6 to 3.1 % v/v, however the errors involved are very large at these 
lower CFE concentrations. The values obtained from the Michaelis-Menten plot give 
a maximum value for Vmax of 10.76 mAU s 1, whereas the maximum value produced 
using a Lineweaver-Burk plot is 7.02 mAU s. 
Km values calculated from the Michaelis-Menten plots range between 0.10 and 
0.85 mM but have extremely large errors attached to the higher values, which were 
obtained using the lower CFE concentrations. The values obtained using the 
Lineweaver-Burk plots range between 0.07 and 0.19 mM. The average value for Km 
determined using the Lineweaver-Burk plots was 0.11 mM. This figure differs from 
literature values for RgDAAO against (R)-alanine which range from 0.8(5®  to 
2.6 mM. 57 Both of these literature figures were calculated at pH 8.5 and 25 °C using 
purified enzyme, whereas the data described here were collected at pH 7.6, 25 °C 
using CFE. It was assumed that inaccuracies were due to the use of CFE in this 
experiment and to reduced accuracy of rate determination at low substrate 
concentrations. A substrate concentration well above Km was desired for screening 
purposes and all further assays were carried out at 10 mM (single enantiomer). 
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Summary of Liquid-phase Assay Investigations 
The Z' factor was used to show that the HRP-coupled liquid-phase assay is a good 
screening assay, using either whole cells or CFE. The detection limits were 
determined, through a series of H202 dilutions, to be 25 to <0.05 jiM with excellent 
linearity of absorbance measurement to concentration maintained between these 
points. As the stoichiometiy of amino acid oxidation to H202 formation is one to one 
(Scheme 1.15), the reaction can be monitored for conversions up to 25 tM. It should 
be noted however that the sensitivity decreases significantly when using whole cells 
as the background in this case is much higher. A series of dilutions of both (R)-
alanine and CFE using the HRP-coupled assay indicate that rate of colour formation 
increases until V,,, is reached at 0.63 mM substrate but that rate decreases at CFE 
concentrations above 1.6 % v/v. Additionally, background colour formation due to 
the light sensitivity of assay components was minimised through the use of black 
polystyrene assay plates. 
Development of high-throughput liquid-phase screen 
The biggest disadvantage of the liquid-phase assay compared with the solid-phase 
assay is screening throughput. Thousands of colonies can easily be screened in a 
single solid-phase assay experiment but this is very labour intensive in 96-well plate 
format. For example, in order to screen the estimated 1 176 000 required to cover the 
entire RgDAAO epPCR library, 12 250 96-well plates will be required. In screening 
this RgDAAO epPCR library two main steps were taken to increase throughput. A) 
An increase in the number of colonies screened per well and B) automation of the 
screening process. 
A) Growth of variant libraries in semi-solid agarose 
One method of screening in the liquid-phase would be to transfer individual colonies 
from an agar plate containing a library of RgDAAO expressing variants to a 96-well 
culture plate and grow these as liquid cultures in preparation for screening. It was 
decided instead to grow the colonies in 96-well plate format using semi-solid agarose 
(SeaPrep Agarose from Lonza). The agarose contains enough gelling strength to hold 
the colonies and provide an equal and separated growing environment for each 
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individual but is liquid enough for the grown colonies and agarose to be separated by 
centrifugation. This presents a method of growing and screening more than one 
colony per well. The screening throughput is increased, for example, from 96 to 960 
colonies per plate and the amount of substrate required is decreased. Figure 2.27 
describes the overall process. 
Grow BL2 I (DE3) 	2) Prepare glycerol 	 4) Inoculate semi- 	5) Transfer inoculated 
RgDAAO library on agar stock of BL2I (DE3) solid agarose/media agarose to deepwell 
plates or in semi solid 	library. Freeze for 	 with glycerol stock 	plates for growth. Average 
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of variants. 	 10 cfu/welL) 	 I 	-nin,,, 	I 
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cell pellets and 
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by centrifugation. 
7) Wash cell pellet 
deep well plate and freeze deepwell 
to assay plate. plate for storage. 
15) Reassay to detect 'hit' 
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Fiirthct 
analysis oI - Iiif 
variant 
Figure 2.27 - Protocol for increasing throughput of the liquid-phase assay using growth of 
colonies in semi-solid agarose. Cfu = colony forming unit. The steps 1 to 14 are described in 
more detail in the text below. 
The steps in this figure are discussed in more detail through the use of one example 
which demonstrates the method from beginning to end. 
75 
RESULTS AND DISCUSSION 
- Figure 2.27: Steps I and 2 
The RgDAAO epPCR library was used to transform the E. coli expression strain 
BL21(DE3) which was grown on agar plates and transferred to storage tubes as a 
glycerol stock. 
- Figure 2.27: Steps 3 and 4 
Prior to inoculation of the glycerol stock to semi-solid agarose two factors had to be 
determined: i) the minimum gel strength required to hold the growing colonies and 
ii) the appropriate inoculation volume of glycerol stock. 
i) In order to determine the minimum strength of agarose which would hold the 
growing colonies, three gel strengths were prepared by the method described in 
Section 3.2.3 such that the final agarose concentration in a 1 to 1 agarose/media 
mixture was 0.45, 0.5 and 0.55 % w/v. 10 mL of each preparation was transferred to 
a sample tube and inoculated with RgDAAO BL2 1 (DE3) glycerol stock. The liquid 
mixture gelled when cooled at 4 °C for 2 h and colonies formed overnight at 37 °C. 
The results are shown in Figure 2.28. Tube (A) contained 0.45 % w/v agarose and 
'trails' can be seen where the colonies have slipped through the gel matrix as they 
grew. Individual colonies were observed in tubes (B) and (C) and 0.5 % w/v agarose 
was the minimum concentration of SeaPrep agarose which held the growing colonies 
but which was still liquid enough to be removed by centrifugation. This 
concentration was used for inoculation of the glycerol stock library. 
U 
- 	!... 
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Figure 2.28 - Determination of percentage (w/v) SeaPrep Agarose required to hold growing 
colonies. A = 0.45 % w/v, B = 0.50 % w/v, C = 0.55 % w/v SeaPrep agarose. 
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ii) The appropriate volume of glycerol stock to be added to the SeaPrep agarose was 
assessed using similarly prepared glycerol stocks of parental (RgDAAO/pPOT3) 
BL21(DE3) and empty vector (pPOT3) BL21(DE3) cells. It was accepted that these 
results would represent an approximation of the library (epRgDAAO/pPOT3) 
BL21(DE3) glycerol stocks. Aliquots from one preparation of each of the three 
glycerol stocks were used in all the experiments performed. A series of dilutions 
(Table 2.12) of parental and empty vector glycerol stocks were prepared and 50 j.tL 
of each was spread onto 90 mm TSB/agar plates in triplicate. The plates were 
incubated overnight and the number of colonies which formed on each is shown in 
Table 2.12. The averaged results are also shown in the plot in Figure 2.29. 
Table 2.12 - Average numbers of colonies formed by spreading 50 piL of a series of dilutions of 
parental and empty vector glycerol stocks onto agar plates. The experiment was repeated in 
triplicate and the data shown are the mean values obtained ± one standard deviation. Samples E 
and H were measured in duplicate only. 
dilution factor 
average number 
of colonies  
RgDAAO 
A 1 x104 2581±628  
B 1x106 451±40  
C 1x108 85±12  
D 1x10'°  18±4 
Empty Vector 
E 1x104 168 8±88 
F 1x106 90±20 
C 1x108 22±7  
H 1x101° 1± 1  
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Figure 2.29 - Averaged numbers of colonies obtained by spreading 50 iL of each dilution of 
parental and empty vector working glycerol stocks onto TSB/agar plates. Data are the mean 
values obtained from triplicate measurements with the exceptions of empty vector 1x104 and 
lxlO'° dilutions which were measured in duplicate only. Each point is shown ± one standard 
deviation. 
It was decided to grow approximately 15 variant RgDAAO producing colonies in 
500 tL SeaPrep agarose per well. This number reduces the number of 96-well plates 
to be screened for full coverage of the library from 12 250 to 817. In addition, this 
figure makes the deconvolution of a 'hit' well, to find the variant(s) responsible for 
the colour change, possible on one 96-well plate. According to Equation 1, the 
number of wells (1 colony per well) required to be statistically certain of re-screening 
each variant from the hit well is 85. Using Table 2.12 as guidance, 50 mL SeaPrep 
agarose was inoculated with 250 iL of a lx 106  dilution of RgDAAO glycerol stock. 
Positive and negative controls (cells producing parental RgDAAO and cells 
containing empty vector respectively) were prepared at the same time. 
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- Figure 2.27: Step 5 
The inoculated agarose was transferred to a 1.1 mL plate, referred to as growth plate 
1 in Figure 2.27, by multi-channel pipette (500 pL per well). The colonies were 
grown and protein production induced as described in Section 3.2.3. The number of 
colonies observed per well was between 10 and 20 and the approximate overall 
numbers in each plate were monitored. Positive and negative controls were prepared 
similarly on a separate 1.1 mL plate. 
- Figure 2.27: Steps 6 and 7 
The semi-solid agarose was removed from the cells by centrifugation and the 
resulting cell pellets were washed with buffer (Section 3.2.3) and stored in 96-well 
format in the growth plates at -20 °C. 
B) Automated screening process 
Screening throughput was increased further through the use of a robot to perform the 
assay and measure the absorbance. 
- Figure 2.27: Steps 8 and 9 
A Tecan Genesis Workstation 150 was used to perform a similar protocol to that 
described in Section 2. 1, using the following protocol:- 
Resuspend the pelleted cells in growth plate 1. 
Transfer cells, assay mix (HRP, 4-AAP and TBHBA) and substrate to black 
polystyrene, 96-well assay plates (assay plate 1 in Figure 2.27). 
Move assay plate 1 to a plate reader and measure absorbance at 510 nm 
(time = 0). 
Lid assay plate 1 and move to a storage carousel for room temperature 
incubation. 
Move assay plate 1 to a plate reader and remeasure absorbance at 510 nm 
(time = 24 h). 
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The carousel on which the plates were stored allowed up to 50 plates to be assayed 
during each screening set. To screen the 817 plates required to cover the full library, 
17 sets of 48 plates each were needed. The RgDAAO epPCR library was screened 
against 20 mM (rac)- 3-homophenyla1anine. 
- Figure 2.27 Step 10: Data analysis 
The absorbance measurement taken at time 0 was subtracted from the measurement 
taken at 24 h (LAbs). The data obtained for each plate were viewed as shown in 
Figure 2.30. The LAbs calculated for each well was plotted against the well location 
on the plate. The column numbers (1-12) are shown on the x-axis and the rows (A-H) 
are denoted as shown in the legend. For example, the point marked with a red circle 
shows the LAbs value for well Dl of this particular plate. 
Z' was calculated using positive and negative controls (in triplicate) which were 
treated in exactly the same manner as the library plates and resulted in values of 
between 0.4 and 0.7. This range indicates that this method of growth and assaying 
reduces the accuracy of the assay but is still within the regions of a useful screening 
assay. 
80 






















U 	 U * 	 U  
. 	 V 
A 	 •is:i:. 
A 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Column Number 
Figure 2.30 - Screening results for one plate of the RgDAAO epPCR library. The change in 
absorbance over 24 h (AAbs) for each of the 96 wells is plotted against well location. Column 
number (1-12) is shown on the x-axis and rows (A-H) are identified by the markings in the 
legend. 
-Figure 2.27: Steps 11 to 14 
'Hit' wells such as Dl in Figure 2.30, contained between 10 and 20 colonies and 
these had to be deconvoluted to select the active variant. A sample (50 tL) was 
removed from well Dl of growth plate 1 and streaked onto a TSB/agar plate which 
was incubated overnight at 37 °C. 88 colonies were picked and transferred to liquid 
media in individual wells of a 96 x 1.1 mL plate (growth plate 2 in Figure 2.27) for 
growth and induction of protein expression. 
- Figure 2.27: Step 15 
The resulting cell pellets were resuspended and transferred to an assay plate (assay 
plate 2 in Figure 2.27). A re-assay was performed, using 3-homophenylalathne as 
substrate with the aim of identifying the active variant from plate 1, well Dl. The 
data from assay plate 2 were handled in the same way as for plate 1 and the results 
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are shown in Figure 2.31. Two wells on assay plate 2 showed some colour formation, 
C9 and Gb. The change in absorbance measured for well E9 was also high but no 
colour formation was visible by eye. The cell pellet in this well was not fully 
resuspended and was not selected for further analysis as the higher absorbance 
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Figure 2.31 - Results for assay plate 2 (reassay of individual variants from plate 1, well Dl). The 
change in absorbance over 24 h (AAbs) for each of the 96 wells is plotted against well location. 
Column number (1-12) is shown on the x-axis and rows (A-H) are identified by the markings in 
the legend. 
Cells variants designated C9 and GlO were recultured in 50 mL volumes. Parental 
RgDAAO and cells containing empty vector were prepared similarly. A whole cell 
HRP-coupled assay was performed with the aim of comparing the activity of parental 
RgDAAO with C9 and Gb. The substrates assayed were (R)-alanine, (rac)-j3-
phenylalanine and (rac)-3-homophenylalanine. The layout of the plate is shown in 
Figure 2.32 and the contents of each well are explained in the legend. Two negative 
controls were included, (i) cells containing empty vector were tested against each 
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RESULTS AND DISCUSSION 
assay was performed in triplicate and repeated with separately prepared cell cultures. 
Both C9 and GlO retained activity towards (R)-alanine and GlO appeared to have 
increased activity towards both (rac)-J3-homophenylalariine and (rac)-13-
phenylalanine with respect to parental RgDAAO activity. 
Parental 	Empty 	Variant 	Variant 
RgDAAO vector C9 	('110 
1 2 3 4 5 6 7 8 9 10 11 12 
Figure 2.32 - Whole cell assay in triplicate. Each well contains HRP, 4-AAP and TBHBA. 
Columns 1-3 contain cells expressing parental RgDAAO, columns 4-6 cells transformed with 
empty vector, columns 7-9 cells expressing C9 and columns 10-12 cells expressing Gb. The 
substrates used were (R)-alanine (10 mM, rows A and E), (rac)-fi-phenylalanine ((rac)-f3-Pheala, 
20 mM, rows B and F) and (rac)-13-homophenylalanine ((rac)-J3-h-Pheala, 20 mM, rows C and 
G). Rows D and H contained no substrate and the volume was adjusted in these wells with 
water. Rows E-H are a control duplicate of rows A-D using separately cultured cells. 
The variants were investigated further using CFE obtained from cell cultures 
expressing parental RgDAAO and the GlO and C9 variants. Extracts were also 
obtained from cells which contained empty vector. These were assayed using the 
HRP-coupled assay against the substrates (rac)-J3-phenylalanine and (rac)-1 3-
homophenylalanine. The assay was performed in triplicate and Figure 2.33 shows the 
averaged absorbances measured over a period of 11.5 h. These plots show that the 
increase in absorbance for both C9 and GlO with each of the substrates is similar to 
that for parental RgDAAO but that in both cases this is greater than for the extracts 
from cells containing empty vector. Table 2.13 presents the rate of change in 
absorbance for each and confirms that the activities of C9 and GlO are similar to 
parental RgDAAO. The rates obtained using (rac)--homophenylalathne as substrate 
are between 1.5 and 2.0 times greater than for (rac)-3-phenylalanine in all three 
cases. 
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The genes producing C9 and G 1 were sequenced and both proved to be the parental 
RgDAAO gene. This highlights the problem of attempting to detect small 
improvements in activity towards a substrate for which the parental enzyme has little 
or no activity. Absorbance values are likely to be close to the background levels and 
are easily misinterpreted. 
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Figure 2.33 - Plots of absorbance against time for RgDAAO, Gb, C9 and empty vector CFE 
assays. Each well contained CFE, HRP, 4-AAP, TBHBA and substrate (20 mM). (A) Substrate 
= (rac)-2, (B) substrate = (rac)-1. The assays were performed in triplicate and the averaged data 
is shown ± one standard deviation. 
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Table 2.13 - Comparison of parental RgDAAO and variants using CFE HRP-coupled assay. 









(rac)-2 1.8x10 2 ±2.6x10 4 1.8x10 2 ±6.4x10 4 1.8x10 2 ±3.1x10 4 9.2x10 3  ± 8.9x10 4 
(rac)-1 1.2x10 2 ± 1.9x10 3 1.0x10 2 ±3.6x10 3 8.9x10 3 ±5.4x10 3 6.9x10 3 ± 1.3x10 3 
To confirm (rac)-13-homophenylalanine oxidation by HPLC analysis, conversion of 
at least 5 % is required. The observed rate of 8.8x10 3 AU h' (measured rate less 
empty vector rate) relates to a conversion of 5.1x10 5 mM h 1 (see Figure 2.22) or 
2.4x10 3  mM over 48 hours. This is just 0.02 % conversion and will not be 
accurately measurable by HPLC. 
Approximately 72 000 colonies (50 plates) were screened using this liquid-phase 
assay and no activity resulting in colour formation sufficiently above the background 
activity was observed towards the tested substrates. The combined coverage of the 
liquid and solid-phase screening performed represents 10 % of the desired screening 
number (in order to be 95 % certain of viewing 100 % of the variants, see Equation 
1). However, given the difficulty of detecting any improvement in RgDAAO activity 
towards substrates for which there is little or no parental activity it was decided to 
attempt a more directed approach and to select specific sites for saturation 
mutagenesis so that the screening efforts could be reduced. 
2.3.4 Conclusions 
Two random DAAO libraries were generated, a TvDAAO library through 
propagation in the imitator strain XL 1-Red and an RgDAAO library by epPCR. The 
TvDAAO library was found to have a mutation in the start codon in at least 18 of the 
20 genes sequenced and no other observable mutations. This library and method 
were therefore not considered for further work. The 20 genes sequenced from the 
RgDAAO library indicated 2.7 nucleotide exchanges per gene which yielded a 
similar amino acid exchange profile to that which was predicted by a MAP analysis 
of the RgDAAO gene using a similar epPCR method. 
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It was calculated that 1176 000 colonies should be screened in order to be 95 % 
certain of covering 100 % of the library members. Although screening for improved 
variants on solid-phase is an established and powerful technique, the HRP-coupled 
solid-phase assay used in this work did not prove to be robust enough to screen this 
number of variants. An HRP-coupled liquid-phase assay was therefore investigated. 
This assay demonstrated good separation between the distributions of the positive 
and negative controls, giving a Z factor close to 1, and could therefore be considered 
a good screening assay. The detection limits for H202 were found to be between 25 
and 0.05 tM with good linearity of absorbance measurements between these two 
points. A serial dilution of (R)-alanine showed that Vmax was reached at 0.63 mM and 
Km was estimated to be approximately 0.03 mM, although literature values are in the 
range 0.8 to 2.6 mM. Screening assays were carried out at 10 mM substrate 
concentration with the aim of assaying at a concentration above the Km for various 
substrates. A similar set of dilutions of RgDAAO CFE showed that the rate of colour 
formation decreased at concentrations above 1.6 % v/v and therefore concentrations 
no greater than 5.0 % v/v CFE were used in further assays. It was also shown that 
background colour formation was minimised through the use of black polystyrene 
assay plates. 
A method was developed for screening of the library in liquid-phase in 96-well plate 
format. Throughput was increased by increasing the number of colonies which could 
be screened in each well through growth of the variants in semi-solid agarose. This 
resulted in a reduction of the number of plates to be screened from 12 250 to 817. 
Further increases in throughput were made through automation of the assay process 
using a robot for resuspension of the cells, transfer of cells, assay mixture and 
substrate to the assay plate and measurement absorbance at 0 and 24 h. 
Although this methodology did improve the screening rate, the precision and 
sensitivity of the assay was reduced and detecting small improvements towards 
substrates for which parental RgDAAO had little or no native activity was found to 
be extremely difficult. In total approximately 122 000 variants were screened by 
either solid or liquid-phase assay and although this was only 10 % of the desired 
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screening number, it was decided that a more useful approach may be to dramatically 
reduce the library size required for screening by focussing on selected active site 
residues. 
As no improvements in RgDAAO activity towards the two 3-amino acid substrates 
screened were observed in the epPCR library, it was considered that evolution of 
activity towards these substrates may not be feasible. In a-amino acids the carboxyl 
group and the amino group are adjacent to one another. In the RgDAAO active site 
the carboxyl group is involved in binding to the active site(26) and the amino group 
is then in good alignment with the flavin N5 in order for hydride transfer to occur. In 
13-amino acids, the presence of the methylene group between these functionalities 
will alter the ability of the bound substrate to be in correct alignment with the flavin 
to allow hydride transfer to occur. Therefore, in conjunction with reducing the library 
size by selecting active site residues, the substrates to be screened were broadened to 
include a-amino acids with the aim of producing an overview of the beneficial and 
deleterious amino acid exchanges at the selected sites towards a range of amino acid 
substrates. 
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2.4 SATURATION MUTAGENESIS OF PARENTAL RHODOTORULA 
GRACILIS D-AMINO ACID OXIDASE 
Saturation mutagenesis at selected residues in the active site of RgDAAO was 
performed in order to reduce the size of the variant library which required to be 
screened. In addition, the substrate scope was broadened to include non-
proteinogenic a-amino acids with the aim of producing an overview of the beneficial 
and deleterious amino acid exchanges at selected active site residues towards a range 
of amino acid substrates. 
2.4.1 Selection of key residues for saturation mutagenesis 
The crystal structure of RgDAAO in complex with (R)-alanine 4 was obtained from 
the RCSB Protein Data Bank (PDB ID code icOp). (S)-3-phenyla1anine was 
superimposed onto (R)-alanine by overlaying the C(1)-C(2)-N bonds in (R)-alanine 
with the C(2)-C(3)-N bonds in the 13-amino acid, as shown in Figure 2.34. 
NH2 NH2 0 
)0H 
ROH 
(R)lanine p-amino acid analogue 
Figure 2.34— n-amino acids were docked into the active site of the RgDAAO crystal structure by 
overlaying the bonds shown in red. 
The amino acid residues closest to the substrate are shown in Figure 2.35. (A) shows 
the original structure with co-crystallised (R)-alanine in the active site and (B) shows 
the same structure with (5)-13-phenylalanine superimposed in place of (R)-alanine. In 
these representations, Y223, Y238 and R285, the 3 active site residues conserved in 
all DAAOs, are shown on the left of each picture. Single-site saturation libraries 
were prepared at two of these three residues (Y238 and R285, coloured green and 
blue respectively). Two further single-site saturation libraries were created at the 
active site residues F58 (red) and M213 (pink) which can be seen to the right of each 
picture in Figure 2.35. 
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Figure 2.35 - RgDAAO crystal structure, (4  PDB ID code icOp. (A) co-crystallised with (R)-
alanine, (B) (5)-1. Residue colour code: light blue = N54, red = F58, pink = M213, orange = 
Y223, green = Y238, blue = R285, purple = S335, brown = Q339. The flavin molecule is shown in 
yellow. Y223, Y238 and R285 are conserved residues. Y223, Y238, M213 and F58 were selected 
for single-site saturation mutagenesis. 
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Given an appropriate range of substrates (towards which RgDAAO shows good to 
low activity) saturation mutagenesis at this selection of residues will allow study of 
the effect of modifications around the active site, at both conserved and non-
conserved residues. The substrates selected for screening of the libraries will be 
discussed separately for each library. 
2.4.2 Preparation of saturation mutagenesis libraries 
Fresh plasmid DNA (RgDAAO/pPOT3) was prepared from TOP 10 E. coli cells and 
used in a saturation mutagenesis PCR (Section 3.2.2). The primers for this PCR 
contained a degenerate NNS codon at the site of interest (Section 5.2.3). N refers to 
any of the four DNA nucleotides and S to either a G or a C. NNS is therefore 
shorthand for the degenerate codon (A/T/G/C)(AIT/G/C)(G/C). The single letter 
nucleotide codes are shown in Section 5.6. Table 2.14 shows the genetic code 
(compare with Table 1.1) with those codons containing an A or a T at the third 
position removed. It can be seen that NNS degeneracy gives access to 32 codons 
covering all 20 amino acids. 
Table 2.14 - Codons provided by the degenerate codon NNS. The amino acid residues encoded 
have been arbitrarily numbered (1-20) for clarity. Ter = terminator codon. 
\Pos 2 
T C A G 
Pos 	I 
TTC F (1) TCC S(6) TAC Y (10) TGC C (17) 
T 
TTG L (2) TCG S(6) TAG Ter TGG W (18) 
CTC L(2) CCC P(7) CAC H(11) CGC R(19) 
CTG L (2) CCG P (7) CAG Q (12) CGG R (19) 
ATC 1(3) ACC T (8) AAC N (13) AGC S (6) 
A 
ATG M(4) ACG T(8) AAG K(14) AGG R(19) 
G 
GTC V (5) GCC A (9) GAC D (iS) GGC G (2O 
GTG V(5) GCG A(9) GAG E(16) 
Parental DNA was removed from the PCR products as described in Section 3.2.2 and 
the digested products were used for the transformation of XL1-Blue E. coli. Several 
transformations resulted in the colony numbers for each library shown in Table 2.15. 
According to Equation 1'(51)  the number of variants which should be screened in 
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order to ensure 99 % certainty of covering 100 % of the possible variants is 260. The 
numbers of colonies obtained were therefore sufficient to cover each library in its 
entirety apart from the Y238 library. Y238 RgDAAO colonies were difficult to 
produce and, as this mutagenesis site was at a conserved residue, it was decided that 
an initial screening of the 180 variants would be made prior to deciding whether to 
generate more colonies. 
Table 2.15 - Number of colonies obtained for each single site saturation mutagenesis library. 





2.4.3 Verification of RgDAAO saturation mutagenesis libraries 
Ten XL 1-Blue colonies from each library were cultured overnight and the plasmid 
DNA extracted from these. The plasmid DNA was sequenced by MWG Biotech, 
Germany, using sequencing primers shown in Appendix 5.2.1. The results are shown 
in Table 2.16. 
Table 2.16 - RgDAAO saturation mutagenesis results. 
Position 1 (N) Position 2 (N) Position 3 (S) Copies Amino acid residue 
Codon at amino acid position 58. Parent = TCC, Phe. 
T T G 3 Leu 
T A C 1 Tyr 
C A G 1 GIn 
C G G I Arg 
A A C 1 Asn 
A C G 1 Thr 
G T C 1 Val 
G T G 1 Val 
Codon at amino acid position 213. Parent = ATG, Met. 
T T G 1 Leu 
T G G 1 Trp 
C T C 3 Leu 
92 
RESULTS AND DISCUSSION 
Position 1 (N) Position 2 (N) Position 3 (S) Copies Amino acid residue 
A C C 1 Thr 
A G G I Arg 
G T G I Val 
G T C 1 Val 
G A C I His 
Codon at amino acid position 238. Parent = TAC, Tyr. 
T T G I Leu 
T C C 3 Ser 
C T G I Leu 
C G C I Arg 
A C G 1 Thr 
A A G 3 Lys 
Codon at amino acid position 285. Parent = CGA, Arg. 
T C C I Ser 
T C G I Ser 
T A G 2 Ter 
T G C I Cys 
C A C I His 
C T G 1 Leu 
A T G 1 Met 
A A C 1 Asn 
G G C 1 Gly 
With the exception of saturation library Y238, the degenerate NNS codon designed 
into the primers for the saturation mutagenesis reaction provided the expected 
distribution of nucleotide exchanges in the sequenced colonies. Each of the 4 
nucleotides can be found at positions 1 and 2 of the codon and a G or a C is seen at 
position 3. It was therefore statistically likely that the F58, M213 and R285 libraries 
contained all possible combinations of NNS and therefore the 32 available codons 
encoding all 20 possible amino acid residues, at the desired positions. In the 
sequenced sample of the Y238 library the nucleotide G was not observed at position 
1 where it is part of the code for Val, Ala, Asp, Glu and Gly. However, as mentioned 
above, it was decided to review this library following the outcome of an initial 
screen. 
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2.4.4 Growth and expression of RgDAAO saturation mutagenesis variants 
The libraries were transferred from XL1-Blue E. coil to BL21(DE3) E. coil for 
expression of protein by the method described in Section 3.2.2. The BL21(DE3) 
colonies were grown on agar plates as shown in (i) of Figure 2.36 which describes 
the procedure for the transfer of variant libraries from agar plates to 96-well plate 
format. A detailed description can be found in Section 3.2.3. 
(i) Library variants on agar 





Figure 2.36 - Protocol for transfer of RgDAAO saturation mutagenesis variants from agar plate 
to 96-well plate format. (i) BL21(DE3) cells containing variant RgDAAO plasmid were cultured 
on agar plates. (ii) Individual variant colonies were picked and inoculated to 96 well, 2.2 mL 
master plates and cultured overnight. (iii) The overnight cultures were inoculated to copy plates. 
Protein expression was induced during growth in these plates and the cells were pelleted and 
resuspended in buffer. (iv) The resuspended cells were transferred to assay plates (one plate for 
each substrate tested). The master plate cultures were pelleted and glycerol stocks of these were 
prepared for storage and future use. 
The layout of the master and copy plates is shown in Figure 2.37. Positive, negative 
and blank controls were included. The positive and negative controls were 
individually picked BL21(DE3) colonies containing parental RgDAAO plasmid and 
empty plasmid (no gene insert) respectively. Blank wells contained media but were 
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not inoculated with a colony. A diagonal of blank wells starting at Al was created to 
provide a check for any cross-contamination between the wells during growth and 
transfer to the copy plates. Some cross-contamination was observed in the blank 
wells when media volumes of 1 mL were used for growth of the cultures in the 
master and copy plates. This problem could be solved by reduction to 800 PLL media 
volume. Six master plates were produced from the RgDAAO F58 library and 5 from 
each of the other libraries. This represents 480 variants from the F58 library and 400 
from each of the other libraries. These numbers ensure adequate over-sampling of 
each variant library. 









Figure 2.37 - Layout of master plate for saturation mutagenesis libraries. B= blank, N = 
negative control (cells containing empty plasmid), P = positive control (cells containing parental 
plasmid) and v = RgDAAO variant. 
To check for consistent growth in the copy plates, the relative 0D600 values of the 
resulting cultures were compared. Figure 2.38 shows the data for a single plate from 
the RgDAAO F58 library which indicates less growth in the wells to the top left of 
the plate. The average 0D600 was 1.4 with a standard deviation across the plate of 
0.1. Maximum observed 0D600 divided by minimum observed 0D600 gave a value of 
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Figure 2.38 - Saturation mutagenesis plate layout for growth and expression. P = positive 
control (RgDAAO/pPOT3), N = negative control (pPOT3), B = blank. Colours relate to final 
0D600 values. 
2.4.5 Process for screening of RgDAAO saturation mutagenesis variants 
The assay plates were direct transfers from the copy plate but additionally, cells 
expressing parental RgDAAO from wells 12A and 12B were added to wells 12G and 
12H which had been blank in the copy plate. Two sets of assay mix were prepared, 
both containing HRP, 4-AAP and TBHBA. The substrate to be assayed (test 
substrate) was added to one of these and control substrate ((R)-serine unless 
otherwise mentioned) was added to the other. Assay mix containing test substrate 
was added to all wells in columns 1-1 1 and to wells 12G-H. The control substrate 
assay mix was added to wells 12A-F. The final concentration of substrate in each 
well was 10 mM single enantiomer or 20 mM racemate. Figure 2.39 shows the 
layout of the assay plates. The positive controls (parental RgDAAO assayed against 
(R)-serine) are boxed in red, the negative controls (empty vector assayed against (R)-
serine) are boxed in blue and the parental comparison wells (parental RgDAAO 
assayed against test substrate) are boxed in green. 
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1 2 3 4 5 6 7 8 9 1011 12 
Figure 2.39 - Example of an F58 library plate assayed against (R)-alanine. The positive controls 
(parental RgDAAO assayed against (R)-serine) are boxed in red, the negative controls (empty 
vector cells assayed against (R)-serine) are boxed in blue and wells containing parental 
RgDAAO assayed against the test substrate are boxed in green. The blank wells IA to 7G are 
clearly visible (811 was inoculated with a variant in this example). The remaining blank wells are 
the result of inactive variants. 
Following addition of assay mix and substrate, the plate was immediately transferred 
to a plate reader and the absorbance at 510 rim was recorded. The timescales over 
which further measurements were taken are discussed below. This process was 
repeated for each substrate. 
Substrate selection for screening of the RgDAAO F58 saturation mutagenesis library 
Substrates were chosen for screening of the saturation mutagenesis libraries with the 
aim of detecting improved or novel oxidase activity but also with the purpose of 
revealing the beneficial and deleterious effects of substitutions at the selected 
residues. In order to develop a parental profile, substrates towards which RgDAAO 
showed a range of activities, from good to poor, were required. The substrate panel 
therefore included known a-amino acid substrates, non-proteinogenic a-amino acids 
and n-amino acids. The six RgDAAO F58 saturation library plates were screened 
against the 10 substrates shown in Table 2.17. (R)-serine was used as positive control 
because RgDAAO activity towards this substrate provides detectable colour 
development within 3 min which increases linearly over a period of approximately 
2 h. (R)-serine is therefore a suitable positive control to use alongside test substrates 
towards which the parental enzyme shows a range of activities. Parental RgDAAO 
activity towards each test substrate is shown relative to activity towards (R)-serine. 
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Certain aliphatic a-amino acids are good substrates for RgDAAO (Section 2.2.3) and 
(R)-alanine with 246 % relative activity was selected as a probe for deleterious 
exchanges. Although the parent enzyme is highly (R)-selective in the case of larger 
amino acids, low activity has been demonstrated towards (S)-alanine which was 
added to the substrate panel to highlight any changes in enantioselectivity generated 
by saturation mutagenesis. RgDAAO shows no activity towards (rac)-tert-leucine 
and this substrate was chosen as a non-proteinogenic aliphatic cc-amino acid towards 
which activity might be developed. The parent RgDAAO has a relative activity of 
54 % towards (R)-allo-threonine which was included in the substrate panel to 
determine whether saturation mutagenesis at F58 would yield improvements towards 
a substrate with medium activity. RgDAAO shows good activity towards the cyclic 
amino acid (R)-proline but much lower activity towards the cyclic non-proteinogenic 
amino acids (rac)-tetrahydroisoquinoline-3-carboxylic acid (40 %) and (R)-
pipecolinic acid (3 %). It was assumed that favourable exchanges might improve 
RgDAAO activity towards these two substrates. No RgDAAO activity has been 
detected towards 13-amino acids. As the relative activity of 4 (246 % for (R)-alanine) 
is very high, the 13-homo-analogue (rac)-3-aminobutyric acid (or 13-homoalanine) 
was included in the substrate panel. In addition, the f3-homo-analogue ((rac)-13-
homophenylalanine) and 0-isomer ((rac)-3-phenylalanine) of (rac)-phenylalanine for 
which RgDAAO has a relative activity of 130 % were added to the screen with the 
aim of detecting variant RgDAAO activity towards 13-amino acids. 
Table 2.17 - Substrates used for screening RgDAAO F58 saturation library 
Structure Name Parental activity 
(relative to (R)-serine) 
0 
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Structure Name Parental activity 
(relative to (R)-serine) 
0 	NH2 
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Description of screening method using RgDAAO F58 library master plate 6 
The libraries were prepared and screened using the above substrates. In addition, one 
plate, RgDAAO F58 library plate-6, was screened in triplicate to assess the screening 
method and data analysis. The averaged data from this plate will be used to describe 
the methods applied. 
Three copies of the plate 6 variants were grown and pelleted according to step (iii) in 
Figure 2.36. These copy plates are referred to as F58 plate-6.2, -6.3 and -6.4 and each 
was assayed against the substrates in Table 2.17. The data collected from these plates 
were used to assess the assay method and data handling. 
i) Assay duration 
The activity range of RgDAAO variants towards the test substrates varied 
significantly and the timescale over which to measure colour formation therefore had 
to be appropriately chosen. Figure 2.40 shows the average rate of colour formation 
for a selection of F58 RgDAAO master plate 6 variants towards (R)-alanine, a good 
substrate for the parental enzyme. Rates determined for wells GI to G12 from 
plates-6.2, -6.3 and -6.4 were averaged for comparison. Well G7 was a blank control 
containing no cells and well G12 contained parental RgDAAO. The remaining wells 
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Figure 2.40 - Rate of colour formation per hour for wells GI to G12 (RgDAAO F58 plates 6.2, 
6.3 and 6.4) towards the substrate (R)-alanine. The average rate of colour formation for each 
well is shown and the error is given as ± one standard deviation. 
The rates observed with these variants towards (R)-alanine demonstrate that 
measurements at several timepoints must be taken in order to capture meaningful rate 
data. A balance is required between measuring the rate of very active variants, 
detecting the rate of poorly active variants and minimising plate time in the 
spectrophotometer in order to maximise the number of plates measured. In the case 
of very active enzymes, for example, the parent G12 and variant G2, the maximum 
absorbance reading measurable by the spectrophotometer detector (4.5 AU) is 
reached within approximately 20 mm. The collection of rate data for these enzymes 
must therefore be complete within this period. However, the less active variant G4 
required an incubation period of approximately 3 h before colour formation due to 
enzyme activity could be separated from the background colour formation observed 
in well G7. The incubation time required for clear separation of activity from 
background was greater still for substrates such as (R)-pipecolinic acid towards 
which the RgDAAO P58 variants were less active. The absorbance on each plate was 
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therefore monitored over a 3 to 10 minute period at the start of the assay followed by 
two measurements taken after incubation periods of approximately 3 and 20 h. 
ii) Rate calculations 
The maximum slope for each curve over a selected number of data points was 
determined using Microsoft Excel. Figure 2.41 (A) shows the average rates obtained 
towards (R)-alanine for plates-6.2, -6.3 and 6.4 for selected wells where the rate 
calculation was made over 3, 5, 7 and 9 data points and plot (B) shows the average 
rate obtained towards (R)-pipecolinic acid for each of the wells with calculations 
made over 3, 5 and 7 data points (measurements were not taken over 9 data points for 
this substrate). The parental enzyme is very active towards (R)-alanine and poorly 
active towards (R)-pipecolinic acid. The wells shown all contained substrate and 
assay mix and included two different negative controls, well G7 which contained no 
cells and well F12 which contained empty vector cells. Well G12 contained parental 
enzyme and wells G4 and G9 contained variants displaying poor and medium 
activity towards (R)-alanine respectively. 
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Figure 2.41 - Difference in maximum rate obtained by calculation over 3, 5, 7 and 9 data points 
for the substrate (R)-alanine (A) and over 3, 5 and 7 data points for the substrate (R)-pipecolinic 
acid (B). The rates obtained for wells G4 (variant RgDAAO), G7 (blank well containing no cells) 
and G12 (parental RgDAAO) (averaged data from plates 6.2, 6.3 and 6.4) are shown for 
comparison along with the associated error of± one standard deviation. 
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Plot (A) shows the rates obtained in response to (R)-alanine. The active enzymes in 
wells G9 and G12 show that the highest rates with smallest error are obtained when 
the calculation is taken over 3 to 5 data points. Lower rates with increased error over 
a larger number of data points are due to the detection maximum for the 
spectrophotometer having been reached within this number of data points. This is 
reflected by a reduction in the R2 value calculated for each gradient. Table 2.18 
compares the R2 values of the slopes obtained for parental enzyme against (R)-
alanine and against (R)-pipecolinic acid, calculated over a range of data points. The 
'poorer' substrate (R)-pipecolinic acid stays within the linear range over the 
maximum number of data points, whereas the assay against (R)-alanine reaches the 
detector maximum and linearity decreases when the slope is calculated over the 
maximum number of data points. 
Table 2.18 - R2 values calculated from the gradients obtained for parental enzyme (well G12) 
assayed against both (R)-alanine and (R)-pipecolinic acid. n.m. = not measured. 3, 5, 7, and 9 
represent the number of data points over which the slope calculation was made. 
3 5 7 9 
(R)-pipecolinic acid 1.0 1.0 1.0 n.m. 
(R)-alanine 1.0 1.0 0.9 0.8 
Plot (B) in Figure 2.41 shows the rates calculated for the response of each selected 
well to (R)-pipecolinic acid. It should be noted that the y-axis scale in this plot is 
much lower than in plot (A). This plot demonstrates that it is not until the slope 
calculation is taken over 7 data points that the rates obtained for the active enzymes 
G9 and G12 reach higher values than for the negative control G7. The negative 
controls show an increase in absorbance due to mixing during the first 5 to 10 min of 
the assay but this increase is not continued throughout the remaining incubation time. 
In every case the mixing effect is more pronounced in wells containing no cells than 
in negative control wells containing empty vector cells. Although the effect is 
negligible when compared with active enzymes towards substrates for which they 
show reasonable activity, it becomes dominant in the case of less active variants 
towards poor substrates. The raw data for each of these wells (plate 6.3 only) is 
shown in Figure 2.42. When compared to the rate calculations shown in Figure 2.41 
(B) it can be seen that the most accurate representation of relative colour formation 
104 
RESULTS AND DISCUSSION 




















Figure 2.42 - Raw data for plate 6.3 wells G4 (variant RgDAAO), G7 (blank well containing no 
cells) and G12 (parental RgDAAO) assayed against (R)-pipecolinic acid and well F12 (empty 
vector cells) assayed against the control substrate (R)-serine. 
It was decided that the most appropriate method of calculating meaningful rate data 
for each plate was to incorporate the maximum number of data points possible prior 
to any of the wells reaching the detector maximum of 4.5 AU. Where the positive 
controls resulted in significantly higher rates than the test substrate, that is for the 
substrates towards which the parental enzyme showed no activity, the data for the 
positive control wells were considered separately (the slope was calculated using 
only the data until the absorption maximum had been reached). 
A small but continuous decrease in absorbance was observed over time for the 
substrates 	(rac)-3-phenylalanine, 	(rac)-3 -aminobutyric 	acid, 	(rac)-J3- 
homophenylalanine and (rac)-tert-leucine when in the presence of cells. The average 
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values are shown in Table 2.19. Given that the background initial absorbance 
readings of wells containing cells, assay mix and substrate is approximately 0.4 to 
0.5 AU and the background initial reading for wells containing assay mix and 
substrate only is approximately 0.1 AU, the observed decrease in absorbance may be 
due to partial cell lysis caused by the presence of toxic substrates. In order to observe 
improvements in activity towards these substrates, the rate of increase in absorbance 
due to production of hydrogen peroxide will need to be greater than the rate of 
decrease in absorbance due to eventual cell lysis. 
Table 2.19— Average rates of decrease in absorbance observed in wells containing cells and non-
active substrates. The measurements were made in triplicate and the error shown is ± one 
standard deviation. 




(rac)-3-amiriobutyric acid -0.8+0.04 
iii) Normalisation of data 
Z' values were calculated for each assay plate with the purpose of providing an 
insight into differences in performance originating from growth in copy plates-6.2, 
-6.3 or -6.4 and into the performance of each individual assay plate. These values 
were calculated using the triplicate of positive and negative controls on each assay 
plate and are shown in Table 2.20. 
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Table 2.20 - Z' factor values calculated for each assay of plate-6.2, -6.3 or -6.4. n.m. = not 
measured. 
Substrate 6.2 6.3 6.4 
(R)-alanine 0.6 0.4 0.0 
(R)-serine 0.5 0.3 n.m. 
(rac)-a/lo-threonine 0.6 0.4 0.0 
(R)-threonine 0.3 0.3 0.1 
(S)-alanine -0.7 0.3 0.2 
(R)-pipecolinic acid -0.8 0.3 0.1 
(rac)-13-homophenylalanine 0.7 0.3 0.1 
(rac)-3-aminobutyric acid -1.1 0.3 0.0 
(rac)--pheny1alanine 0.7 0.4 0.1 
(rac)-tert-leucine 0.7 0.3 0.0 
average 0.3 0.3 0.1 
As discussed in Section 1.3.3, Z' values of greater than 0.5 indicate a good assay and 
although it was demonstrated in Section 2.3.3 that this assay can provide very good 
Z' values, overall these data are poor. It was decided to investigate this further by 
analysing the positive and negative control data generated for each source. These are 















Figure 2.43 (A) 
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Figure 2.43 - Positive and negative control data collected for copy plates-6.2 (A), -6.3 (B) and 
-6.4 (C). Positive controls are parental RgDAAO and negative controls are empty vector cells. 
Both were assayed against (R)-serine. (The negative controls do not show in most of the plots.) 
Compilation of the control data provides a significant amount of information. In most 
cases the performance order of the three positive controls on each plate is Al2 and 
B12 > C12. In particular, the control well C12 performed very poorly on 3 of the 
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assay plates produced from copy plate-6.2 (see (S)-alanine, (R)-pipecolinic acid and 
(rac)-3-aminobutyric acid.). The poor performance of well C12, is seen in all three 
regrowth plates and may be due to a contamination carried forward from the master 
plate well. The literature Km for the parental enzyme towards (R)-serine is 
13.7 mM. 5 This means that, at the working concentration of 10 mM, the observed 
rate will be sensitive to any changes in substrate concentration. A systematic 
pipetting error was considered but a liquid handler was used to prepare the assay 
plates and no significant error was observed on checking the method. It was decided 
to omit data from control well C12 in all further calculations. The revised Z' values 
are shown in Table 2.21. 
Table 2.21 - Revised Z' values (following removal of C12 data). n.m. = not measured. 
Substrate 6.2 6.3 6.4 
(R)-alanine 0.8 0.8 0.3 
(R)-serine 0.6 0.8 n.m. 
(rac)-allo-threonine 0.6 0.8 0.3 
(R)-threonine 0.8 0.8 0.3 
(S)-alanine 0.7 0.8 0.4 
(R)-pipecolinic acid 0.7 0.8 0.4 
(rac)-3-homopheny1a1anine 0.8 0.8 0.4 
(rac)-3-aminobutyric acid 0.8 0.8 0.3 
(rac)-3-phenyIaIanine 0.9 0.8 0.4 
(rac)-tert-leucine 0.8 0.8 0.3 
Average 0.8 0.8 0.4 
The removal of control C12 data improves the Z' values significantly, although the 
values originating from copy plate-6.4 are still low. The information provided by the 
control data in Figure 2.43 shows that this is because the B12 wells also performed 
poorly on these plates. Despite this, B12 positive control wells were retained for data 
normalisation in order that manipulations for all plates were consistent. 
To make the data between plates comparable, the data were normalised with the 
response of the control wells for each individual plate using the normalisation 
calculation shown in Equation 4. The variation observed in rates calculated for 
different assay plates which originated from the same copy plate (6.2, 6.3 or 6.4) is 
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partly due to the duration of initial absorbance measurements taken which is identical 
for all the wells on a particular plate. N is the average rate calculated for the triplicate 
of negative controls on the assay plate and P is the average rate calculated for the 
duplicate positive controls on the plate (well C12 not used). 
rate — N 
Normalised rate =_______ 
P—N 
Equation 4 
A summary of the procedure used to assess the RgDAAO saturation mutagenesis 
libraries is shown below. 
Table 2.22 - Data handling procedure used to assess the RgDAAO saturation mutagenesis 
libraries. 
T Assess linear region for the majority of the variants on the plate and calculate the 
maximum slope within this range. 	For substrates towards which the parental 
enzyme is inactive the positive controls on the plate must be considered 
- separately. 
2 Assess control data and Z' for each plate to provide an insight into the 
performance of the controls 
3 Normalise the data using Equation 4. 
4 Compare high results for each substrate of interest. 
Substrate profiles 
The data produced using the RgDAAO F58 copy plates-6.2, -6.3 and -6.4 were 
normalised as described and the results were averaged. In order to consider the data 
for all six active substrates on a single scale plot, the data were manipulated by 
dividing the normalised rates for a particular substrate by the average normalised rate 
obtained for the parental enzyme towards that substrate. The resulting data are 
therefore shown relative to the parental activity towards each substrate which is set 
equal to 1. Therefore any number greater than one implies improved activity over 
parental activity and any number smaller than one implies that the variant showed 
lower activity towards the test substrate than the parent. This manipulation could 
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only be performed for substrates towards which the parental enzyme showed 
reasonable activity. The parental RgDAAO activities obtained towards these 
substrates are shown relative to the rate obtained towards (R)-methionine in Table 
2.23. For substrates towards which the parental enzyme showed only low activity the 
accuracy of the parental control data was not sufficient to provide meaningful 
relative rates. It was apparent from the data obtained for plate-6 that activity profiles 
for individual variants could be detected. The amino acid exchange at position 58 for 
selected variants was confirmed by gene-sequencing, and where more than one 
example of the same amino acid exchange was identified, the activity profiles were 
compared. Figure 2.44 shows the activity profiles of all the F58T, F58S, F58C, F58L 
and F581 variants sequenced from this plate. These profiles prove to be reproducible 
with the exception of well DO 1 which was shown by sequencing to be an RgDAAO 
F58L variant. In all three measurements of this well the variant performed poorly 
towards each substrate. The 0D600 values confirmed that the cells in this well had 
grown to a similar density as the rest of the wells in each of the growth plates and the 
poor response may have been due to a contamination carried to the copy wells from 
the master plate. The reproducibility is reduced in the case of less active variants 
such as F58S. 
Table 2.23 - For reference: parental RgDAAO relative activities calculated for the profiling 
substrates. Shown relative to RgDAAO activity towards (R)-methionine (1.6 mAU s 1). 
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RgDAAO F58T, F58S and F58C 
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Figure 2.44 - Substrate profiles obtained for all F58T, F58S, F58C, F58L and F581 variants 
identified on plate-6 of the RgDAAO F58 saturation mutagenesis library. Parental RgDAAO 
activity is set as one. Any number greater than one implies improved activity over parental 
activity and any number smaller than one implies that the variant showed lower activity 
towards the test substrate than the parent. 
The activity profiles obtained for each well on plate-6 (average of triplicate) were 
assessed and set into groups comprising identical or very similar profiles with the 
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aim of identifying the 20 possible activity profiles. These groupings produced the 23 
activity profiles shown in Figure 2.45. The amino acid at position 58 is known for 14 
of these profiles and variants with unknown amino acid exchanges are labelled Ui to 
U9. The reduced reproducibility observed in the activity profiles for less active 
variants means that these are more difficult to group and results in 23 observed 
profiles rather than the maximum of 20. This assumes that all possible amino acid 
exchanges were present on plate-6, which contained 88 variants. 
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 Figure 2.45 - 23 substrate profile patterns determined in F58 RgDAAO saturation mutagenesis 
library. * = well DOl not included in average. U! to U9 = unknown amino acid exchanges. 
Parental RgDAAO activity is set as one. Any number greater than one implies improved activity 
over parental activity and any number smaller than one implies that the variant showed lower 
activity towards the test substrate than the parent. 
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In Figure 2.45, the activity profiles have been ordered in relation to their activity 
towards (R)-serine. No activity improvements were observed towards the substrates 
(R)- and (S).-alanine in this set of variants(,late 6, F58 RgDAAO). 
It was observed in the variants identified by sequencing that exchanges from F58 to 
V, T, I, M, L and Q showed improved activity towards some of the substrates tested. 
However, exchanges to C, G and A led to variants with less activity than the parental 
enzyme towards most of the substrate set. Exchanges from F58 to R, N and P 
produced variants which were inactive towards all substrates tested. 
Although the F58Q variant displays improved activity towards (R)-serine and (R)-
pipecolinic acid and retains activity towards the remaining substrates, reduction of 
the residue length by one methylene group (change from glutamine to asparagine) in 
the F58N variant renders the enzyme inactive towards all the screened substrates. 
The impact of shortened residue length is also seen in the aliphatic group of residues. 
Both the F58G and F58A variants are less active than the parental enzyme towards 
the majority of substrates tested while the F58V, F581, F58L and F58M variants all 
maintain or improve activity (with the exception that F58V and F581 show reduced 
activity towards (R)-pipecolinic acid). 
The variants F58V and F581 have similar activity profiles, with 2- to 4-fold improved 
activity towards (R)-serine, (rac)-allo-threonine and (R)-threonine but reduced 
activity towards (R)-pipecolinic acid. In contrast, the F58L variant shows 2- to 4-
fold improvements in activity towards (R)-serine, (R)-threonine and (R)-pipecolinic 
acid but no change in activity towards (rac)-allo-threonine. The responses of these 
three variants (F58V , F581 and F58L) towards the stereoisomers (R)-threonine and 
(rac)-allo-threonine were compared. Improved activity towards (R)-threonine over 
the parental response is observed for all three variants but only F58V and F581 show 
improved activity towards (rac)-allo-threonine. Both residues (valine and isoleucine) 
are branched at the J3-carbon. 
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Additionally, variants with residues in position 58 that are branched at the J3-carbon 
appear to be unfavourable for activity towards (R)-pipecolinic acid. Variants F58V, 
F58T and F581 all show reduced activity towards this substrate, whereas variants 
F58M, F58L and F58Q show improved activity (between 3- to 4-fold). The F58A, 
F58G and F58S variants approximately maintain the activity observed by the 
parental enzyme towards (R)-pipecolinc acid. In contrast to these results, variant 
F58C, which might be expected to behave similarly to the F58A or F58S variants, 
shows reduced activity. 
Variant F58T has a fairly similar profile towards the substrates tested as that of the 
F58V variant and both exhibit improved activity towards the substrates (R)-serine, 
(rac)-al/o-threonine and (R)-threonine. However, exchange of one methyl group in 
the residue F58V for a hydroxyl group in residue F58T somewhat reduces these 
improvements. In addition, comparing the F58T variant with F58S shows that the 
presence of the hydroxyl group alone, with no methyl group at the 3-position of the 
residue, reduces the activity further. The F58S variant displays activity below that of 
the parental enzyme towards all of the substrates except (R)-pipecolinic acid, towards 
which the level of activity is maintained. 
2.4.6 Screening of RgDAAO saturation mutagenesis libraries 
The RgDAAO F58 saturation mutagenesis library was screened against the ten 
substrates described in Table 2.17. This set of substrates was also used for screening 
of the RgDAAO R285 library, with the exception of (rac)-tert-leucine. The Y238 
library was screened against 4 substrates; (R)- and (S)-alanine, (R)-pipecolinic acid 
and (rac)-3 -aminobutyric acid. However, the substrate set was altered to include 
more chromogenic compounds for screening of the M213 library. The purpose of 
this was to provide more straightforward HPLC analysis, should any of the variants 
be selected to perform biotransformation reactions on the compounds. The full set of 
substrates screened against RgDAAO M213 is shown in Table 2.24. 
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Table 2.24 - Substrates used for screening of RgDAAO M213 saturation mutagenesis library 
Activity (relative to (R)- 
serine, data extracted from 
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117 
RESULTS AND DISCUSSION 
The Z' values obtained for each plate assayed were calculated and are shown in 
Table 2.25. The growth in all the RgDAAO Y238 library plates was poor. This is 
reflected in the control data, and therefore in the values provided for Z'. The values 
calculated for plates F58-1.1, M213-4.1 and R285-4.1 were also poor but as these 
libraries were over-sampled and the remaining plates provided the statistical 
likelihood that every amino acid exchange would be covered, the data from these 
plates could be dismissed. The majority of the remaining Z' values are good, 
indicating that the assay has worked well on these plates. 
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Table 2.25 - Z' values obtained for each library plate. * = 1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid. n.m. = not measured. **Well  C12 positive control was removed from the Z' 
calculation for plate F58 3.1. Each library was prepared and stored on 5 or 6 microtitre plates. 
Copies of these master plates are referred to as copy plates 1.1 to 6.1. 
F58 (positive control substrate = (R)-alanine) 1.1 2.1 3.1** 4.1 5.1 6.1 
(R)-alanine -0.1 1.0 0.9 0.8 0.6 1.0 
(rac)-al/o-threonine 0.0 0.9 0.8 0.9 0.7 0.9 
(R)-threonine -0.3 0.9 0.8 0.9 0.7 0.8 
(S)-alanine 0.0 1.0 1.0 0.9 0.6 0.9 
(R)-pipecolinic acid -0.1 0.9 -0.1 0.8 0.7 0.8 
(rac)tiq* -0.1 0.9 1.0 0.8 0.6 1.0 
(rac)-3-aminobutyric acid -0.1 0.8 0.8 0.8 0.8 0.9 
(rac)-13-homophenylalanine 0.0 1.0 0.8 1.0 0.6 1.0 
(rac)-f3-phenylalanine 0.0 n.m. 0.6 0.7 0.7 0.9 
(R)-tert-Ieucine -0.3 0.9 0.9 0.7 0.6 0.9 
R285 (positive control substrate = (R)-serine) 1.1 2.1 3.1 4.1 5.1 6.1 
(R)-alanine 0.7 0.8 0.9 0.8 0.4 0.9 
(rac)-allo-threonine 1.0 0.3 0.8 -0.3 0.6 0.6 
(R)-threonine 0.4 n.m 0.3 -2.1 0.4 0.2 
(S)-alanine 0.8 0.7 0.9 0.9 0.7 0.5 
(R)-pipecolinic acid 0.6 0.4 0.9 0.0 0.7 0.6 
(rac)tiq* 0.3 0.5 0.8 -0.1 0.5 0.6 
(rac)-3-aminobutyric acid 0.5 0.9 0.0 0.2 0.4 0.4 
(rac)-3-homopheny1aIanine 0.5 0.7 0.6 -0.6 1.0 0.6 
(rac)--pheny1aIanine 0.7 0.8 0.7 -1.6 0.6 -0.3 
M213 (positive control substrate = (R)-serine) 1.1 2.1 3.1 4.1 5.1 
(rac)tiq* 0.8 0.5 0.6 -1.0 0.8 
(rac)-f3-methylphenylalanine 0.7 0.8 0.3 -1.0 0.6 
(rac)-phenylalanine 0.8 0.4 0.3 -0.9 0.7 
(rac)-3-pyridy1alanine 0.9 0.5 0.4 -2.2 0.8 
(R)-serine 0.6 0.2 0.9 -0.8 1.0 
(rac)-homophenylalanine 0.4 0.1 0.7 -1.4 0.6 
(rac)-3-aminobutyric acid 0.7 0.6 0.9 -1.5 0.7 
(rac)-13-homophenylalanine 0.6 0.4 0.0 -2.4 0.8 
(rac)-fl-phenylalanine 0.8 0.8 0.7 -0.2 0.8 
Y238 (positive control substrate = (R)-serine) 1.1 2.1 3.1 4.1 5.1 
(R)-alanine 0.6 -0.1 -0.6 0.5 0.4 
(5)-alanine 0.0 -0.4 -0.8 -2.6 -0.1 
(R)-pipecolinic acid 0.8 0.5 -0.9 -0.6 0.4 
(rac)-3-aminobutyric acid 0.7 0.6 -0.6 -0.5 0.3 
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The analysis procedure described in Table 2.22 was used to assess the RgDAAO 
F58, M213, Y238 and R285 libraries. In the case of these single measurements the 
profiles were not reproducible between plates from the same library, although similar 
profiles could be identified within the same plate. The profiles were calculated for 
the 10 highest normalised rates on each library plate towards each substrate and these 
are recorded in the Appendix (Section 5.9). 
In several cases the profiles display very high rates for a particular substrate or 
substrates. An example of this is shown by comparing the profiles produced from 
library plates 2.1 and 3.1 from the RgDAAO F58 library. These are shown in Figure 
2.46 where activity profiles for variants with the highest normalised rates towards 
























Figure 2.46 - Activity profiles for variants producing the highest rates towards (rac)-aio-
threonine from saturation mutagenesis library RgDAAO F58 identified on plates-2.1 and -3.1. 
Parental RgDAAO activity is set as one. Any number greater than one implies improved activity 
over parental activity and any number smaller than one implies that the variant showed lower 
activity towards the test substrate than the parent. Tiq = 1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid, Pip = pipecolinic acid. 
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Plate F58 3.1 in Figure 2.46 shows that exceptionally high activity data were 
observed towards (rac)-allo-tbreonine in this case. These are in contrast to the rate 
improvements seen for the plate-2.1 variants which produce data approximately a 
factor of 3 lower than the variants on plate 3.1. 
A reason for this can be seen in the normalised rates obtained for the parental 
controls (wells G12 and H12 on each plate which contained assay mix, test substrate 
and cells expressing parental RgDAAO). For example, Figure 2.46 shows high 
improvements of the plate-3.1 variants towards (R)-threonine. However, Figure 2.47 
shows that low normalised rates were obtained for parental control wells G12 and 
H12 toward (R)-threonine on this plate compared to the same wells on plate-2.1. 
This results in much higher apparent rate enhancements towards (R)-threonine being 
displayed by all the active variants on plate-3.1 than observed for the variants on the 
other RgDAAO F58 library plates (although F58 plate 6.1 variants also display high 
results towards this substrate for the same reason). 
1.4x10 2 
1.2x10 2 
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Figure 2.47 - Normalised rates for the parental control wells (assay mix, (S)-alanine and cells 
expressing parental RgDAAO) for plates 2.1 and 3.1 of the RgDAAO F58 saturation 
mutagenesis library. 
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Although these factors describe limitations of this liquid-phase assay method, the 
problems can easily be identified by assessing the data. This is a significant 
advantage over solid-phase screening which allows only a visual comparison of the 
responses of the positive and parental controls with those of the variants. In addition, 
although the limitations make it difficult to identify identical profiles on two 
different assay plates, similarities can be identified within the activity profiles on a 
single assay plate. Similar activity profiles can be identified on the plates shown in 
Figure 2.46, for example the profiles for variants in wells A08, B09 and H04 of 
plate-2.l. Figure 2.48 shows the profiles of the ten RgDAAO F58 variants displaying 
the highest activity towards (rac)-allo-threonine from plate 6.1. Gene-sequencing 
confirmed that the similar activity profiles identified for the variants in wells A09, 
H05 and G02 were all from RgDAAO F581 variants. (The high activity 
improvements shown by some variants towards (R)-threonine are exaggerated due to 



















Figure 2.48 - Substrate profiles for variants producing highest rates towards (rac)-aIlo-
threonine from saturation mutagenesis library RgDAAO F58 plate-6.1. Parental RgDAAO 
activity is set as one. Any number greater than one implies improved activity over parental 
activity and any number smaller than one implies that the variant showed lower activity 
towards the test substrate than the parent. Tiq = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid, Pip = pipecolinic acid. 
The activity profiles were also useful for assessing the substrates towards which 
parental RgDAAO showed no activity. The profiles for the 10 variants producing the 
highest normalised rates on each plate towards each of these substrates were 
assessed. Plates-2.1 and 3.1 from the RgDAAO F58 library are again used as an 
example in Figure 2.49, this time with the activity profiles of the variants displaying 
the highest activities towards (rac)-J3-homophenylalanine. It can be seen that blank 
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wells (containing no cells and marked *) are listed within the top 10 results for both 
these plates. The top results for plate 3.1 also include parental RgDAAO (well 1112). 
It was expected that by viewing the activity profiles of these highest results, similar 
profiles would be identified in cases where more than one example of the responsible 
variant was present on the plate, thus confirming the improved activity. On plate 2.1 
the variants in wells B03 and E08 showed apparently similar profiles and on plate 3.1 



























Figure 2.49 - Substrate profiles for variants producing highest rates towards (rac)-J3-
homophenylalanine from saturation mutagenesis library RgDAAO F58 plates-1.1 and -2.1. 
Parental RgDAAO activity is set as one. Any number greater than one implies improved activity 
over parental activity and any number smaller than one implies that the variant showed lower 
activity towards the test substrate than the parent. Tiq = 1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid, Pip = pipecolinic acid, * = blank well. 
The rates for these 5 variants range from 5.0x10 7 to 1.4x10 6 AU s 1. According to 
Figure 2.22 this relates to conversion of between 0.5 and 1.4 tM over 48 h. These 
conversion rates cannot be confirmed using HPLC as the error associated with the 
method to be used, where the oxidation is assumed to be entirely enantioselective 
and the unoxidised enantiomer is used as the internal standard, is around 5 %. 
Therefore in order to confirm assay results by HPLC, a minimum conversion of 
123 
RESULTS AND DISCUSSION 
0.5 mM is required from a 20 mM racemic solution over 24 - 48 h. This relates to a 
change in absorbance of between 1.0x10 3 and 5.0x10 4 s 1. These changes in 
absorbance are visible by eye and no such change was observed for any of the 
variants when assayed against substrates for which the parental RgDAAO was 
inactive. 
Summary of activity observed in the RgDAAO saturation mutagenesis libraries 
As discussed, the ten highest normalised rates achieved towards each substrate for 
each library plate were compiled. The curves produced from the raw absorbance data 
against time and the influence of the positive controls (assay mix, control substrate, 
cells expressing parental RgDAAO) in the normalisation calculation were assessed 
for these variants to confirm any apparent improvements. The activity profiles were 
also compared to detect i) similarities in the most active variants and ii) errors caused 
by the influence of both positive and parental controls (assay mix, test substrate, cells 
expressing parental RgDAAO). 
No new activity was observed in the libraries towards the 3-amino acids (rac)-13-
homophenylalanine and (rac)-3-pheny1alanine both of which were used to screen the 
RgDAAO F58, M213 and R285 libraries. Neither was activity found towards (rac)-
3-aminobutyric acid in any of the four libraries, nor towards (rac)-tert-leucine in the 
F58 library. No visible colour formation was observed on the assay plates for these 
substrates. The variants producing the highest normalised data were compiled and 
the activity profiles compared. In a few cases, similar activity profiles could be 
identified in the 10 highest results on each plate but in no case was the conversion 
rate sufficient for confirmation by HPLC. Tables comparing the 10 highest results 
from each plate with the average parental control from that plate are given in the 
Appendix (5.9). The compared activity profiles for a selection of these data are also 
shown below. 
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RgDAAO Y238 
The RgDAAO Y238 library was difficult to analyse because of poor growth of the 
cells in the control wells on all of the plates, which distorted the normalised data. For 
this reason no conclusions can be drawn about the performance of this library. 
However, observations from screening of the library were; i) a range of activities was 
demonstrated towards the substrates (R)-alanine, (S)-alanine and (R)-pipecolinic 
acid, ii) the highest rates (prior to data normalisation) towards these substrates were 
comparable with those obtained for the same substrates against the RgDAAO F58 
library and iii) an average of 23 % of the variants per plate were inactive towards 
(R)-alanine, compared to 7 % for the RgDAAO F58 library. The highest rates 
obtained for the variants on each plate towards each of the substrates are shown 
without normalisation in the Appendix (Section 5.9). 
RgDAAO R285 
This library contained an average of 53 % of variants inactive towards (R)-alanine 
per plate, suggesting that most amino acid exchanges at position R285 are 
deleterious. Figure 2.50 shows the activity profiles obtained for the ten variants 
showing the highest rates towards (R)-alanine on plate-5. 1. Only 8 variants on this 
plate showed reasonable activity towards (R)-alanine, including the two parental 
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Figure 2.50 - Substrate profiles for variants producing the highest rates towards (R)-alanine 
from saturation mutagenesis library RgDAAO R285 plate-5.1. Parental RgDAAO activity is set 
as one. Any number greater than one implies improved activity over parental activity and any 
number smaller than one implies that the variant showed lower activity towards the test 
substrate than the parent. Tiq = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. 
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The cells in all of the assay plates for this library had overall reduced activity, 
including the control wells, making the data less reliable. However, comparison of 
the activity profiles obtained on each plate suggests that a few amino acid exchanges 
either maintain or improve activity towards some of the substrates screened. For 
example, the variants in wells H06 and GlO in Figure 2.50 have similar activity 
profiles and indicate an approximately 6-fold improvement towards (rac)-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid. The data collected on the RgDAAO R285 
saturation mutagensis library are recorded in the Appendix (Section 5.9). Due to the 
poor overall activity and therefore reduced accurancy observed for these assay plates, 
the data must be considered in conjunction with the control data and Z' values. These 
indicate that no improvements can be detected towards (R)- and (S)-alanine. The 
reduced activity in these assay plates brought detection of activity towards (rac)-
pipecolinic acid to the limits and it was not possible to approximate any 
improvements towards this substrate. Moderate improvements of approximately 2-
fold were detected towards (rac)-allo-threonine and rate enhancements of up to 6-
fold were recorded for (rac)- 1,2,3 ,4-tetrahydroisoquinoline-3 -carboxylic acid. 
RgDAAO M213 
No rate improvements were seen towards (rac)-phenylalanine and only small 
enhancements were identified towards (R)-serine. Up to 3-fold improvements were 
observed towards (rac)-homophenylalanine. Some variants displayed 8-fold rate 
enhancements towards (rac)-pyridylalanine and up to 5-fold rate increases were 
recorded towards (rac)-13-methylphenylalanine. A few variants indicated 
exceptionally high enhancements but the curves produced by the raw data showed 
these to be false positives. This is also the case for several of the variants which 
produced high activities towards (rac)- 1,2,3 ,4,-tetrahydroisoquinoline-3 -carboxylic 
acid. The more consistent rates achieved towards this substrate suggest that 
improvements of up to 10-fold can be achieved. 
126 
RESULTS AND DISCUSSION 
RgDAAO F58 
One set of variants (plate 6) from the library produced by saturation mutagenesis at 
RgDAAO F58 were investigated in triplicate to assess the screening method and a 
description of these variants has been given above (see page 114). Additional 
information gained from screening the remainder of the library is discussed here. No 
improvements were observed towards (R)-alanine but one variant (well E09 on plate-
5.1, see Appendix Section 5.9) indicated a 2.5-fold improvement towards (S)-alanine. 
Although the activity profiles produced for two of the library plates show very high 
improvements towards (R)-threonine, these results can be related to either poor 
performance of the positive control wells or of the parental control wells. The 
remaining data suggest rate enhancements of up to 5-fold for this substrate. Many, 
but not all, of the variants which demonstrated activity improvements towards (R)-
threonine also showed similar improvements towards the stereoisomer, (rac)-allo-
threonine, as shown for the highest results for both substrates on library plate-4.1 in 
Figure 2.51. The improvements observed in this library plate are 2.0 to 2.5-fold 
greater than the activity of the parental enzyme towards these substrates, although the 
remaining library plates suggest that up to 6-fold activity improvements may be 
possible. The F58 library contained variants which also showed improved activity 
towards 	(rac)- 1,2,3 ,4-tetrahydroisoquinoline-3 -carboxylic 	acid. 	The 	best 
improvements towards this substrate were approximately 4-fold greater than parental 
activity. Enhancements of up to 8-fold greater than parental activity were observed 
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Figure 2.51 - Substrate profiles for variants producing the highest rates towards A) (rac)-aI!o-
threonine and B) (R)-threonine from saturation mutagenesis library RgDAAO F58 plate-4.1. 
Parental RgDAAO activity is set as one. Any number greater than one implies improved activity 
over parental activity and any number smaller than one implies that the variant showed lower 
activity towards the test substrate than the parent. Tiq = 1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid. 
2.4.7 Conclusions 
Four RgDAAO saturation mutagenesis libraries were prepared and the presence of 
each type of nucleotide exchange was confirmed by sequencing the genes. Cells 
expressing the corresponding variants were grown in 96-well plates for assay in 
liquid-phase. The libraries were assayed against a variety of substrates and the 
maximum slope for each variant against each substrate was determined. The data 
from each plate were normalised and Z' was assessed to provide an insight into the 
performance of the controls. The highest results towards each substrate were 
compared. Activity profiles for the most active variants were produced and 
compared. These profiles allowed the identification of identical or similar variants. 
The RgDAAO variant libraries produced by saturation mutagenesis at the conserved 
residues R285 and Y238 both produced more inactive variants than the other active 
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site saturation mutagenesis libraries. Different activity profiles observed for the R285 
saturation library variants indicated that this site does tolerate some amino acid 
exchanges. An approximately 6-fold improved activity was observed towards the 
substrate (rac)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid by several of these 
variants. Additionally, no improvements were detected towards (R)- and (S)-alanine 
and approximately 2-fold improvements were observed towards (rac)-allo-threonine 
for some variants in the R285 library. 
Saturation libraries were also generated at the non-conserved active site residues 
M213 and F58. The range of substrates used to screen these two libraries was not 
identical but four substrates were screened against both. These were 
(rac)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and three n-amino acids; 
(rac)- 3-phenylalanine, (rac)-3-homophenylalanine and (rac)-3 -aminobutyric acid. 
In addition, one plate from the F58 library (plate 6, which was used to assess the 
screening method and has been discussed above) was screened against 
(R)-pipecolinic acid. The full M213 library was screened against this substrate. No 
variant was found in either library which was active towards the 13-amino acids but 
both libraries contained variants with improved activity towards 
(rac)- 1,2,3 ,4-tetrahydroisoquinoline-3 -carboxylic acid. The improvements towards 
this substrate were up to 5-fold for some variants in the F58 library and up to 10-fold 
for some variants in the M213 library (although the results for the M213 library 
towards this substrate may be over-estimated due to poor control data being obtained 
during screening). Both libraries also contained variants with improved activity 
towards (R)-pipecolinic acid. For example, the variant F58Q shows a 4-fold 
improvement over the parental enzyme and M213 variants were observed with 8-fold 
improvements towards (R)-pipecolinic acid. 
The M213 saturation library also contained variants which showed improved activity 
towards the substrates (rac)-homophenylalanine (3-fold), (rac)-pyridylalanine (8-
fold) and (rac)-13-methylphenylalanine (5-fold). 
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The RgDAAO F58 saturation library was the most closely analysed of the four 
libraries. F58 exchanges which proved beneficial for enzyme activity towards some 
of the substrates tested were those to V, T, I, M, L and Q. Variants with exchanges to 
C, G and A at this position were generally less active than the parental enzyme 
towards the substrates and exchanges from F58 to R, N and P produced variants 
which were inactive. 
The data show that the length of the residue at amino acid 58 has an effect of the 
activity of the variants. For example, the variant F58Q shows some improvements in 
activity towards the substrates over the parental enzyme while the F58N variant is 
inactive towards all of the screened substrates. Additionally, branching at the 3-
carbon of the exchanged residue is beneficial for the activity of the variants towards 
(rac)-allo-threonine but detrimental for activity towards (R)-pipecolinic acid. The 
variants in the screened library (plates 1 to 6) produced rate enhancements over the 
parental activity of up to 6-fold greater towards (rac)-allo-threonine, up to 5-fold 
greater 	for 	(R)-threonine, 	4-fold 	greater 	towards 	(rac)-1,2,3,4- 
tetrahydroisoquinoline-3-carboxylic acid and up to 8-fold greater towards (R)-
pipecolinic acid. 
The main overall observation from all of the saturation mutagenesis libraries was that 
no new activity was developed towards substrates, including the f3-amino acids 
screened, for which parental RgDAAO showed no activity. Additionally, activity 
towards substrates upon which the parental enzyme is very active, such as 
(R)-alanine, were not improved further. However the activity for substrates towards 
which the parental RgDAAO performs more moderately could be improved. 
The use of a heat inducible promoter for induction of protein expression was not 
ideal for expression in 96-well format, as this adds another level of variability in 
protein production from cells. If the control wells on each plate are either more or 
less affected by a temperature gradient than the other wells, then the normalised data 
will be distorted. Therefore use of an alternative expression system would improve 
this method. In addition, more consistent data were achieved when the initial 
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measurement duration was 20 to 30 min and although this time for each plate in the 
spectrophotometer decreases the screening throughput, the data produced are more 
reliable. 
Although some reproducibility problems were observed in the liquid phase assay, 
these were easily identified. This is a significant advantage over solid-phase 
screening. In addition, information collected on each variant screened is recorded and 
stored, whereas with the solid phase assay, information only remains for those 
variants reassayed and sequenced. Further, the activity profiles, provided by 
substrates towards which the parental enzyme has activity, can be compared for the 
variants demonstrating the highest activities towards 'poor' substrates. This provides 
some insight into whether these highest results are random or produced by similar 
variants. 
As the activity of the variants on plate-6 of the RgDAAO F58 library had been 
repeated in triplicate, giving the most accurate results, four of these variants were 
carried forward to perform biotransformation reactions with the aim of confirming 
the activity demonstrated by the assay by HPLC analysis. 
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2.5 	BIOTRANSFORMATIONS USING VARIANT ENZYMES 
Variant RgDAAO enzymes which were identified from the liquid-phase assay with 
improved oxidase activity towards selected substrates were employed in whole cell 
biotransformation reactions. The reaction progress was followed by HPLC analysis. 
These reactions were carried out using pellets (1 g wet cell mass) from cells 
expressing the appropriate RgDAAO variant. The initial reaction volume was 10 mL 
from which 1 mL samples were removed during the course of the reaction for 
analysis by reversed-phase chiral HPLC as described in Section 3.2.6. 
2.5.1 Biotransformation of pipecolinic acid 
According to the liquid-phase assay data produced by screening the F58 RgDAAO 
saturation mutagenesis library, the F58M and F58Q variants oxidise (R)-pipecolinic 
acid at rates approximately 2.5 and 3.5 times greater than the parental enzyme 
respectively. Initial biotransformations of pipecolinic acid were performed at 20 mM 
substrate concentration and the enantiomers separated using an Astec Chirobiotic-T 
reversed-phase column. As this amino acid does not contain a chromophore which 
allows convenient UV detection, the relative absorbance measurements produced by 
the enantiomers were weak compared with unidentified compounds also present in 
the reaction mixture. The concentration of pipecolinic acid in the biotransformation 
was increased to 80 mM to improve the relative signal intensity (Figure 2.52). The 
enantiomers of pipecolinic acid show retention times of 10.9 mm (5) and 14.2 mm 
(R). 
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Pipecolinic acid 
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Figure 2.52 - HPLC trace produced by the separation of a sample taken from a pipecolinic acid 
biotransformation on a Chirobiotic-T reverse-phase column. Retention times are 10.9 min for 
(S)-pipecolinic acid and 14.2 min for (R)-pipecolinic acid. 80 % Acetonitrile, 20 % water, 
2 mL min', 10 °C, injection volume 5 giL. Reaction run at 80 mM substrate concentration, 100 g 
cells U'. 
At this substrate concentration the signals for pipecolinic acid could be identified. 
Alternatively, a D-penicillamine ligand exchange colunm can be used for chiral 
separation of amino acids. The copper complex of pipecolinic acid observed with 
this analysis method shows higher absorption compared to the free amino acid 
observed in the previous method. This method also produces an improved peak 
shape (Figure 2.53). However, the negative peak which runs in advance of the (5)-
enantiomer at 6.3 min could not be separated and the retention times of both 
enantiomers did not stabilise even after long equilibration times. 
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Figure 2.53 - HPLC trace produced by the separation of a sample taken from a pipecolinic acid 
biotransformation on a D-penicillamine ligand exchange column. Retention times of the 
enantiomers are approximately 6.4 and 10.0 mm. It was not possible to reduce drifting retention 
times even after long equilibration periods. 2 mM CuSO4 3 % methanol, 0.8 mL/min, injection 
volume 1 piL. Reaction run at 20 mM substrate concentration, 100 g cells U'. 
Satisfactory data could not be obtained using either analysis method to follow the 
biotransformations but one example where the oxidation of pipecolinic acid was 
monitored using the Chirobiotic-T column for separation is shown in Figure 2.54. 
The oxidation is not complete for any of the RgDAAO variants after a reaction time 
of 41 h (F58Q 40 % conversion, F58M 31 % and parental RgDAAO 19 %). These 
data indicate that the F58M and F58Q variants oxidise (R)-pipecolinic acid 1.3 and 
2.0 times faster than parental RgDAAO respectively. In comparison, the relative rate 
enhancements observed in the liquid phase assay were 2.5 times for F58M and 3.5 
times for F58Q. However, the liquid phase assay was carried out using 10 mM (R)-
pip and the biotransformation was carried out with 80 mM (rac)-pip. 
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Figure 2.54 - % e.e. over time calculated from samples removed from (rac)-pipecolinic acid 
biotransformations using cells expressing F58M, F58Q and parental (F58) RgDAAO. The 
biotransformations were carried out at 80 mM substrate concentration, 100 g cells U1, 100 mM 
buffer, 37 °C, 225 rpm. Samples were separated on a Chirobiotic-T column. 
The technical problems associated with monitoring the progress of the (rac)-
pipecolinic acid biotransformations led to the selection of a substrate better suited for 
UV detection, (rac)- 1,2,3 ,4-tetrahydroisoquinoline-3-carboxylic acid ((rac)-tiq), with 
the aim of producing more consistent HPLC data to confirm improved RgDAAO 
variants identified using the liquid phase assay. 
2.5.2 Biotransformation of (R)-tiq 
Liquid-phase screening of the RgDAAO F58 saturation mutagenesis library 
suggested respective rate enhancements of 2.8 and 2.4 times that of parental 
RgDAAO in the oxidation of (rac)-tiq by the F58L and F581 variants. The tiq 
enantiomers could be separated and the signals were not overlaid by signals from 
impurities or by-products (Figure 2.55). The analysis method allowed convenient 
monitoring of the biotransformation reaction. 
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(S)-tiq 	 (R)-tiq 
Jr 
Figure 2.55 - HPLC trace produced by the Chirobiotic-T separation of samples taken over the 
course of a 10 mM tiq biotransformation (100 g cells U1). 90% methanol, 10% water, 1 
mL.min', 25'C, injection volume I IiL. 
Tiq biotransformation reactions were performed using cells expressing the RgDAAO 
variants F58L and F581 and parental RgDAAO. These were compared with 
biotransformations using empty vector cells. All reactions were carried out using 
10 mM (rac)-tiq. The oxidation of (R)-tiq was monitored by HPLC and the 
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Figure 2.56 - Observed % e.e. over time obtained for samples removed from (rac)-tiq 
biotransformations (10 mM substrate concentration, 100g cells U1, 100 mM buffer, 37 °C, 
225 rpm) using cells expressing F58L, F581 and F58 RgDAAO and empty vector cells. The 
biotransformations were performed in duplicate and the data shown are the averaged results. 
The biotransformation reactions demonstrated that (R)-tiq oxidation by the F58L and 
F581 RgDAAO reached 99 and 98 % conversion within 30 min respectively, while 
parental RgDAAO takes 240 min to reach 100 % conversion. The initial conversion 
rates observed by HPLC in whole cell biotransformation reactions are 1.5 times 
higher with the F58L variant and 1.6 times higher with the F581 variant compared to 
parental RgDAAO (activity of cells with empty vector was subtracted). These are 
lower than the figures suggested by the liquid-phase assay (2.8 and 2.4 times 
respectively). The disappearance of (R)-tiq using cells containing empty vector, 
shown in Figure 2.56, was not anticipated and occurs at a rate approximately 2/3 that 
of cells expressing parental RgDAAO. This background activity towards (R)-tiq by 
the E. coli BL21(DE3) cells was not observed in the liquid phase assay. The empty 
vector controls on the assay plate were assayed against a control substrate ((R)-serine 
or (R)-alanine) rather than the test substrate, and these control wells do not provide 
any information on the background reaction observed with (R)-tiq. However, several 
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wells on each plate contained cells expressing inactive RgDAAO variants, for 
example wells DOl and FOl in Figure 2.57 which shows RgDAAO F58 saturation 
mutagenesis variants assayed against A) (R)-alanine and B) (rac)-tiq. The 0D600 
values recorded for the growth of the cells associated with these assay plates confirm 
that all the wells on the plate contained comparable densities of cells, with the 
exception of the diagonal of blank wells from AOl to G07. Rates of colour 
formation 1/3 lower than those produced by parental RgDAAO towards (rac)-tiq 
(wells G12 and H12) are detectable by the liquid-phase assay. Had the (R)-tiq 
background reaction been coupled to hydrogen peroxide production, colour 
formation would be detectable in any well containing E. coli cells, including those 
expressing inactive RgDAAO. It seems that the background activity observed here is 
not D-amino acid oxidase activity but some other enantioselective enzymatic system, 
for example, a decarboxylase. 
Figure 2.57 - RgDAAO F58 saturation mutagenesis library (assay plate-5) assayed against A) 
(R)-alanine and B) (rac)-tiq. The positive and negative control wells are in column 12 and there 
is a diagonal of blank wells containing no cells from AOl to G07. 
2.5.3 Conclusions 
RgDAAO F58 variants were selected for use in biotransformations of (rac)-
pipecolinic acid and (rac)-tiq based on the enhanced oxidation rates towards these 
substrates displayed in the liquid-phase assay. The HPLC analysis of the pipecolinic 
acid biotransformation was not robust enough to provide consistent results but 
indicated that the F58M and F58Q RgDAAO variants oxidised (R)-pipecolinic acid 
1.4 and 2.2 times faster than parental RgDAAO respectively. The rate enhancements 
in the liquid-phase assay were 2.5 and 3.5 times parental RgDAAO. The discrepancy 
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here could be due to the different experimental conditions. The assay was carried out 
using 10 mM (R)-pip and the biotransformation using 80 mM (rac)-pip). 
HPLC analysis following the course of the (rac)-tiq biotransformations showed that 
(R)-tiq oxidation rates produced by F58L and F581 RgDAAO variants are 5.2 and 4.6 
times greater than by parental RgDAAO which is greater than the rate enhancements 
provided by the liquid-phase assay of 2.8 and 2.4 times the parental rate. These data 
confirm that the liquid-phase assay can be a useful guide to detecting improved 
variants for use in a biotransformation experiment. (R)-tiq oxidation by both F58L 
and F581 RgDAAO variants were complete within 30 mm (at 10 mM substrate 
concentration, 100 g cells U1, 100 mM buffer, 37 °C, 225 rpm). 
An (R)-selective background reaction by E. coli BL21(DE3) cells was observed in 
biotransformations of (rac)-tiq using empty vector cells. The empty vector controls 
in future liquid phase assay experiments should be assayed against the test substrate 
(rather than the control substrate, (R)-alanine or (R)-serine). This will allow detection 
of hydrogen peroxide forming background oxidations with a particular substrate. 
Non-hydrogen peroxide forming background reactions will remain a possibility and 
should be monitored by HPLC. 
No amino acid derivatisation methods were attempted in this work. A quantitative 
derivatisation method applied to the biotransformation samples would allow 
extraction of the amino acids from the reaction mixture. The samples could then be 
analysed by normal-phase HPLC and undesired signals caused by other compounds 
present in the reaction mixture could be reduced. Appropriate derivatisation, for 
example using Marfey's Reagent, (58)  could also improve the monitoring of 
conversion of amino acids which are harder to detect by UV absorption such as 
pipecolinic acid. 
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2.6 OVERALL CONCLUSIONS 
The aim of the project was to develop an oxidase enzyme for use in eventual 
deracemisation reactions of 13-amino acids, or of unusual a-amino acids. To this end, 
a culture collection comprising approximately 500 microorganisms was screened 
with the aim of identifying 13-amino acid oxidase enzymes already present in nature. 
As no activity towards f3-phenylalanine or f3-homophenylalanine was detected by this 
route, existing oxidase enzymes were examined for their activity towards J3-amino 
acids. 
The flavin-dependent enzymes, monoamine oxidase-N and D-amino acid oxidase 
were screened using an HRP-coupled solid phase assay for activity towards 13-amino 
acids. Again, no activity was observed and D-amino acid oxidase was selected for 
directed evolution experiments with the aim of evolving activity. The parental 
profiles of TvDAAO and RgDAAO were assessed against a range of proteinogenic 
and non-proteinogenic amino acids. The TvDAAO gene was propagated in an E. 
coli mutator strain but as the start codon was found to be mutated in all the TvDAAO 
genes later sequenced it was decided to generate mutations by epPCR. EpPCR was 
performed on the gene encoding RgDAAO and the variant libraries produced were 
initially screened using a solid-phase HRP-coupled assay. This assay method proved 
not to be robust enough for consistent screening of the library and an HRP-coupled 
liquid-phase assay was therefore used as an alternative. The liquid-phase assay was 
favourably assessed for its suitability as a screening assay. In order to improve 
screening throughput a method was developed, whereby RgDAAO variants were 
grown in semi-solid agarose in 96-well plates. This allowed the growth of ten 
individual colonies per well for subsequent screening. Any active variant could later 
be identified by deconvoluting the variants in the active well. Throughput was further 
increased by the use of a robot. Approximately 100 000 colonies were screened 
against f3-homophenylalanine but no activity towards this substrate was identified. 
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It was decided to reduce the number of variants which required to be screened by 
focussing mutations on residues around the active site. Four single-site saturation 
mutagenesis libraries were prepared using the RgDAAO gene, at positions F58, 
M213, Y238 and R285. In addition, cc-amino acids were added to the substrate set to 
further probe the effects of the residue exchanges. Methods for screening the libraries 
and for handling the data produced were developed. The method was found to be 
reproducible within each plate and although inconsistencies were apparent between 
plates, the source of these could be identified. 
It was found that substrate profiling was a useful method for identifying variants 
although these could only be reliably compared within a single plate. By comparing 
the profiles of the variants demonstrating the highest activity towards a particular 
substrate, 'hits' could be confirmed. This 'hit profiling' could potentially be useful to 
identify new or improved activity with higher certainty in the first round of a screen. 
As expected, the screening in liquid phase of mutagenesis libraries provides more 
information than the solid-phase assay about the effects of particular residue 
exchanges. In addition, this information is recorded and can be returned to for further 
analysis. 
The main observations from the saturation mutagenesis libraries were that the 
libraries produced at conserved residues showed more inactive variants than those 
produced at the other active site residues. The substrate profiles obtained for 
RgDAAO R285 variants suggest that this residue will tolerate a few amino acid 
exchanges. No new activity was developed in any of the libraries towards the 13-
amino acid substrates or tert-leucine, for which the parental RgDAAO also shows no 
activity. Activity towards substrates such as (R)-alanine, towards which the parental 
enzyme is very active, could not be improved further.However the activity for 
substrates towards which the parental RgDAAO performs more moderately could be 
improved. For example, some M213 variants displayed up to 8-fold activity 
improvements towards (R)-pipecolinic acid and the F58V variant showed a 4-fold 
improvement towards (R)-threonine. 
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Specific variants were identified from the RgDAAO F58 saturation library by gene 
sequencing. Exchanges which proved beneficial for enzyme activity towards some of 
the substrates tested were those to V, T, I, M, L and Q. F58 variants with exchanges 
to C, G and A were less active than the parental enzyme towards the majority of the 
substrates and exchanges from F58 to R, N and P produced variants which were 
inactive. The length of the residue at position 58 appears to be important and the 
F58Q exchange improves the activity of RgDAAO towards (R)-pipecolinic acid and 
(R)-serine while the F58N variant is inactive towards all of the screened substrates. 
Branching at the 13-carbon of the exchanged residue is beneficial for the activity of 
the variants towards the substrate (rac)-allo-threonine but detrimental for activity 
towards (R)-pipecolinic acid. For example, F581 has 3-fold better activity towards 
(rac)-allo-threonine but a reduced activity to (R)-pipecolinic acid compared with 
RgDAAO F58. There is no improved activity for the variant F58L towards (rac)-
allo-threonine but this variant has a 3-fold better activity to (R)-pipecolinic acid than 
the parental enzyme. 
Neither the random methods of mutagenesis used, nor saturation mutagenesis yielded 
DAAO variants active on 13-amino acids. However, the reduced size of the libraries 
required for screening in the rational design approach allowed more substrates to be 
screened against each library. Substrates for which the parental enzyme showed a 
range of activities were selected for the screen, allowing a pattern of increased or 
decreased activity for each variant towards these substrates to be determined. In this 
way, much more information about the variants was generated. The activity observed 
in the substrate profiles show that another advantage of rational design is that there is 
a much higher chance of generating improved activities, at least towards some 
substrates, than in the case of random mutagenesis. While random mutagenesis 
allows discovery of beneficial mutations which would be difficult to predict, many of 
the variants generated will have no observable effect on substrate catalysis. 
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2.7 OVERALL FUTURE WORK 
The RgDAAO gene had been cloned into the pPOT3 plasmid which contains a heat-
inducible promotor. Protein production was induced by placing the growing colonies 
at elevated temperatures. It is possible however, that uneven heat transfer resulted in 
a difference in the protein production of different colonies on the same plate and 
therefore led to varied response in the liquid-phase assay. Heat induced expression 
must also be volume dependent at larger volumes. The experiments may have been 
more controlled using an alternative system such as IPTG-induced expression. 
An alternative method of preparing the site-saturation libraries would have been to 
prepare distinct mutants of a single site thereby reducing the number of colonies to 
be screened to 20. 
It is possible that further saturation mutagenesis studies at residues around the active 
site of RgDAAO could identify a variant active towards 3-amino acids. Tishkov 
suggests that the Ser335 residue participates in hydrogen bonding of the a-amino 
group. 44 This residue can be seen at the bottom of Figure 2.58 (coloured light 
purple) which shows the active site of RgDAAO with (R)-alanine bound. 
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Figure 2.58 - RgDAAO crystal structure co-crystallised with (R)alanine.(42)  PDB ID code icOp. 
Residue colour code: light blue = N54, red = F58, pink = M213, orange = Y223, green = Y238, 
blue = R285, purple = S335, brown = Q339. The flavin molecule is shown in yellow. 
Alternative enzymes could be screened for 13-amino acid oxidase activity, for 
example, D-aspartate oxidase (EC-Number 1.4.3.1). Monoamine oxidase-N (variant 
135) did not show activity towards 13-amino acids but might be an interesting subject 
for further rounds of directed evolution or site mutagenesis. Apart from 13-amino 
acids the substrate panel could also include derivatives such as the corresponding 
esters or 13-amino nitriles. 
Alternative screening strategies could be pursued, for example, selection growth on 
minimal media where all nitrogen sources apart from the 13-amino acid are removed 
during growth of colonies containing variant RgDAAO. Only colonies processing 




All reagents were purchased from Sigma-Aldrich unless otherwise stated. Sterile 




Agarose gel electrophoresis Biorad Minisub Cell GT gel chamber 
Balances Mettler Toldedo Analytical Balance 
AB204-S 
Mettler Toledo Balance PP 1502-S/FACT 
Biophotometer Eppendorf Biophotometer 
Blotting transfer cell Biorad Transblot SD Semidry Transfer Cell 





96-well, 2.2 mL plates 
Eppendorf 5414 R 
Eppendorf 5810 R 
Beckmann-Coulter Avanti J-E 
Beckmann-Coulter Avanti J-E 
Electroporator Biorad Genepulser Xcell 
FPLC GE Healthcare Akta Explorer 100 
HPLC Agilent 1100 series 
Liquid handler Tecan Miniprep 75 
pH Meter Hanna pH2l3 
Plate readers BMG Labtech Fluostar Optima 
Tecan Rainbow 
Polyacrylamide gel electrophoresis Biorad Miniprotean 3 cell 
Power suppliers Biorad Powerpack 400 




Rocker Grant Boekel BFR25 
Roller mixer Stuart SRT1 
Thermocycler Eppendorf Mastercycler Gradient 
White light transilluminator UVP 
Vortex VWR lab dancer 
3.2 METHODS 
Parental RgDAAO and parental TvDAAO refer to the enzymes generated from the 
DNA with the sequences shown in the Appendix (sections 5.1.1 and 5.1.2 
respectively). The primers used in this work are shown in the Appendices (Section 
5.2). 
3.2.1 DNA purification and manipulation 
Plasmid DNA extraction 
QlAprep Spin Miniprep Kits were purchased from Qiagen and were supplied with 
pre-prepared buffers and columns. 
1.5 ml, was removed from an overnight culture (section 3.2.3) and the cells isolated 
by centrifugation at 15 700 x g for 10 mm. Plasmid DNA was extracted using the 
'Plasmid DNA Purification Using the QlAprep Spin Miniprep Kit and a 
Microcentrifuge' method described the handbook provided with the kit!") The 
overall procedure is: resuspension of the cell pellet, alkaline lysis of the cells, 
neutralisation of the resulting lysate and precipitation of unwanted cellular 
components at high-salt concentration. This if followed by binding of plasmid DNA 
to a silica column under high-salt conditions, washing in ethanol-buffer and, finally, 
elution of plasmid DNA in a low-salt buffer or water. Concentrations were 
determined by spectroscopy on a biophotometer at a wavelength of 260 nm and 





Generic method: Restriction endonucleases and bovine serum albumin (BSA) were 
purchased from New England Biolabs (NEB). All restriction enzymes were supplied 
with the appropriate buffer (1 OX concentrate). Buffers for use in double digests were 
selected 	using 	NEB's 	double 	digest 	calculator 
(http://www.neb.com/nebecomm/DoubleDigestCalculator.asp). BSA was added to 
the reaction mixture where recommended by NEB. 1 tL of each endonuclease, 2 .iL 
buffer (X10) and 0.2 .tL BSA were placed in a 0.2 mL PCR tube and made up to a 
volume of 5 jiL with sterile reverse osmosis (RU) H20. This mixture was added to 
15 tL plasmid DNA and placed at 37 °C for between 1 and 4 h, or overnight at room 
temperature. 
NcoI digest: 20 iL NEB buffer 4 (X 10) and 5 tL NcoI (10 000 U mU1) were mixed 
in a 1.5 mL tube and made up to 100 tL with sterile RU H20. 10 tL of this mixture 
was added to 10 .tL plasmid DNA obtained from each of the 10 samples, the 
reactions were spun briefly and placed at 37 °C for 2 h. The digested samples were 
analysed by agarose gel electrophoresis. The gel was run at 80 V and analysed at 30 
and 50 mm. 
DpnI digest: The endonuclease DpnI is used to remove parental template DNA from 
PCR products. This is possible because the DNA generated by growth in dam E. 
coli strains is methylated at the adenine occurring within the sequence 5' -GATC-3', 
whereas the DNA produced by amplification in a PCR reaction is not. DpnI digests 
DNA methylated at these positions. 50 tL PCR products from site-directed, 
saturation or epPCR mutagenesis reactions were incubated with 1 .iL DpnI 
(20 000 U mL-') at 37 °C for 1 h in a thermocycler. 
DNA agarose gel electrophoresis 
Agarose was purchased from Fisher Bioreagents, SYBR Safe DNA stain from 
Invitrogen and Blue/Orange Loading Dye and Benchtop 1 kb Ladder from Promega. 
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0.5 g agarose was added to 50 mL tris-acetate ethylene diamine tetraacetic acid 
buffer (TAB, Section 3.2.7), dissolved in a microwave and cooled in a water bath to 
50 °C. The solution was poured into a gel mould and DNA stain was mixed in by 
stirring with a pipette tip (1 .tL ethidium bromide (10 mg mU') or 5 iL SYBR safe 
(10 000 X)). The gel was allowed to set and submerged in 1X TAE buffer in a gel 
tank. Blue/Orange Loading Dye (6x) was added, in a 1 in 6 dilution, to samples of 
digested plasmid or PCR product (20 - 200 ng DNA, maximum volume 24 tL) and 
to BenchTop 1 kb DNA Ladder. The samples and marker were loaded onto the gel 
and run at 80 to 100 V for 1 h. Ethidium bromide gels were viewed on a UV 
transilluminator and SYBR-safe gels on a blue-light transilluminator. 
Agarose gel DNA extraction 
An Agarose Gel DNA Extraction Kit was purchased from Roche, and contained 
agarose solubilisation buffer, nucleic acid binding buffer, washing buffer and silica 
matrix suspension. 
Following separation of DNA fragments by agarose gel electrophoresis, the fragment 
of interest was cut from the gel leaving as little agarose as possible. The DNA was 
separated from the remaining gel by the method described in the kit manual .(60) The 
overall procedure was: solubilisation of the agarose surrounding the fragment and 
binding of the DNA fragment to a silica-matrix in the presence of a chaotropic salt, 
followed by washing of the DNA and then elution in a low-salt buffer. Absorbance 
was measured on a biophotometer at 260 and 280 nm to determine the concentration 
and purity of the DNA which was stored at -20 °C. 
Preparation for DNA sequencing 
ABI prism BigDye terminator V3.1 and sequencing buffer (5X) were purchased from 
Applied Biosystems. Samples were sequenced by either The Institute of Cell and 
Molecular Biology (ICMB) at The University of Edinburgh (sequencing only) or by 
MWG Biotech AG (amplification and sequencing). Sequencing primers are 
described in Section 5.2.1. 
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Samples submitted to ICMB were amplified by the following method. The reagents 
were added to a 0.2 mL thin-walled PCR tube in the following order: 2 [IL 
sequencing buffer (5X), 1.6 tL sequencing primer (1 pmol iL'), 4 tL template 
DNA (40 - 75 ng ixL'), 4 .iL ABI prism BigDye terminator V3.1 (2.5X), and the 
volume adjusted to 10 VtL with DI H20. The tube was placed in a thermocycler and 
subjected to the cycling programme shown in Table 3.1. 
Table 3.1 - Thermal cycling programme used for sequencing PCR. 
Step Temperature/°C Time/min Repetitions 
1 95 1 1 
2 96 0.5 
30 
4 
3 50 0.5 
4 60 
5 4 hold - 
The resulting PCR products were submitted to ICMB without purification. 
Alternatively, sequencing primers and plasmid DNA were sent to MWG Biotech AG 
(10 pmol .tL 1 each primer and 1 j.tg precipitated plasmid DNA) for both the 
amplification and sequencing steps. 
DNA plasmid precipitation 
Ammonium acetate solution (5 M) was added to the purified plasmid to a final 
concentration of 2.5 M, followed by 2 volumes of ethanol. This mixture was placed 
at -20 °C for> 20 min and centrifuged at 15 700 x g for 10 mm. The supernatant was 
removed and the pellet washed with 70 % ethanol. The pellet was dried overnight at 
room temperature. 
3.2.2 Mutation Protocols 
Mutator strain 
Transformation and subsequent growth of XL1-Red colonies on agar plates is 
described in Section 3.2.3. LB/KAN (2 mL) was added to the plate and the colonies 
were gently scraped off the surface of the agar using a sterile plastic spreader and 
resuspended in a further, 10 mL LB/KAN. The culture was then diluted to an 0D600 
of 0.0005 in LB/KAN containing (R)-alanine (250 p.M) and grown at 37 °C and 
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225 rpm for 24 h when an 0D600 of approximately 2 was reached. This dilution and 
growth procedure was repeated a further 5 times and from the final culture 4 x 5 mL 
samples were removed. These were pelleted and the plasmid DNA extracted. For 
storage purposes TOP 10 cells were transformed with this DNA. Following growth 
on agar plates the colonies were removed from the plate as described above and the 
DNA was re-extracted and stored at -20 °C. For screening purposes, the E. coli 
expression strain BL21(DE3) was transformed with the plasmid DNA. 
Error-prone PCR (epPCR) 
The megaprimer PCR of whole plasmid (MEGAWHOP) method described by 
Miyazaki (61)  was followed. There are 6 stages; (i) an error-prone PCR to generate a 
library of variant genes, (ii) purification of the PCR products generated, (iii) a sub-
cloning step, performed by PCR, in which the mutated genes are used as 
megaprimers and the parental construct is used as template, (iv) removal of parental 
constructs from the mixture by restriction digest, (v) repair of nicked DNA resulting 
from the whole plasmid PCR by transformation of highly competent cells with the 
products, and (vi) plasmid purification. 
(i) epPCR 
See Section 5.2.2 for epPCR primers. Taq polymerase and dNTPs were purchased 
from NEB. Reagents were added to a 1.5 mL tube in the following order: 246.6 IL 
DI H20, 1.4 tL freshly prepared RgDAAO/pPOT3 template DNA (from TOP 10 
cells) (75.9 ng iL'), 20 tL forward primer (10 .tM), 20 tL reverse primer (10 tM), 
5tL dTTP (100 mM), 5 .tL dCTP (100 mM), 1 tL dGTP (100 mM), 1 iL dATP 
(100 mM), 140 tL MgCl2 (25 mM), 5 iL MnC12 (5 mM), 50 iL reaction buffer 
(1 OX), 5 tL Taq polymerase (5000 U mL-1). These were mixed by gentle pipetting 
and aliquoted to 5 times 100 .tL in 0.2 mL PCR tubes. The tubes were placed in a 
gradient thermocycler at the appropriate positions to achieve annealing temperatures 




Table 3.2 - epPCR thermal cycling protocol 
Step Temp/°C Time/min Repetitions 
1 95 3 1 
2 95 1 
16 
2 
3 50.0, 56.1, 60.2 or 65.5 1 
4 72 
5 72 1 1 
6 4 Hold - 
PCR product purification 
QlAquick PCR purification kit was purchased from Qiagen and the method 
'QIA quick PCR Purification Kit Protocol using a microcentrfuge' described in the 
manual (62)  was followed. Pre-optimised buffers and columns were provided with the 
kit, the principle of which was, binding of the PCR product to a silica column in the 
presence of a chaotropic salt, pH < 7.5, washing in ethanol-buffer and elution in low 
salt buffer (10 mM Tris-HC1) at pH 8.5. 
MEGA WHOP 
The reaction was carried out at various concentrations of mega-primer, dNTPs and 
polymerase as shown in Table 3.3. The reagents were added to a 0.2 ml, PCR tube in 




Table 3.3 - Volumes of reagents added to each reaction for MEGAWHOP PCR 
Reaction vol/FL 
7Reagent A B C D E F G 
RO H20 
36.3 37.3 36.8 35.4 35.4 37.3 37.3 
RgDAAO/pPOT3 template 
p1asmid(75.9ngtL) 1.3 1.3 1.3 1.3 1.3 1.3 1.3 
epPCR products 
(112ngpL) 0.4 0.4 0.9 1.8 1.8 0.9 0.9 
dNTPs (10 mM each) 
0.5 0.5 1 0.5 - 0.5 
DMSO 
5 5 5 5 5 5 5 
Pfu turbo polymerase 
buffer(X10) 5 5 5 5 5 5 5 
Pfu turbo polymerase (2.5 
U j.tL) 1 0.5 0.5 0.5 1 0.5 - 
Table 3.4 - MEGAWHOP thermal cycling protocol 
Step Temp/°C Time/min Repetitions 
1 95 3 1 
2 95 0.5 
30 
6 
3 55 1 
4 68 
6 4 Hold - 
(iv) Digestion of methylated DNA from PCR products, (v) repair of nicked DNA by 
transformation ofXLl-Blue cells and (vi) plasm idpurification. 
The PCR products were digested to remove parental DNA as described in Section 
3.2.1 and then the nicked plasmid DNA produced by PCR was repaired by 
transforming highly competent XL 1-Blue cells (chemically- or electro-competent) 
with the PCR products. The transformed cells were grown on 90 mm LB agar/CAP 
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plates (Section 3.2.3). The library of XL1-blue colonies containing variant DAAO 
genes were transferred from the plate to centrifuge tubes by suspending the colonies 
in 2 mL LB/CAP, using a sterile plastic spreader to remove them from the surface of 
the agar, and pipetting the mixture to the tube. This step was repeated with a further 
1 mL of LB/CAP. The library DNA was extracted from the cells using the plasmid 
purification method described in Section 3.2.1. For the purposes of storage this 
plasmid DNA was used for the transformation of TOP 10 cells (Section 3.2.3) from 
which the DNA was again extracted and stored at -20 °C. For screening purposes 
BL2 1 (DE3) cells were transformed with the library DNA. 
Saturation mutagenesis 
Saturation mutagenesis was performed using a PCR-based method, with primers 
containing the degenerate NNS codon at the site selected for randomisation. This 
codon provides for any of the 4 nucleotides at positions 1 and 2 and either 
deoxycytidine monophosphate (dCMP) or deoxyguanosine monophosphate (dGMP) 
at position 3. This degeneracy allows access to all 20 proteinogenic amino acid 
residues at the selected site. PfuTurbo DNA Polymerase and lox reaction buffer 
(200 mM Tris-HCl (pH 8.8), 20 mM MgSO4, 100 mM KC1, 100 mM (NH4)2SO4, 
1 % Triton X- 100, 1 mg mU' nuclease-free BSA) were purchased from Stratagene. 
The procedure used was a modification of that described in PfuTurbo DNA 
Polymerase Instruction Manual version B. 63 The following were mixed in a thin-
walled 0.2 mL PCR tube placed on ice, in the order given: 5 .IL reaction buffer (I OX 
concentrate), 1 tL template DNA (55 ng j.tL'), 1 tL each of forward and reverse 
primers (10 LM), 1 p1 dNTPs (10 mM ea), 40 p1 sterile RO water and 1 tL 
pfuTurbo polymerase (2.5 U tL'). The tube was placed in a thermocycler 
(Eppendorf Mastercycler Gradient) and subjected to the denaturing, annealing and 
extension cycle shown in Table 3.5. 
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Table 3.5 - PCR cycling parameters for site specific saturation mutagenesis 
Step Temp/°C Time Repetitions 
1 95 30s X  
2 95 30s 
X16 
S min 3Os  
3 68 1 min 
4 68 
5 4 Hold X  
The PCR products were processed further as described in steps (iv), (v) and (vi) of 
the preparation of epPCR libraries to produce unmethylated, nick-repaired plasmid 
ready for the transformation of the protein expression E. coli strain, BL21(DE3). 
3.2.3 Transformation, growth and protein expression methods 
Transformation of E. coli BL21 (DE3) chemically competent cells. 
One Shot BL2 1 (DE3) chemically competent E. coli were purchased from Invitrogen 
and stored at -80 °C. One vial of cells (50 tL) per transformation was thawed on ice, 
DNA (0.1 - 50 ng) was added, mixed by gentle tapping and the suspension incubated 
on ice for 30 mm. The cells were heat-shocked at 42 °C for 30 s and replaced to the 
ice. SOC medium (250 jiL) prewarmed to 42 °C was added and the vial incubated on 
its side at 37 °C and 225 rpm for 1 h.'64 
Transformation of E. coli TOP 10 chemically competent cells 
One Shot TOP 10 chemically competent E. coli (50 iL/via1) were purchased from 
Invitrogen, stored at —80 °C and transformed as described for BL21(DE3) cells. (65)  
Transformation of E. coli XL1-Blue chemically comnetent cells 
XL1 -Blue chemically competent cells (200 .tUvialj were purchased from Stratagene 
and stored at -80 °C. The cells were thawed on ice and aliquoted (50 jtL) to pre-
chilled 15 mL polypropylene tubes. 1.42 M -mercaptoethanol (0.85 tL) was added 
and the suspension mixed by gentle swirling. The tube was placed on ice for 10 mm, 
with gentle mixing every 2 mm. DNA (1-3 iL PCR products) was added and mixed 
by tapping the tube gently. The tubes were incubated on ice for 30 mm, heat-pulsed 
154 
EXPERIMENTAL 
in a 42 °C water-bath for 45 s, before a further 2 min incubation on ice. Prewarmed 
Soc medium (900 p.L, 42 °C) was added and the tube was transferred to a shaking 
incubator (37 °c, 225 rpm, 1 h). 66 
Transformation of E. coli XL 1-Blue electrocompetent cells 
XL 1-Blue electrocompetent cells (200 tL/vial) were purchased from Stratagene and 
stored at -80 °c. The cells were thawed on ice and aliquoted (40 .iL) to 1.5 mL 
polypropylene tubes. DNA (1-3 tL PCR products) was added to each aliquot and the 
cells and DNA mixed by gentle tapping of the tube. The sample was transferred to a 
pre-chilled electroporation cuvette (0.1 cm gap) and pulsed once (1700 V, 200 Q, 
25 j.tF) using an electroporator. Prewarmed SOC medium (37 °C, 960 jtL) was 
immediately added and the cells transferred to a 15 mL polypropylene tube and 
incubated (37 °C, 225 rpm, 1 h). 67 
Transformation of E. coil XL 1-Red chemically competent cells 
XL 1-Red chemically competent cells (200 iL/vial) were purchased from Stratagene 
and stored at -80 °C. The cells were transformed as described in section 3.2.3, with 
the exceptions that 100 pL cells were used and 1.7 tL 3-mercaptoethanol (1.42 M) 
was added to these. (68)  
Antibiotic solutions 
Antibiotic resistance is conferred to cells by the plasmids used as vectors for the 
DAAO gene. Those used in this work are shown in Table 3.6 which also shows the 
stock concentrations prepared. These were filter-sterilized and stored at -20 °C. 
Working concentrations were a 1 in 1000 dilution of the stock solution for all media 
types. 
Table 3.6- Antibiotic resistance provided by plasmids used 
Plasmid Antibiotic resistance Supplier Stock concentration 
pJLM402 Kanamycin (KAN) Sigma- 50 mg mL-' in RO H20 
Aldrich 
pPOT3 Chioramphenicol (CAP) Fluka 34 mg mU' in ethanol 
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Growth of transformants on LB agar plates 
LB or TSB agar/antibiotic plates were prepared. Transformed cells were either 
streaked or spread onto the plates. Volumes used were adjusted according to the 
efficiency of the transformation in order to ensure a sufficient number of isolated 
colonies. The volumes generally required for the different cell strains used are shown 
in Table 3.7. 
Table 3.7 - Approximate transformation volume plated to ensure many isolated colonies 
E. co/i strain 90 mm plate 145 mm plate 
BL2I(DE3) chemically competent cells  
TOP 10 chemically competent cells  
XLI-Blue electrocompetent cells 100 tL  
XL1-Blue chemically competent cells 100 .iL  
XLI-Red chemically competent cells  
The plates were incubated at 37 °C overnight to allow colony formation. Exceptions 
to this were BL21 (DE3) cells which were incubated at 30 °C and XL1-Red cells 
which were grown for 24 to 30 h. 
Growth of transformant in semi-solid agarose. 
Media and SeaPrep agarose (Lonza) were prepared at double concentration. Thus, 40 
or 60 g L 1 LB broth or TSB respectively and 10 g U' SeaPrep agarose solutions 
were prepared, autoclaved and stored at 4 °C. The autoclaving time for SeaPrep 
agarose was 5 min rather than the standard 15 min to protect gelling strength. Before 
use, the agarose was melted in a waterbath at 60 °C and both agarose and media 
(TSB or LB) were equilibrated to 37 °C. The solutions were mixed in a 1 to 1 ratio in 
50 mL falcon tubes and transformed XL1-Blue cells (12.5 pL/mL) or BL21(DE3) 
glycerol stock (5 j.tL/mL of a lx 106  dilution) were added and mixed by gentle 
inversion of the tubes 2 to 3 times. For growth in 1.1 mL, 96-well plates, the 
inoculated agarose was transferred from the tube to a sterile trough and from there to 
the plate using a multi-channel pipette (500 [tL/well). The tubes/plates were placed at 
4 °C for -2 h to allow the agarose to gel and then overnight at 37 °C for colony 
formation. Where protein expression was required, this was induced by placing the 
tubes/plates at 45 °C for 1 h and followed by growth at 37 °C. for a further 4 h. The 
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tubes and plates were transferred to a shaking incubator (225 rpm, 37 °C) for 1 h to 
loosen the colonies and the agarose was removed by centrifugation at 3220 x g for 30 
mm. The cell pellets were washed twice with warm (40 °C) potassium phosphate 
buffer (25 mL, 0.1 M, pH 7.6). 
Small scale bacterial cultures 
Following BL21 (DE3) colony formation on agar plates, an isolated colony was 
picked with a sterile inoculation loop, inoculated to 5 to 10 mL media containing the 
appropriate antibiotic and grown overnight at 37 °C, 225 rpm. The resulting cultures 
were used for DNA isolation (Section 3.2.1), or inoculation to larger volumes of 
media for expression of protein (below). 
Fermentation of E. co/i expressing DAAO 
Volumes of 50 to 700 mL LB/antibiotic were inoculated with a 1 in 1000 dilution of 
small-scale BL21 (DE3) cultures and placed at 30 °C, 225 rpm until log phase 
growth was reached (0D600 of between 0.4 and 0.6). Protein expression was induced 
by increasing the temperature to 45 °C. The cells were grown for a further 4 h at 
37 °C, 225 rpm post induction and harvested by centrifugation. 50 - 100 mL cultures 
were transferred directly to 50 mL falcon tubes and centrifuged at 3220 x g for 
10 mm. The supernatant was removed and the pellet resuspended in 30 mL 
potassium phosphate buffer (0.1 M, pH 7.6). The buffer was removed by a repeat of 
the centrifugation procedure and the cell pellets were stored at -20 °C. Larger 
volumes were first transferred to 500 mL centrifuge tubes and centrifuged at 
6371 x g for 20 mm. The supernatant was removed and the pellets were resuspended 
in 30 mL potassium phosphate buffer (0.1 M, pH 7.6) and transferred to 50 mL 
falcon tubes. The buffer was removed as above and the pellets stored at -20 °C. 
For analysis of protein expression during growth, 1.5 mL samples were removed, the 
0D600 recorded and the samples centrifuged at 15 700 x g for 5 mm. The supernatant 
was removed and the pellet stored at -20 °C prior to analysis by sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE, Section 3.2.4). 
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Growth and fermentation of E. coli expressing DAAO saturation mutagenesis 
libraries in 96-well, 2.2 mL plates 
Master plates were created by picking BL21(DE3) E. coli colonies containing variant 
DAAO genes from agar plates and transferring these individually to 800 jtL LB/CAP 
in 96-well, 2.2 mL plates using sterile pipette tips. The plates were covered with gas 
permeable membranes (Thermo Scientific) and placed overnight at 37 °C, 225 rpm. 
5 tL overnight culture from each well of the master plates was transferred to fresh 
2.2 mL, 96-well plates containing 800 tL LB/CAP using a multi-channel pipette 
with sterile tips. The copy plates were covered with a gas-permeable membranes and 
placed at 30 °C until 0D600 values of approximately 0.5 were reached, protein 
expression was induced and the cultures were grown overnight at 30 °C, 225 rpm. 
Master and copy plates were centrifuged at 3315 x g for 20 min and the supernatant 
removed. Master plate cell pellets were resuspended in 50 iL sterile glycerol 
solution (15 % v/v in H20). Master and copy plates were sealed with aluminium foil 
and stored at -20 °C. Prior to assay, pellets in the copy plates were resuspended in 
1 mL potassium phosphate buffer (0.1 M). 50 .iL of the suspension was used in the 
assay described in Section 3.2.5). Pellet resuspension and transfer of cells to the 
assay plates were carried out at 4 °C. 
Expression of oxidase enzyme by heat inducible promoter (pPOT3 and pJLM402 
vectors). 
Upon reaching log phase growth, protein expression was induced by heating the 
sample to 42 °C with continued shaking at 225 rpm. Culture volumes of 50 mL were 
held at this elevated temperature for 15 mm, 100 mL for 20 min and 700 mL for 1 h. 
Cultures grown in 96-well, 2.2 mL plates were held at 42 °C for 30 mm. 
Glycerol stocks 
50 L samples were removed during log phase growth (Section 3.2.3) and 
transferred 1.5 mL storage tubes. 50 tL sterile glycerol solution (30 % v/v in H20) 
was added and mixed by vortexing. The vials were frozen in liquid nitrogen and 
stored at -80 °C. 
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3.2.4 Protein purification and analysis 
Preparation of CFE 
SoluLyse Bacterial Protein Extraction Reagent was purchased from Genlantis. 
Frozen cell pellets produced from an expression culture (Section 3.2.3) were 
defrosted and resuspended in SoluLyse reagent. Pellets from 1.5 mL culture were 
resuspended in 150 tL reagent. Larger pellets were resuspended in 20 mL reagent 
for every gram wet cell weight. (69) The resuspended pellets were rotated at room 
temperature for 10 mm. 1.5 mL tubes were centrifuged at 15 700 x g for 5 min and 
50 mL tubes were centrifuged at 3 220 x g for 30 mm. The supernatant containing 
soluble protein was retained. 
SDS-PAGE 
SDS-PAGE was used to separate and estimate the molecular weight of proteins. 
Kaleidoscope 10 - 250 kD precision plus protein standard and precast 
polyacrylamide gels (10-20 %) were purchased from Biorad. SDS sample buffer 
(according to Lämelli, X2) and EZB1ue gel staining reagent were purchased from 
Sigma-Aldrich. Cell pellets were resuspended in RO water and normalised according 
to the measured 0D600 at the time of sampling, with the resuspension volume given 
by 0D600 x 100 tL. Resuspended pellets, cell free extracts or purification fractions 
were mixed in a 1 to 1 ratio with 2X SDS sample buffer. Resuspended cells were 
subjected to three freeze-thaw cycles using a heat block (95 °C) and liquid nitrogen 
and then all samples were denatured on a heat block at 95 °C for 10 mm. A precast 
gel was placed in an SDS tank which was filled with Lämelli buffer (Section 3.2.7). 
10 tL protein standard and 25 p.L of each buffered sample was loaded onto the gel. 
The electrophoresis was carried out at 100 V for -4 h. The gel was then incubated 
with EZBlue gel staining reagent on an orbital shaker for 1-2 h and with RO H20 for 
several hours to remove background stain. 
Total protein concentration 
There are several methods for the determination of the total protein concentration of 
a sample. Measurement of UV absorbance is the quickest and easiest but also the 
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least accurate. For a pure sample with a known extinction coefficient (c) the Beer-
Lambert Law (Section 5.7.2) can be used to determine protein concentration. If the 
sample is not pure an approximation can be made based on the absorbance of 
tyrosine and tryptophan residues at 280 nm. Nucleic acids also absorb at 280 nm 
but more strongly at 260 nm and the expression in Equation 5 has been derived to fit 
with experimental data. (70) This allows an estimation of protein concentration. 
protein concentration (mg mU') = (1.55 x A280) - (0.76 x A260) 
Equation 5 - A280 = absorbance measured at 280 nm, A260=  absorbance measured at 260 nm. 
The protein sample was diluted until a measurement could be obtained within the 
linear region of the curve (less than 1.0), transferred to a measuring cuvette and the 
absorbance at 260 and 280 nm measured using a spectrophotometer. The 
measurements were blanked using the relevant buffer. 
A more accurate method for determining protein concentration is the bicinchoninic 
acid (BCA) assay. Cu 2+  is reduced by the amino acid residues cysteine, cystine, 
tyrosine and tryptophan, as well as by the peptide backbone, when in alkaline 
solution. Cu ions complex with two molecules of BCA to form a complex with an 
absorbance maximum at 562 nm. A standard curve was produced using dilutions of a 
sample of BSA of known concentration which was measured in triplicate. These data 
were used to produce a standard curve from which the concentration of the 
experimental sample was estimated (Figure 2.18). The standard curve was 
reproduced each time a protein concentration estimation was made. 
A BCA Protein Assay Kit was purchased from Pierce and contained BCA Reagent A 
(bicinchoninic acid in buffer), BCA Reagent B (4% cupric sulfate) and Albumin 
Standard (BSA. 2.0 mg mU' in 0.9% saline and 0.05% sodium azide). BSA dilutions 
from 2000 to 0 .ig mU' were prepared as standards and BCA reagents A and B were 
combined in a 50 to 1 ratio. 25 tL of each standard and sample was placed in a 
microtitre plate in triplicate. 200 .iL of the combined BCA reagents was added to 
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each well containing sample or standard and the plate was incubated at 37 °C for 30 
mm. The plate was cooled to room temperature and the absorbance measured at 562 
nm on a plate reader. The readings were blanked, the standard curve was produced 
from the wells containing BSA dilutions and the total protein content of the sample 
wells was estimated against the resulting curve. 
3.2.5 Colorimetric assays 
Liquid-phase assay 
Enzyme turnover is coupled to a peroxidase-based colorimetric assay. There are 
several chromogenic compounds which can be used for this purpose and here 4-
amino antipyrine (AAP) and 2,4,6-tribromo-3-hydroxybenzoic acid (TBHBA), 
which form a red quinone-imine dye (Xm = 515 nm) upon co-oxidation, were 
used.7 1) 
Stock assay solution 
140 .tL AAP (1 M) and 1.85 mL TBHBA (53.4 mM in DMSO) were added to 20 mL 
potassium phosphate buffer (1 M, pH 7.6). This solution was made up to 45 mL with 
RO water and stored in a foil-covered bottle at -20 °C. Prior to use, 5 mL horseradish 
peroxidase (HRP) (1 mg mL-1) was added to the defrosted solution. 
Stock substrate solutions 
Substrates were dissolved in RO water at a D-enantiomer concentration of 20 mM 
unless otherwise stated. The pH was adjusted to between 7.0 and 8.0 using 0.1 M 
NaOH or 0.1 MHC1. 
Standard liquid-phase assay procedure 
Assays were performed in Costar 96 well, flat-bottom microtitre plates. The stock 
substrate and assay mixtures were combined in a ratio of 2:1. 50 tL resuspended 
cells or 10 iL cell free extract (CFE) and 40 .iL RO water was added to each well, 
followed by 150 iL of the substrate/assay mixture and the plate immediately placed 
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in a plate reader. Final concentrations in each reaction were 0.7 mM AAP, 0.5 mM 
TBHBA, 100 mM potassium phosphate, 0.025 mg mL' HRP and 10 mM substrate 
(R-enantiomer). 
Solid-phase assay 
Stock assay solution 
400 1iL HRP (1 mg mL_') and 4 mL potassium phosphate buffer (1 M, pH 7.6) were 
added to 1 SIGMAFASTTM  3,3'-Diaminobenzidine tablet which had been dissolved 
in 15 mL RO water and the solution was made up to 20 mL using RO water. 
Stock substrate solution 
These were prepared as for liquid-phase assay stock substrate solutions. 
Standard solid-phase assay procedure 
BL21(DE3) cells were transformed with library or control DNA as described in 
section 3.2.3, with the exception that 900 iL SOC was added. The resulting 
transformed cells were spread onto PVDF membranes (Hybond-N, Amersham 
Biosciences) placed on LB agar plates containing the relevant antibiotic, taking care 
to ensure an even spread of the transformation mixture over the whole membrane. 
The plates were incubated overnight at 30 °C. 50 tL of cells transformed using this 
procedure produced approximately 3000 evenly separated colonies on a 145 mm 
diameter plate. 
Filter paper was placed into a Petri dish and soaked with 0.1 mg mL-1 HRP solution. 
The colony containing membrane was removed from the agar plate, frozen in liquid 
nitrogen for 30 s causing partial cell lysis, dried and then placed onto the HRP-
soaked filter paper. The Petri dish was lidded and left to incubate at room 
temperature for 20 mm, allowing any background HRP activity to take place. 
The stock assay and stock substrate solutions described above were combined in a 
1:1 ratio. A fresh filter paper was placed in a Petri dish and soaked with 2 to 3 mL of 
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this assay/substrate mixture. The colony-containing membrane was moved from the 
HRP filter to the substrate filter and allowed to develop at room temperature 
overnight. 
Colonies showing an increase in colour development over the parental colonies with 
respect to test substrates were picked and grown overnight in 10 mL LB/antibiotic at 
37 °C, 225 rpm. The resulting cultures were divided and used both for re-assaying in 
the liquid-phase as whole cells or CFE (section 3.2.4) and in preparation for DNA 
sequencing (section 3.2.1). 
3.2.6 Biotransformations 
An approximately 1.3 g pellet was resuspended in 5 mL potassium phosphate buffer 
(pH 7.6). 5 mL solution of racemic substrate was added (0.04 M) and the reaction 
placed at 37 °C, 225 rpm. Samples were removed for analysis at T = 0 and at 
appropriate time points thereafter. 
Analysis - Reverse-phase chiral HPLC 
Chirobiotic-T column was purchased from Astec (Sigma-Aldrich). A 0.5 mL sample 
of biotransformation mixture was removed and centrifuged at 15 000 x g for 5 mm. 
The supernatant was transferred to a fresh tube and placed at 95 °C for 10 min before 
a further centrifugation as above. The final supernatant was filtered (0.45 tiM) and 
transferred to an HPLC vial. 
HPLC conditions: 
Column: Astec Chirobiotic-T 
1 ,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid: 90% MeOH, 10% water, using a 
flow rate of 1 mL.miii', at 25 °C, and an injection volume of 1 .iL. The retention 
time of each enantiomer was 14.2 and 27.3 min respectively. 
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Pipecolinic acid: 80% Acetonitrile, 20% water, using a flow rate of 2 mL.min', at 10 
°C, and an injection volume of 5 LL. The retention time of each enantiomer was 10.9 
and 14.2 min respectively. 
3-homopheny1alanine: 95% MeOH, 5%TEA buffer (0.1%, pH 4.1), using a flow rate 
of 0.4 mL.min', at 25 °C. The retention time of each enantiomer was 23.0 and 
26.3 min respectively. 
Phenomenex D-penicillamine 
Pipecolinic acid: 2 mM CuSO4, 3 % MeOH, 0.8 mL/min, injection volume 1 tL. 
The retention time of each enantiomer was 6.4 and 10.0 min respectively. 
3.2.7 Buffer and reagent recipes 
Growth media 
Media were prepared at the concentrations specified by the supplier in DI or RU 
water, autoclaved and stored at 4 °C. 
LB broth 
Dehydrated LB (10 g U1 tryptone, 5 g U' yeast extract, 5g U1 NaCl) was purchased 
from Sigma-Aldrich. 
TSB 
Dehydrated TSB (17.0 g U' caseine peptone, 3.0 g U' soya peptone, 5.0 g U' NaCl, 
2.5 g U' K2HPO4, 2.5 g U' glucose, pH 7.3) was purchased from Oxoid. 
LB agar 
Dehydrated LB agar (20 g U' LB, 15 g U' agar) was purchased from Sigma-Aldrich. 
Alternatively, pre-prepared, sterile LB agar was purchased from MIB stores. 
Agar 




Soc medium (2 % tryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM 
Mg02, 10 mM MgSO4, 20 mM glucose) was purchased from Invitrogen. 
fli iffer'z 
Triethylammonium acetate buffer (TEAA) 
A solution of triethyl amine (0.1 %) was prepared in HPLC grade water and acetic 
acid was added to pH 4.1. The resulting solution was filtered (0.2 .xM). 
Stock ammonium acetate solution (5 M) 
192.7 g ammonium acetate, purchased from BDH Laboratory Supplies, was 
dissolved in 0.5 L RO water (5 M) and stored at room temperature. 
Potassium phosphate buffer (1 M) 
Mono- and dibasic potassium phosphate were purchased from Fisher Scientific. 1 M 
solutions of each were prepared in RO water (136.09 g and 174.18 g respectively, 
1 L each), autoclaved and stored at 4 °C. Prior to use, the solutions were combined 
according to the ratio given by the Henderson-Hasselbalch equation (Equation 6) to 
give the desired pH (pKa = 6.88), which was checked and adjusted using a pH meter. 
pH = pKa + log {K
2HPO4]
[KH2Po4] 
Equation 6 - Henderson-Hasselbaich equation 
EDTA stock solution (0.5 M) 
93.1 g disodium EDTA dihydrate was dissolved in 400 mL DI H20, the pH adjusted 
to 8.0 using NaOH pellets and the volume made up to 500 mL with DI H20. 
TAE buffer (50X) 
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242.2 g Tris base was dissolved in 800 mL DI H20. 57.1 mL glacial acetic acid and 
100 mL EDTA (0.5 M, pH 8.0) were added and the volume made up to 1 L with DI 
H20. 
LOmelli buffer (SDS running buffer) 
30.3 g Tris-base (0.025 M), 144.1 g glycine (0.192 M) and 10.0 g SDS (1 %) were 
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5.1 PARENTAL DNA SEQUENCES 
5.1.1 R. gracilis DAAO 
1 	ATGCACTCGCAGAAGCGCGTCGTTGTCCTCGGATCAGGCGTTATCGGTCTGAGCAGCGCCCTCATCCTCG 
M H S Q K R V V V L 	S 	V I 	L S S A L I L 
71 CTCGGAAGGGCTACAGCGTGCATATTCTCGCGCGCGACTTGCCGGAGGACGTCTCGAGCCAGACTTTCGC 
AR K 	Y S V H IL A RD L P ED VS S 	T F A 
141 TTCACCATGGGCTGGCGCGAATTGGACGCCTTTCATGACGCTTACAGACGGTCCTCGACAAGCAAAATGG 
S P W A 	A N H T P F M T L T D 	P R Q A K H 
211 GAAGAACCGACTTTCAAGAAGTGGGTCGAGTTGGTCCCGACGGGCCATGCCATGTGGCTCAPGGGGACGA 
E E P T F K K HI V E L V P T 	H A M N L K 	T 
281 GGCGGTTCGCGCAGAACGAAGACGGCTTGCTCGGGCACTGGTACPJGGACATCACGCCAAATTACCGCCC 
R R FAQ N E D I L L 	H W Y K DI T P N Y 	P 
351 CCTCCCATCTTCCGAATGTCCACCTGGCGCTATCGGCGTAACCTACGACACCCTCTCCGTCCACGCACCA 
L P S S E C p p 	A I 	V T Y D T L S V H A P 
421 AAGTACTGCCAGTACCTTGCAAGAGAGCTGCAGAAGCTCGGCGCGACGTTTGAGAGACGGACCGTTACGT 
K Y C Q Y L A R E L Q K L 	A T F K R R T V T 
491 CGCTTGAGCAGGCGTTCGACGGTGCGGATTTGGTGGTCAACGCTACGGGACTTGGCGCCAAGTCGATTGC 
S L E 	A F D 	A D L V V NAT 	L 'AK S IA 
561 GGGCATCGACGACCAAGCCGCCGAGCCAATCCGCGGCCAAACCGTCCTCGTCAAGTCCCCATGCAAGCGA 
	
I D D Q A A E P I R 	Q T V L V K S P C K R 
631 TGCACGATGGACTCGTCCGACCCCGCTTCTCCCGCCTACATCATTCCCCGACCAGGTGGCGAAGTCATCT 
C T N D S S P P A S P A Y I I P R P 	E V I 
701 GCGGCGGGACGTACGGCGTGGGAGACTGGGACTTGTCTGTCAACCCAGAGACGGTCCAGCGGATCCTCAA 
C I 	 T Y 	V 	D N D L S V N P K T V Q R I L K 
771 GCACTGCTTGCGCCTCGACCCGACCATCTCGAGCGACGGAACGATCGAAGGCATCGAGGTCCTCCGCCAC 
H CL R L D PT I SS D 	TIE 	1EV L R  
841 AACGTCGGCTTGCGACCTGCACGACGAGGCGGACCCCGCGTCGAGGCAGAACGGATCGTCCTGCCTCTCG 
N V 	L R P A R R 	P R V E A E R I V L P L 
911 ACCGGACAAAGTCGCCCCTCTCGCTCGGCAGGGGCAGCGCACGAGCGGCGAAGGAGAAGGAGGTCACGCT 
D R T K S P L S L 	R 	S A R A A K E K E V T L 
981 TGTGCATGCGTATGGCTTCTCGAGTACGGGATACCAGCAGAGTTGGGGCGCGGCGGAGGATGTCGCGCAG 
V H A Y 	F S S T 	Y Q Q S N 	A A F D V A Q 
1051 CTCGTCGACGAGGCGTTCCAGCGGTACCACGGCGCGGCGCGGGAGTCGAAGTTGTAG 
L 	DEAF Q R Y H 	A ARE SK L * 
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5.1.2 T. variabilis DAAO 
1 	atggctaaaatcgttgttattggtgccggtgttgccggtttaactacagctcttcaacttcttcgtaaag 
MA K IV VI 	A IVA 	L T T AL Q L L R K 
71 gacatgaggttacaattgtgtccgagtttacgcccggtgatcttagtatcggatatacctcgccttgggc 
HE VT IV SE F T P 	DL S 	Y T S P WA 
141 aggtgccaactggctcacattttacgatggaggcaagttagccgactacgatgccgtctcttatcctatc 
A NW L T F Y D 	K LADY D A VS Y P1 
211 	ttgcgagagctggctcgaagcagccccgaggctggaat tcgactcatcaaccaacgctcccatgttctca 
L RE LA R SS PEA 	I R L 	N Q R S H V L 
281 agcgtgatcttcctaaactggaaggtgccatgtcggccatctgtcaacgcaacccctggttcaaaaacac 
K R D L P K L H 	A N S A I C Q R N P W F K N T 
351 agtcgattctttcgagattatcgaggacaggtccaggattgtccacgatgatgtggcttatctagtcgaa 
V D SF HI I ED R SRI V H D DV A Y L 	H 
421 tttgcttccgtttgtatCcacaccggagtctacttgaactggctgatgtcccaatgcttatCgctcggcg 
F A S V C I H T 	V Y L N W L M S Q C L S L 
491 ccacggtggttaaacgtcgagtgaaccatatcaaggatgccaatttactacactcctcaggatcacgccc 
A T V V K R P. V N H I K D A N L L H S S 	S R P 
561 cgacgtgattgtcaactgtagtggtctctttgcccggttcttgggaggcgtcgaggacaagaagatgtac 
D V I V N C S 	L F A H F L 	V H D K K N Y 
631 cctattcgaggacaagtcgtccttgttcgaaactctcttccttttatggcctccttttccagcactcctg 
P1 R 	Q V V L 	RN S L P F NA S F S S T P 
701 	aaaaagaaaatgaagacgaagctctatatatcatgacccgattcgatggtacttctatcattggcggt tg 
EKE N E D E AL Y I MT R F D 	T S 	I 	C 
771 tttccaacccaacaactggtcatccgaacccgatccttctctcacccatcgaatcctgtctagagccctc 
F Q P N NW SS E PD PS L T H RI L SR AL 
841 gaccgattcccggaactgaccaaagatggccctcttgacattgtgcgcgaatgcgttggccaccgtcctg 
D R F P H L T K D I P L D I V P. E C V 	H R P 
911 	gtagagagggcggtccccgagtagaattagagaagatccccggcgt tggct ttgttgt ccataactatgg 
H E 	P R V E L E K I P 	V 	F V V H N Y 
981 tgccgccggtgctggttaccagtcctcttacggcatggctgatgaagctatttcttacgtcgaaagagct 
A A 	A 	Y Q SS Y 	MADE A IS Y V E R A 
1051 cttactcgtccaaacctttag 




Primers were purchased from Sigma-Genosys or MWG Biotech AG. and, if located 
on a gene, are referred to by the starting position on that gene. 'f and 'r' designate 
forward and reverse primers respectively. 
5.2.1 Sequencing primers 
TvDAAO 1308 	5' -CCATGTCGGCCATCTGTCAA-3' 
(20 bp; 55 % GC; Tm 69.4 °C; MWt 6053) 
TvDAAO f648 	5'-CGTCCTTGTTCGAAACTCTC-3' 
(20 bp; 50%GC; Tm 61.4 °C; MWt 6019) 
TvDAAO 1978 5 '-TGGTGCCGCCGGTGCTGGTT-3' 
(20 bp; 70%GC; Tm 79.0 °C; MWt 6172) 
pPOT f4725 5 '-GGCGACGTGCGTCCTCAAGC-3' 
(20 bp; 70%GC; Tm 74.7 °C; MWt 6119) 
RgDAAO f531 5'-CGCTACGGGACTTGG-3' 
(15 bp; 67%GC; Tm 58.7°C; MWt 4609) 
RgDAAO f801 5'-GAGCGACGGAACGA-3' 
(14 bp; 64%GC; Tm 57.6°C; MWt 4346.82) 
RgDAAO r150 5'-CCATGGTGAAGCGA-3' 
(14 bp; 57.14%GC; Tm 55.17°C; MWt 4312.77) 
RgDAAO fl 5'-ATGCACTCGCAGAAG-3' 
(15 bp; 53.33 % GC; Tm 53.33 °C; MWt 4585.96) 
RgDAAO ri 107 5'-CTACAACTTCGACTC-3' 
(15 bp; 46.67% GC; Tm 40.81° C; MWt 4471.87) 
5.2.2 epPCR Primers 
RgDAAO fl 	5'-ATGCACTCGCAGAAG-3' 
(15 bp; 53.33 %GC; Tm 53.33°C; MWt 4585.96) 
RgDAAO ri 107 	5'-CTACAACTTCGACTC-3' 
(15 bp; 46.67% GC; Tm 40.81° C; MWt 4471.87) 
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5.2.3 Saturation mutagenesis primers 
Primers for saturation mutagenesis were selected on the basis of 15 - 20 bp 
homology on either side of the site selected for mutagenesis. These primers are 
named after the amino acid subjected to mutagenesis and it's position in the enzyme 
amino acid sequence. 
F58 f 5'-GCG AAT TGG ACG CCT NNS ATG ACG CTT ACA GAC-3' 
(33 bp; 54.5 %GC; 	Tm 72.0°C; MWt 10143) 
F58 r 	5'-GTC TGT AAG CGT CAT SNN AGG CGT CCA ATT CGC-3' 
(33 bp; 	54.5 % GC; 	Tm 72.0 °C; MWt 10125) 
M213 f 5'-CCA TGC AAG CGA TGC ACG NNS GAC TCG TCC GAC CCC-3' 
(36 bp; 	66.7%GC; 	Tm >75°C; MWt 10957) 
M213 r 5'-GGG GTC GGA CGA GTC SN1J CGT GCA TCG CTT GCA TGG-3' 
(36 bp; 	66.7%GC; 	Tm >75°C; MWt 11170) 
5.3 VECTOR MAPS 
5.3.1 pJLM402 
1
PR BItiHI 896 
5617 	 625 
EcoRl 1149 












5.4 	GENOTYPES OF E. COLI STRAINS USED 
5.4.1 TOP10 
F- mcrA L\(mrr-hsdRMS-mcrBC) p80lacZAMl5 AlacX74 recAl araD139 
A(araleu) 7697 galU galK rpsL (StrR) endAl nupG 
5.4.2 BL21 (DE3) 
F- ompT hsdSB (rB-MB-) gal dcm 
5.4.3 XL1-Blue 
recAl endAl gyrA96 thi-1 hsdRl 7 supE44 relAl lac [F' proAB 	 TnlO 
(Tetr)] 
5.4.4 XL1-Red 
endAl gyrA96 thi-1 hsdR17 supE44 relAl lac mutD5 mutS mutT TnlO (Tetr)a 
5.5 SYMBOLS OF THE NATURALLY OCCURRING AMINO ACIDS 
Letter Code Amino acid Letter Code Amino acid 
A Ala Alanine M Met Methionine 
C Cys Cysteine N Asn Asparagine 
D Asp Aspartic acid P Pro Proline 
E Glu Giutamic acid Q Gln Glutamine 
F Phe Phenylalanine R Arg Arginine 
G Gly Glycine S Ser Serine 
H His Histidine T Thr Threonine 
I lie Isoleucine V Val Valine 
K Lys Lysine W Trp Tryptophan 
L Leu Leucine Y Tyr Tyrosine 
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5.6 SINGLE LETTER NUCLEOTIDE CODES 
(Codes of the International Union of Biochemistry). 72 
Base 	Name 	Bases 	 Complementary base 
T Thymine T A 
C Cytosine C G 
A Adenine A T 
G Guanine G C 
V pYrimidine C T R 
R puRine AG Y 
S Strong (31-1) G C S 
W Weak (2H) AT W 
K Keto TG M 
M aMino AC K 
B not  CGT V 
D not  AGT H 
H not  ACT D 
V not  ACG B 
N aNy ACGT N 
5.7 CALCULATIONS 
5.7.1 Pearson Product moment correlation coefficient (R2) 
Linear relationships between two sets of variables were assessed using R2 values. 
These were produced in MS Excel using the expression below. It is described as "the 







5.7.2 Beer-Lambert Law 
Acl 
A = absorbance, s = molar extinction coefficient, 1 = pathlength 
5.8 MICROORGANISMS SCREENED FOR ACTIVITY TOWARDS (rac)-
f3-PHENYLALANINE AND (rac)-f3-HOMOPHENYLALANINE 
The microorganisms screened form part of the Chirotech Technology Limited culture 
collection. 
Name Classification Name Classification 
Achromobacter denitr?JIcans Bacteria Beauveria densa Fungi 
Achromobacter xylosoxidans ssp. 
xylosoxidans Bacteria Beauveria stephanoderis Fungi 
A cinetobacter baumannii Bacteria Blakeslea trispora Fungi 
A cinetobacter calcoaceticus Bacteria Botryotinia narcissicola Fungi 
A cinetobacterjunii Bacteria Calcarisporium antibioticum Fungi 
Acinetobacter sp. Bacteria Caldariomycesfuinago Fungi 
A ctinoplanes utahensis Bacteria Cephalotrichum stem onitis Fungi 
Agrobacterium radiobacter Bacteria Ceratocystis allantospora Fungi 
Agromyces mediolanus Bacteria Ceratocystis cainii Fungi 
Alcaligenes den itr?fIcans 
ssp denitrfIcans Bacteria Ceratocystis clavata Fungi 
Alcaligenes eutrophus Bacteria Ceratocystis ips Fungi 
Alcaligenesfaecalis ssp. Faecalis Bacteria Ceratocystis monilformis Fungi 
Alcaligenes or Pseudomonas sp. Bacteria Ceratocystis olivacea Fungi 
Alcaligenes sp. Bacteria Ceratocystis pi4fera Fungi 
Alcaligenes sp. Bacteria Ceratocystis prolfera Fungi 
Amycolatopsis orientalis ssp. 
orientalis Bacteria Ceratocystis pseudoeurophioides Fungi 
Aneurinibacillus migulanus Bacteria Ceratocystis radicicola Fungi 
Arthrobacter aurescens Bacteria Ceratocystis stenoceras Fungi 
Arthrobacter globformis Bacteria Ceratocystis tetropii Fungi 
Arthrobacter nicotianae Bacteria Chaetomium globosum Fungi 
Arthrobacter oxydans Bacteria Circinella simplex Fungi 
Arthrobacter sp. Bacteria Cochliobolus sativus Fungi 
Arthrobacter sulfureus Bacteria Con iochaeta nepalica Fungi 
Arthrobacter viscosus Bacteria Con iochaeta nodulisporioides Fungi 
Aureobacterium sp. Bacteria Co#ynascus sepedonium Fungi 
Azospirillum brasilense Bacteria Cryptosporiopsis tarraconensis Fungi 
Bacillus aminovorans Bacteria Cunninghamella elegans Fungi 
Bacillus cereus Bacteria Cylindrocarpon didymum Fungi 
Bacillus coagulans Bacteria c'yptospora chysosperma Fungi 
Bacillus fastidiosus Bacteria Diheterospora cylindrospora Fungi 
Bacillus gibsonii Bacteria Dimargaris verticillata Fungi 
Bacillus licheniformis Bacteria Embellisia proteae Fungi 
Bacillus inegaterium Bacteria Exserohilum heteropogonicola Fungi 
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Name Classification Name Classification 
Bacillus polymyxa Bacteria Filosporellafistucella Fungi 
Bacillus pseudojIrmus Bacteria Filosporella viersimorpha Fungi 
Bacillus smithii Bacteria Fomesfomentarius Fungi 
Bacillus sp. Bacteria Fusarium oxysporum Fungi 
Bacillus sphaericus Bacteria Fusarium oxysporum Esp. Pisi Fungi 
Bacillus stearothermophilus Bacteria Fusidium coccineum Fungi 
Bacillus subtilis Bacteria 
Gibberellafujikuroi var. 
Moniliformis Fungi 
Bacillus subtilis ssp. Subtilis Bacteria Gliocladium virens Fungi 
Bacillus thuringiensis Bacteria Gloeotinia granigena Fungi 
Bejerinckia indica ssp. lacticogenes Bacteria Gloephyllum separium Fungi 
Brevibacterium lactofermentum Bacteria Glomerella cingulata Fungi 
Brevibacterium linens Bacteria Gnomonia comari Fungi 
Brevibacterium sp. Bacteria Gonotobotryurn apiculatum Fungi 
Burkholderia cepacia Bacteria Harknessia hawaiiensis Fungi 
Burkholderia cepacia Bacteria Hypomyces roseilus Fungi 
Cellulornonas flavigena Bacteria Isariafelina Fungi 
Cellulosirnicrobiurn cellulans Bacteria Keratinophyton terreum Fungi 
Chryseobacterium indoltheticum Bacteria Leptographiurn serpens Fungi 
Citrobacter koseri Bacteria Leptographiurn wageberi Fungi 
Cornamonas terrigena Bacteria Mariannaea elegans Fungi 
Corynebacterium flavescens Bacteria Melanospora zamiae Fungi 
Co,ynebacteriurn glutarnicum Bacteria Memnoniella echinata Fungi 
Corynebacteriurn sp Bacteria Microascus trigonosporus Fungi 
Curtobacterium albidurn Bacteria Monodismafragilis Fungi 
Curtobacterium citreum Bacteria Mortierella elongata Fungi 
Curtobacterium pus ilium Bacteria Mucor circineiloides Fungi 
Deinococcus radio durans Bacteria Myceliophthora lutea Fungi 
Deinococcus radiophilus Bacteria Mycosphaerella pinodes Fungi 
Deiftia acidovorans Bacteria Neosarioryafischeri Fungi 
Enterobacter intermedius Bacteria Nomuraea rileyi Fungi 
Enterococcus sp. Bacteria Ophiostoma novo-ulmi Fungi 
Erwinia sp. Bacteria Paeciloinyces variotii Fungi 
Escherichia coli Bacteria Penicilliurn aurantiogriseurn Fungi 
Escherichia coil Bacteria Penicillium citrinum Fungi 
Fiavimonas oiyzihabitans Bacteria Penicilliurn thomii Fungi 
Fiavobacteriurn lutescens Bacteria Pestalotia microspora Fungi 
Geobacillus stearothermophilus Bacteria Petriella sordida Fungi 
Geobacillus thermogiucosidasius Bacteria Phanerochaete chrysosporiurn Fungi 
Gluconobacter oxydans Bacteria Phialophorafastigiata Fungi 
Gordonia rubripertincta Bacteria Phialophorajaponica Fungi 
Hafnia aivei Bacteria Phomopsis obscurans Fungi 
Haiomonas sp. Bacteria Phycomyces biakesieeanus Fungi 
Hyphomicrobiutn sp. Bacteria Pithomyces chartarurn Fungi 
Janthinobacterium lividuin Bacteria Pithomyces gram inicola Fungi 
Jensenia can icruria Bacteria Poitrasia circinans Fungi 
Klebsiella sp. Bacteria Rain ichioridium anceps Fungi 
Kurthia gibsonii Bacteria Readeriella mirabiiis Fungi 
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Name Classification Name Classification 
Lysobacter sp. Bacteria Rhinocladiella indica Fungi 
Methylobacterium organophilum Bacteria Rhizopus oryzae Fungi 
Methylomonas clara Bacteria Sarophorum palm icola Fungi 
Microbacterium liquefaciens Bacteria Scopulariopsis brevicaulis Fungi 
Micrococcus luteus Bacteria Sordaria Jim/cola Fungi 
Micrococcus varians Bacteria Spegazzinia lobulata Fungi 
Nocardia sp. Bacteria Sphacelotheca destruens Fungi 
Ochrobactrum anthropi Bacteria Stachybotrys chartarum Fungi 
Paenibacillus polymyxa Bacteria Stilbellafimetaria Fungi 
Pediococcus sp. Bacteria Thamnid/um elegans Fungi 
Pseudomonas aeruginosa Bacteria Tolypocladium cylindrosporum Fungi 
Pseudomonas alcaligenes Bacteria Trichocladium asperum Fungi 
Pseudomonas fluorescens Bacteria Trichocladium pyrforme Fungi 
Pseudomonasfrag/ Bacteria Trichoderma harzianum Fungi 
Pseudomonas oleovorans Bacteria Trichoderma reesei Fungi 
Pseudomonas putida Bacteria Wallem/a sebi Fungi 
Pseudomonas sp. Bacteria Zygorhynchus moelleri Fungi 
Pseudomonas testosteroni Bacteria Phanerochaete chysosporium 
Recombinant 
Yeast 
Rhizobium sp. Bacteria Candida albicans Yeast 
Rhodococcus egu/ Bacteria Candida apis var. galacta Yeast 
Rhodococcus erythropolis Bacteria Candida boidinii Yeast 
Rhodococcus globerulus Bacteria Candida curvata Yeast 
Rhodococcus rhodochrous Bacteria Candida etchellsii Yeast 
Rhodococcus sp. Bacteria Candida glabrata Yeast 
Saccharopolyspora horde/ Bacteria Candida glabrata Yeast 
Salmonella enter/ca ssp. enter/ca Bacteria Candida magnoliae Yeast 
Serratia liqufaciens Bacteria Candida maltosa Yeast 
Serratia marcescens Bacteria Candidaparaps/losis Yeast 
Sporosarcina pasteurii Bacteria Candida rugosa Yeast 
Staphylococcus aureus ssp. aureus Bacteria Candida sonorensis Yeast 
Staphylococcus sp. Bacteria Candida tropical/s Yeast 
Streptococcus faecium Bacteria Candida ut/lis Yeast 
Streptococcus sp. Bacteria Exophialia sp. Yeast 
Streptomyces avid/n ii Bacteria Hansen iaspora occidentalis Yeast 
Streptomyces c/nnamoneus Bacteria Hansen iaspora osmophilia Yeast 
Streptomyces clavuligerus Bacteria Hyphopichia burton/i Yeast 
Streptomyces coeruleorubidus Bacteria Issatchenkia oriental/s Yeast 
Streptomyces espinosus Bacteria Kluywromyces thermotolerans Yeast 
Streptomyces griseoruber Bacteria Komagataella pastor/s Yeast 
Streptomyces hiroshimensis Bacteria Lipoinyces starkeyi Yeast 
Streptomyces lincolnensis Bacteria Phaffia rhodozyma Yeast 
Streptomyces peucet/us Bacteria Pichia angusta Yeast 
Streptomyces peucetius ssp. caes/us Bacteria Pichiafinlandica Yeast 
Streptomyces thermovulgaris Bacteria Pichia holst/i Yeast 
Streptomyces tu/rus Bacteria Pichia methanol/ca Yeast 
Vibr/o cyclosites Bacteria Pichia sp Yeast 
Vibr/o proteolyt/cus Bacteria Pichia trehaloph/la Yeast 
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Name Classification Name Classification 
Absidia anomala Fungi Rhodosporidium toruloides Yeast 
Acrocalymma medicaginis Fungi Rhodotorula glutinis Yeast 
Acrophialophorafusispora Fungi Rhodotorula glutinis var. glutinis Yeast 
Allantonectria miltina Fungi Rhodotorula mucilaginosa Yeast 
Alpakesa uniseptala Fungi Rhodotorula rubra Yeast 
Alternaria alternata Fungi Rhodotorula sp. Yeast 
Amerosporium concinnum Fungi Saccharomyces cerevisiae Yeast 
Amorphotheca resinae Fungi Saccharomyces uvarum Yeast 
Aphanoascus biplantanus Fungi Sporidiobolus johnson/i Yeast 
Apiospora montagnei Fungi Sporidiobolus salmon/color Yeast 
Arthrinium phaeospermum Fungi Trichosporon cutaneum Yeast 
Ascodesm is sphaerospora Fungi Trichosporon laibachil Yeast 
Ascotricha xylina Fungi Trichosporon monoliliiforme Yeast 
Aspergillusfiavus var columnaris Fungi Trigonopsis variabilis Yeast 
Aspergillusjaponicus Fungi Unidentified (x2) Yeast 
Aspergillus niger Fungi Williopsis saturnus var saturnus Yeast 
Aspergillus quadricinctus Fungi Xanthophyllomyces dendrorhous Yeast 
Aspergillus tam ar/i Fungi Yamadazymafarinosa Yeast 
Aspergillus terreus Fungi Yarrowia lipolytica Yeast 
Aspergillus versicolor Fungi Unidentified (x22, Aguapharm) Fungi 
Aureobasidium pullulans Fungi Unidentified (x 208, Aguapharm) Bacteria 
181 
APPENDICES 
5.9 PROFILES AND HIGHEST NORMALISED RATES FOR RGDAAO 
SATURATION MUTAGENESIS LIBRARIES 
The assays were performed only once as a screening exercise. Exaggerated activities 
were observed in cases where the activity of the cells in the positive control wells 
was much lower than expected. This gives very high activity data for some variants 
towards some substrates. This particularly relates to the data obtained for the 
RgDAAO R285 and Y238 libraries but examples can also be seen in the M213 and 
Y238 libraries. 
5.9.1 RgDAAO F58: (R)-alanine 
Key: 
WT 	 RgDAAO F58 
Blank or * 	Blank well containing assay mix and substrate with no cells. 
Pos 	 Positive control well containing assay mix, control substrate and cells expressing 
parental RgDAAO 
Neg 	 Negative control well containing assay mix, control substrate and empty vector 
cells. 






(R)-Thr (5)-Ala Pipecolinic 







H12  COl H10 G02 DiD CO2 003 B04 F04 G12  
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(R)-Thr (5)-Ala Pipecolinic 














RgDAAO F58: highest rates towards (R)-alanine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
H12 wt 1.2E+00 C07 2.5E+00 
col l.IE+OO G03 2.5E+00 
H1O 1.IE+00 D03 2.3E+00 
G02 1.1E+00 A05 2.2E+00 
D1O 1.OE+00 H09 2.OE+00 
CO2 1.OE+00 E03 1.9E+00 
D03 1.OE+00 F06 1.8E+00 
B04 I.OE+OO E05 1.7E+00 
F04 9.9E-0I B03 1.7E+00 
G12 wt 9.8E-01 E07 1.6E+00 
Av F58 1.1E+00 Av F58 9.1E-01 
Plate-4.1 Normalised rate Plate-5.1 Normalised rate Plate-6.1 Normalised rate 
HOl 1.2E+00 A04 1.4E+00 A02 1.1E+00 
E01 1.OE-04 H08 1.4E+00 D02 M l.OE+OO 
G12 wt 9.3E-06 A02 1.3E+00 G12 WT l.OE+OO 
H12 wt 2.3E-05 F08 1.3E+00 H12 WT 9.9E-0l 
D02 7.8E-05 H12 wt 1.3E+00 A09 I 9.IE-01 
E03 9.1E-05 All 1.3E+00 H05 I 8.4E-01 
F05 4.4E-05 Bil I.2E+00 E07 8.2E-01 
C04 5OE-05 H05 l.IE+OO C06 7.8E-01 
Bli 4.3E-05 D03 I.OE+OO FIOV 7.8E-01 
HlO 8.7E-05 G03 l.OE+OO F08 7.8E-01 
Av F58 1.1E+00 Av F58 1.1E+00 Av F58 9.9E-01 
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5.9.2 RgDAAO F58: (rac)-tetrahydroisoquinoline-3-carboxylic acid 




 (R)-Thr (5)-Ala Pipecolinic 

















A06 	F02 	Cli 	E07 	Cal 	E02 	A03 	E05 	F09 	G08 
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(rac)- 1,2,3,4- 	 (R)- (rac)- 
(R)-Ala 	tetrahydroisoquino line- 
allo-Thr 	
(R)-Thr 	(5)-Ala 	Pipecolinic 











C08 L 	F08 	A091 	A03 	H06 	A06 	GlO Q 	H09 	G08 	H05 I 
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RgDAAO F58: highest rates towards (rac)-tetrahydroisoquinoline 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
Eli 5.6E-02 A06 2.3E-01 
FlO 5.5E-02 F02 2.3E-01 
Hil 4.3E-02 Cli 2.IE-01 
H04 4.2E-02 E07 2.1E-01 
H02 4.2E-02 Go! 2AE-01 
A06 4.2E-02 E02 2.OE-01 
A04 4.1E-02 A03 2.OE-01 
EOl 4.OE-02 E05 2OE-01 
BOl 4.OE-02 F09 2.OE-01 
GOl 3.9E-02 G08 2.OE-01 
Av F58 1.2E-02 Av F58 1.5E-02 
Plate-4.1 Normalised rate Plate-5.1 Normalised rate Plate-6.1 Normalised rate 
I'll LIE-01 A06 1.1E-01 C08 L 1.9E-0i 
FOl 88E-02 HO! !.OE-01 F08 l.OE-01 
F03 8.OE-02 E01 9.9E-02 A09 I 9.8E-02 
H06 7.8E-02 G09 9.7E-02 A03 9.7E-02 
Hil 7.8E-02 A03 9.6E-02 H06 9.3E-02 
H03 7.7E-02 A07 9.6E-02 A06 9.1E-02 
A06 7.6E-02 A09 9.6E-02 GlO Q 9.OE-02 
A08 7.5E-02 A02 9.4E-02 H09 8.9E-02 
Al! 7.5E-02 E02 9.2E-02 G08 8.8E-02 
A07 7.4E-02 GO! 9!E-02 H05! 8.8E-02 
Av F58 5.9E-02 Av F58 4.7E-02 Av F58 3.6E-02 
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5.9.3 RgDAAO F58: (rac)-allo-threonine 
The activity profiles relating to the variants displaying the highest activities towards 
(rac)-allo-threonine from plates 2.1, 3.1 and 6.1 are shown in the main text (Figure 
2.46 and Figure 2.48). 
(rac)-1,2,3,4- 	 - 	 (R)- 
(R)-Ala tetrahydroisoquinoline- a-lr (R)-Thr (5)-Ala Pipecolinic 










C04 	G08 	H03 	H10 	H06 	FOl 	H05 	D10 	D07 	Eli 
F58 5.1 
Plilut Ii. Ii .1 	 liii 
H05 	D03 	G03 	BOl 	GlO 	A02 	CO2 	B11 	E01 	A04 
RgDAAO F58: highest normalised rates towards (rac)-allo-threonine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
A08 3.2E-01 H09 7.3E-01 
F04 3.1E-01 E03 7.IE-01 
B09 2.9E-01 B03 6.2E-01 
H04 2.9E-01 E07 5.9E-01 
E01 2.8E-01 E05 5.6E-01 
FlO 2.3E-01 E04 5.5E-01 
BOl 2.3E-01 B06 4.7E-01 
A04 2.3E-01 D08 4.2E-01 
B04 2.OE-01 G03 4.1E-01 
D1O 1.4E-01 F04 4.OE-01 












A08 	B04 	H04 	B09 	BOl 	F07 	E01 	A07 	A04 
APPENDICES 
Plate-4.1 Normalised rate Plate-5.1 Normalised rate Plate-6.1 Normalised rate 
C04 3.IE-01 H05 3.7E-01 A08 4.4E-01 
G08 2.9E-0I D03 3.6E-01 A09 I 3.OE-01 
H03 2.8E-01 G03 3.3E-01 B08 2.7E-01 
H1O 2.7E-01 BOl 3.1E-01 H05 I 2.7E-01 
H06 2.6E-01 GlO 3.1E-01 FIOV 2.4E-01 
FOl 2.5E-01 A02 2.6E-0l E07 2.4E-01 
H05 25E-01 CO2 2.6E-01 C06 2.3E-01 
D1O 2.IE-01 Bi 1 2.6E-01 G02 I 2.2E-01 
D07 1.9E-01 E01 2.4E-01 D06 2.IE-01 
Fl! I.9E-01 A04 2.2E-01 D08 2.OE-01 
Av F58 1.5E-01 Av F58 6.OE-02 Av F58 9.5E-02 
5.9.4 RgDAAO F58: (R)-threonine 




 (R)-Thr (5)-Ala Pipecolinic 
3-carboxylic acid 	 acid 
rliw,i rff,. !I w lilp. MIT, v-, il 1pli too W. 
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(rac)- 1,2,3,4- 	 (R)- (rac)- 
(R)-Ala tetrahydroisoquinoline- allo-Thr 
 (R)-Thr (5)-Ala Pipecolinic 
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H051 	A091 	E07 	F1OV 	FOB 	D03 	G021 	C06 	D02 	D06 
RgDAAO F58: highest rates towards (R)-threonine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
F04 1.OE-02 H09 1.8E-02 
A08 9.9E-03 E03 1.6E-02 
B04 9.8E-03 E04 1.4E-02 
H04 9.1E-03 B03 13E-02 
B09 7.9E-03 E05 1.3E-02 
BOl 7.4E-03 Hil 1.3E-02 
F07 7.1E-03 ElO 1.IE-02 
E01 7.OE-03 H07 1.OE-02 
A07 6.8E-03 E07 1.OE-02 
A04 5.7E-03 B06 9.OE-03 
Av F58 1.9E-03 Av F58 6.2E-04 
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B04 F09 	D1O 	F04 	H10 	D03 	A08 	G12 wt 	COl 	H04 
F58 2.1 
F58 3.1 









C04 9.9E-03 H05 4.1E-02 H05 I 3.6E-02 
HlO 9.5E-03 D03 3.8E-02 A09 I 3.5E-02 
H03 7.8E-03 G03 3.7E-02 E07 3.4E-02 
G08 7.8E-03 GlO 3.6E-02 NO V 3.3E-02 
H06 7.5E-03 BOl 3.4E-02 F08 3.2E-02 
FOl 7.5E-03 G08 3.2E-02 D03 3.1E-02 
H05 7.3E-03 Bil 2.8E-02 G02 I 3.OE-02 
B06 6.IE-03 COI 2.6E-02 C06 3.OE-02 
A06 5.8E-03 A02 2.5E-02 D02 M 2.9E-02 
B08 5.5E-03 D06 2.4E-02 D06 2.9E-02 
Av F58 3.7E-03 Av F58 9.OE-03 Av F58 2.6E-03 
5.9.5 RgDAAO F58: (S)-alanine 




(R)-Thr (5)-Ala Pipecolinic 
3-carboxylic acid 	 acid 



















D02 	F1OV 	C06 	B10 	F08 D03 	E07 	G10 	D06 	G021 
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 (R)-Thr (5)-Ala Pipecolinic 














RgDAAO F58: highest rates towards (S)-alanine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
B04 1.2E-02 E04 2.2E-02 
F09 1.2E-02 E03 2.IE-02 
D10 1.2E-02 C07 2.1E-02 
F04 1.2E-02 D03 2.1E-02 
H10 1.2E-02 G03 1.9E-02 
D03 1.1E-02 E05 1.7E-02 
A08 1.1E-02 F08 1.6E-02 
G12 wt 1.1E-02 B03 1.6E-02 
COl 1.1E-02 A08 1.5E-02 
H04 1.1E-02 E07 1.4E-02 








G12 wt 1.IE-02 E09 4.4E-02 D02 M 3.1E-02 
C04 1 .1 E-02 Bit 3 .OE-02 NO V 3 .OE-02 
F05 1.1E-02 D03 3.OE-02 C06 2.7E-02 
D02 I.1E-02 F08 2.8E-02 BlOT 2.1E-02 
H12 wt 1.1E-02 G03 2.4E-02 F08 2.1E-02 
EOi 1.1E-02 H12 wt 2.3E-02 D03 2.1E-02 
G08 i.OE-02 All 2.2E-02 E07 2.OE-02 
B06 I .OE-02 A02 2.OE-02 GlO Q 2.OE-02 
CIO 1.OE-02 GlO 2.OE-02 D06 1.9E-02 
H03 9.6E-03 H08 1.9E-02 G02 I 1.8E-02 
Av F58 1.1E-02 Ày F58 1.7E-02 Av F58 1.4E-02 
5.9.6 RgDAAO F58: (R)-pipecolinic acid 
(rac)-1 ,2,3,4- 	 (R)- 
(R)-Ala tetrahydroisoquinoline- allo-Thr 
(R)-Thr (S)-Ala Pipecolinic 









A06 	B04 	A05 	H05 	GlO 	Eli 	H03 	H02 	C08 	E07 
193 
APPENDICES 
(rac)- 1,2,3,4- 	 (R)- 
(R)-Ala 	tetrahydroisoquino line- 	
(rac)- 
allo-Thr (R)-Thr (5)-Ala Pipecolinic 












H07 	ElO 	E08 	Dli 	E02 	F06 blank 	Cli 	GlO 	A08 	F04 
F58 4.1 
3.0 
ilul iii. p . .i L
B08 All F07 G01 B04 H02 D03 D01 C09 cif 
F58 5.1 









G1OQ 	D05 	A07 	E10 	BOS 	C05 	FOl L 	D02 	H06 	DOB 
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RgDAAO F58: highest rates towards (R)-pipecolinic acid 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
A06 7.6E-03 H07 6.4E-03 
B04 5.7E-03 ElO 6.1E-03 
A05 4.5E-03 E08 5.OE-03 
H05 4.OE-03 Dli 4.7E-03 
GlO 4.OE-03 E02 4.7E-03 
Ell 3.8E-03 F06 blank 4.2E-03 
H03 3.7E-03 Cli 3.3E-03 
H02 3.7E-03 GlO 3.2E-03 
C08 3.4E-03 A08 2.9E-03 
E07 3.4E-03 F04 2.8E-03 








B08 4.2E-03 G09 2.2E-02 GlO Q 1.6E-02 
All 4.2E-03 A06 2.2E-02 D05 L 1.2E-02 
F07 3.5E-03 D09 1.7E-02 A07 L 1.2E-02 
GOl 3.4E-03 A03 1.6E-02 E10  1.IE-02 
B04 3.4E-03 D06 1.6E-02 B05 1.1E-02 
H02 3.4E-03 D02 1.6E-02 C05 9.9E-03 
D03 3.2E-03 COI 1.5E-02 FOl L 9.7E-03 
DOl 3.1E-03 A02 l.4E-02 D02 M 9.OE-03 
C09 3.OE-03 CIO 1.4E-02 H06 5.5E-03 
CIO 2.7E-03 BIl 1.2E-02 D08 5.2E-03 
Av F58 1.6E-03 Av F58 4.3E-03 Av F58 3.1E-03 
5.9.7 RgDAAO F58: (rac)--homopheny1a1anine 
The activity profiles relating to the variants displaying the highest activities towards 
(rac)--homophenyla1anine from plates 2.1 and 3.1 are shown in the main text 
(Figure 2.49). 
(rac)-1,2,3,4- 	 (R)- 
(rac)- 
(R)-Ala tetrahydroisoquino line- allo-Thr 	
(R)-Thr 	(S)-Ala 	Pipecolinic 









A09 	AOl blank 	HOl 	B03 	H11 	G04 	DOl 	G03 	E01 	H02 
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 (R)-Thr (5)-Ala Pipecolinic 
3-carboxylic acid 	 acid 
F58 5.1 









D10 	Dli P AOl Blank 	C08 	D12 	E12 	Eli 	D02 	G04 	DOl L 
Negatie Negatie 
RgDAAO F58: highest rates towards (rac)-3-homopheny1a1anine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
B03 2.5E-04 A09 6.5E-04 
E08 2.IE-04 E04 5.1E-04 
AO  blank 2.OE-04 BlO 5.1E-04 
HOl 1.9E-04 B07 4.8E-04 
E03 1.6E-04 D02 4.5E-04 
BO! 9.9E-05 H12 wt 4.2E-04 
G04 9.5E-05 A07 4.OE-04 
B02 blank 8.7E-05 AO  blank 3.9E-04 
DOl 8.2E-05 HO! 3.8E-04 
D04 blank 7.9E-05 B04 3.7E-04 
Av F58 2.2E-07 av F58 3.2E-04 
xt 
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Plate-4.1 Normalised rate Plate-5.1 Normalised rate Plate-6.1 Normalised rate 
A09 2.4E-04 Dli 1.5E-04 DIOC 1.2E-04 
AO  blank 2.2E-04 C08 1.3E-04 Dli P 1.1E-04 
HOl 2.OE-04 AO  blank 1.1E-04 AOl Blank 5.9E-05 
B03 i.2E-04 AlO 9.3E-05 C08 L 4.8E-05 
Hll 1.1E-04 A08 8.3E-05 Dl2Negative 4.3E-05 
G04 1.IE-04 C09 6.1E-05 El2Negative 4.3E-05 
DOl 1.IE-04 E12neg 4.8E-05 Eli 4OE-05 
G03 1.1E-04 Hi! 4.7E-05 D02  4.OE-05 
EOl 1.OE-04 E07 4.1E-05 G04 R 3.4E-05 
H02 l.OE-04 GOl 3.5E-05 DO! L 3.4E-05 
Av F58 1.6E-05 Ày F58 1.6E-05 Av F58 1.1E-06 
5.9.8 RgDAAO F58: (rac)-tert-leucine 
(rac)-! ,2,3,4- 	 (R)- (rac)- 
(R)-Ala tetrahydroisoquinoline- allo-Thr 
(R)-Thr (5)-Ala Pipecolinic 































H03 I 	H05 I 	HOl 	AOl Blank 	E12 	A02 	CO2 S 	F02 A 
Negatie 
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(rac)- 1,2,3,4- 	 (R)- 
(rac)- 
(R)-Ala 	tetrahydro i soquino line- 
allo-Thr 	
(R)-Thr 	(5)-Ala 	Pipecolinic 








AOl blank 802 blank 	CO2 	E05 blank 	FOl 	004 blank G07 blank 	F02 
HL 












RgDAAO F58: highest rates towards (rac)-tert-leucine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
E03 1.1E-04 D09 2.OE-04 
AO  blank 7.8E-05 All 1.8E-04 
H08 blank TOE-05 AO  blank 1.7E-04 
E08 6.7E-05 A09 1.6E-04 
C07 6OE-05 H08 blank 1.6E-04 
B03 5.9E-05 G07 blank 1.3E-04 
F06 blank 47E-05 F05 1.3E-04 
D04 blank 4.5E-05 BlO 1.2E-04 
G07 blank 4.4E-05 D04 blank 1.2E-04 
E05 blank 4.3E-05 B04 I.IE-04 








AO  blank 1.OE-02 A08 1.3E-03 D02  93E-05 
B02 blank 7.3E-03 HI I 8.4E-05 D12 Negative 4.4E-05 
CO2 7.IE-03 E12 neg 5.OE-05 H03 I 4.3E-05 
E05 blank 6.4E-03 DII 3.7E-05 H05 I 4.2E-05 
FOl 6.2E-03 AOl blank 3.1E-05 HOl 3.7E-05 
D04 blank 5.9E-03 AlO 2.7E-05 AO  Blank 2.7E-05 
G07 blank 5.IE-03 A02 1.4E-05 E12 Negative 2.4E-05 
F02 4.8E-03 D12 neg LIE-05 A02 2.3E-05 
G02 4.8E-03 C08 9.2E-06 CO2 S 2.IE-05 
H08 blank 4.8E-03 Ell 8.9E-06 F02 A 2.OE-05 
Av F58 7.6E-04 Av F58 O.OE+OO Av F58 O.OE+OO 
5.9.9 RgDAAO F58:(rac)- 3-aminobutyric acid 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
E03 2.IE-04 A09 3.8E-04 
C07 1.9E-04 B07 3.1E-04 
AOl * 1.3E-04 All 2.7E-04 
B03 l.OE-04 GOl 2.7E-04 
E08 8.9E-05 H12 F 2.4E-04 
H08 * 8.8E-05 G02 2.4E-04 
G07 * 7.3E-05 H08 * 2.2E-04 
E05 * 6.6E-05 AOl * 2.1E-04 
CO3 * 6.3E-05 E04 2.OE-04 
F06 * 6.1E-05 BlO I.9E-04 










AOl * 9.1E-05 Hi! !.5E-O4 Dii P 1.1E-04 
H08* 8.!E-05 AlO 1.1E-04 E12 neg 8.7E-05 
HO! 8.OE-05 GO! 9.7E-05 D!O C 7.1E-05 
H12 F 7.9E-05 A08 8.OE-05 AOl * 7.OE-05 
G07 * 6.6E-05 Dli 7.7E-05 C09 T 6.OE-05 
D04 * 6.OE-05 Eli 6.2E-05 B09 T 4.6E-05 
F06 * 5.4E-05 F! I 6.OE-05 A09 I 4.2E-05 
E05 * 4.8E-05 AOl * 4.3E-05 All S 2.8E-05 
CO3 * 4.6E-05 C09 3.6E-05 B!O I 2.4E-05 
B02 * 4.4E-05 E12 neg 3.5E-05 A06 2.OE-05 
Av F58 3.9E-05 Av F58 O.OE+OO Av F58 O.OE+OO 
5.9.10 RgDAAO F58: (rac)-3-pheny1a1anine 
Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
n.m. n.m. D09 3.9E-04 
n.m. n.m. AO  * 3.8E-04 
n.m. n.m. B07 3.7E-04 
n.m. n.m. G02 2.4E-04 
n.m. n.m. GO! 2.4E-04 
n.m. n.m. All 2.3E-04 
n.m. n.m. D05 2.2E-04 
n.m. n.m. D02 2.2E-04 
n.m. n.m. H12 F 2.OE-04 
n.m. n.m. H08 * 1.8E-04 








AOl * 1.9E-04 AOl * 1.7E-04 AOl * 1.2E-04 
HO! 1.7E-04 Hil 1.6E-04 E08 8.8E-05 
H04 9.3E-05 AlO 1.OE-04 D1O C 8.2E-05 
DO1 8.4E-05 GOl 8.4E-05 Dil P 3.7E-05 
H08 * 8.3E-05 Eli 8.1E-O5 H08 * 3.4E-05 
B02 * 7.OE-05 A08 6.4E-05 C08 L 3.1E-05 
BO1 6.7E-05 E07 6.4E-05 D12 neg 2.7E-05 
H02 6.6E-05 BIO 6.2E-05 B02 * 2.7E-05 
A04 6.1E-05 DIl 5.9E-05 H12  2.OE-05 
D02 5.9E-05 C08 5.8E-05 E12 neg 1.8E-05 





5.0  L i 0.0 
F03 C04 H06 H11 D04 	D02 	FOl 	B03 	D03 DOl 
M213 2.1 
FOl 	G04 	F04 	D03 	F06 	B03 	C04 	D05 
M213 3.1 




5.9.11 RgDAAO M213: (rac)-tetrahydroisoquinoline-3-carboxylic acid 
(rac)-1,2,3,4- 
tetrahydroisoquinoline- 	(R)-Ser 
(rac)- (rac)-homo- (R)-Phe (rac)-f- 
3-carboxylic acid I 	 I 
























W06 H10 :r.i. E01 D07 ciii. C04 D04 A01 
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RgDAAO M213: highest rates towards (rac)-tetrahydroisoquinoline-3-carboxylic 
acid 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
F03 4.9E-01 G07 6.9E-01 G03 9.2E-01 
C04 3.6E-01 F03 6.1E-01 EO1 6.5E-01 
H06 3.2E-01 FOl 5.3E-01 D09 5.9E-01 
Hil 3.IE-01 G04 3.2E-01 E04 5.5E-01 
DOl 3.1E-01 F04 2.8E-0I G07 4.6E-01 
D04 2.8E-01 D03 2.8E-01 D08 3.7E-01 
D02 2.7E-01 F06 2.4E-01 D1O 3.5E-01 
FOl 2.5E-01 B03 2.OE-01 E08 3.4E-01 
B03 2.3E-01 C04 2.OE-01 H04 2.9E-0l 
D03 2.3E-01 D05 1.9E-01 D02 2.5E-01 


























H12 	G12 	E04 	F09 F03 	Hil 	H06 	A07 	Cli 	AlO 
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5.9.12 RgDAAO M213: (R)-serine 
(rac)-1,2,3,4- 
tetrahydroisoquinoline- 	(R)-Ser 
(rac)- (rac)-homo- (R)-Phe 
3-carboxylic acid 
pyridylalanine phenylalanine methyiphenylalanine 
M213 1.1 






10.0 -. - 
5.0 
-ci 	 ._Jlm.fl _-, ii  










H03 	All 	BlO 	D10 	H12 	G12 	D07 	BOl 	B03 	H04 
RgDAAO M213: highest rates towards (R)-serine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
Dli l.8E+OO G12 M i.IE+OO H12 M 1.2E±OO 
Hil 1.7E+00 H12  7.4E-Ol G12  1.1E+00 
BlO 1.6E+OO E02 7.OE-Oi E04 8.7E-01 
Fil 1.5E+00 CO3 4.8E-01 F09 8.4E-01 
A05 l.2E+OO Cii 3.9E-01 F03 8.4E-01 
E03 9.8E-0i H05 3.8E-01 Hil 7.5E-0l 
G12  8.9E-01 CIO 3.5E-01 H06 7.2E-01 
H12 M 8.8E-OI D03 3.4E-0i A07 7.1E-01 
CO2 8.2E-Oi B06 3.IE-01 Cii 6.7E-01 
F05 8.OE-Ol F05 2.8E-01 AlO 6.6E-01 








H12  8.9E-0l 












E02 D05 G04 Cli FOl 	Fli 	D09 	E01 	B05 	A02 
M213 3.1 
H04 	C06 	H02 	E01 	F05 	E06 
M213 5.1 
HiD 	H06 	D04 	D05 
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I 	3-carboxylic acid i 





















A03 D06 A08 Cli 
20.0 
15.0 
10.0 Lt 0.0 
BlO D07 G06 Nil ElO E01 
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RgDAAO M213: highest rates towards (rac)--pyridy1a1anine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Pate-3.1 Normalised rate 
BlO 2.5E+00 E02 6.7E-01 A03 1.IE+00 
A05 2.1E+00 D05 5.6E-01 D06 9.OE-01 
Dli 1.9E+00 G04 5.2E-01 A08 8.8E-01 
Hil 1.9E+00 Cli 5.1E-01 Cli 6.7E-0l 
Fli 1.6E+00 FOl 3.8E-0l H04 55E-01 
HOI 1.3E+00 Fil 3.6E-0I C06 4.3E-01 
H02 1.2E+00 D09 2.7E-0I H02 4.1E-01 
H07 1.IE+00 E01 2.5E-0I E01 32E-01 
F05 9.5E-01 B05 2.4E-01 F05 2.6E-01 
E01 9.OE-01 A02 2.3E-01 E06 2.4E-0l 












































A03 	A08 	D06 	H12 	G12 	Cli H06 	Hil 	H02 	AlO 
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5.9.14 RgDAAO M213: (rac)-homophenylalanine 
(rac)-1,2,3,4- 
tetrahydoisoquinoline- 	(R)-Ser 
(rac)- (rac)-homo- (R)-Phe 
 (rac) 
methyiphen ylalanine  












D07 	BlO 	H03 	E01 	All 	DlO 	H12 	G12 	G06 	ElO 
RgDAAO M213: highest rates towards (rac)-homophenylalanine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
HI I 3.8E+OO E02 I.4E+00 A03 2.2E+00 
A05 3.8E+OO G12 M I.IE+OO A08 2.2E+00 
BlO 3.5E+OO D05 9.OE-01 D06 2.OE+0O 
Fli 3.4E±OO G04 8.3E-01 H12  I.7E+00 
HOl 3.4E+00 Fil 7.1E-01 G12 M 1.5E+OO 
Dli 2.9E+00 Cli 6.2E-0I Cli 1.3E+OO 
F05 2.8E+00 B06 5.6E-0i H06 1.3E+00 
ElO 23E+00 H12  5.5E-01 Hil 1.3E+OO 
D08 1.8E+00 FO! 5.5E-01 H02 1.2E+OO 
D05 1.6E+OO CIO 5.OE-01 AlO 1.2E+OO 










H12  2.IE+00 
G12  2.1E+00 
G06 1.8E+00 
ElO l.6E+OO 






















A08 	Cii 	A03 	H12 	G12 	AlO 	A07 	Hil 	HOl E06 
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5.9.15 RgDAAO M213: (rac)-phenylalanine 
(rac)-1,2,3,4- 




















(rac)- (rac)-homo- 	(R)-Phe (ra* 
I
I 	3-carboxylic acid I 







BlO 	007 	E03 	H10 	H03 	E01 	All 	H12 	H06 	G12  
RgDAAO M213: highest rates towards (rac)-phenylalanine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
HI! I.OE+Oi G12  4.IE+00 A08 7.6E+00 
Dli 9.7E+00 E02 3.7E+00 Cli 7.3E+00 
HOl 7.8E+00 H12 M 3.6E+00 A03 7.OE+OO 
I'll 7.7E+00 Fil 3.3 E+00 H12  6.1E+00 
BlO 7.3E+00 G04 2.9E+00 G12 M 5.8E+00 
H02 6.5E+00 Cii 2.8E+00 AlO 5.OE+00 
A05 6.4E+00 B05 2.4E+00 A07 4.8E+00 
H12  6.2E+00 CIO 2.4E+00 H!1 4.7E+00 
H03 6.2E+00 D09 2.3E+00 HO! 4.6E+00 
F05 5.9E+00 D05 2.2E+00 E06 4.5E+00 











H12  9.3E+00 
H06 9.2E+00 
G12  8.5E+00 
Av M213 8.9E+00 
210 
D03 	G04 	F06 	CO3 
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) (rac)- (rac)-homo- (R)-Phe (rac)-- 
li I 	3-carboxy 	I 
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I 	3-carboxylic acid I 






BlO 	D07 	H03 	009 	E03 	A02 	G09 	CO2 	EQi 
	
H10 
RgDAAO M213: highest rates towards (rac)-3-methy1pheny1a1anine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
DII 1.3E+00 E03 6.1E-01 G03 8.8E-01 
BlO 1.2E+00 E02 5.4E-01 Cli 6.4E-01 
Hil 1.1E+00 CO2 5.IE-01 A03 5.2E-01 
A05 9.OE-01 D05 4.4E-01 H04 4.7E-01 
Fli 8.1E-01 G05 4.OE-0I A08 4.4E-01 
F05 7.5E-01 FOl 3.9E-0I D06 4.2E-01 
ElO 6.OE-01 D03 3.9E-01 E04 4.1E-01 
CO2 3.8E-0I G04 3.7E-01 D09 4.OE-01 
D08 3.2E-01 F06 3.5E-01 H03 3.IE-01 
HOl 2.9E-01 CO3 3.5E-01 C05 2.8E-0I 














Av M213 1.7E-01 
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10.0 	 otiq 
8.0 •ser 
6.0 	 Dpyala 
4.0 off 
i1r 	iiL: Li, 	 oMeF 






























E07 	F04 	col 	D10 	012 neg 	D04 	BlO 	G04 	Cli 	C04 
RgDAAO M213: highest rates towards (rac)--homopheny1a1anine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
C05 2.4E-01 E03 3.9E-01 G07 1.2E+00 
H06 2.2E-01 D03 3.2E-01 E02 3.7E-01 
C04 2.1E-01 F03 2.1E-01 H03 3.3E-01 
B02 2.OE-01 BO 1.7E-0 E01 2.9E-01 
D05 1.9E-01 F07 1.5E-01 E08 2.3E-01 
BOl 1.8E-01 C06 1.5E-01 H07 2.1E-01I 
Cli 1.7E-01 D04 1.IE-01 E04 2.IE-01 
C08 1.6E-0 Hil l.OE-01 H08 1.9E-01 
C09 1.4E-0l E08 9.8E-02 F03 1.9E-01 
G12 M 1.4E-0l F06 8.9E-02 CO3 1.1E-0 














Av M213 O.OE+OO 
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5.9.18 RgDAAO M213: (rac)- 3-aminobutyric acid 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
C04 1.4E+00 F06 3.OE-01 E04 8.4E-02 
FOl 1.1E+00 E03 2.2E-01 F09 7.4E-02 
C06 7.OE-01 F03 2.OE-01 C04 4.1E-02 
CII 6.2E-01 D02 2.OE-0I G07 4.OE-02 
A08 5.7E-01 CO2 1.7E-01 F02 3.4E-02 
C08 5.2E-01 D03 1.7E-01 F03 2.4E-02 
A06 2.OE-01 C05 1.6E-01 F05 2.3E-02 
BOl 1.8E-01 G04 I.3E-0I Dli 2.IE-02 
E06 1.6E-01 G06 1.3E-0I ElO 2.1E-02 
B06 I.4E-01 F07 1.2E-01 HO! 19E-02 












E09 1.4E-0 I 
G08 1.4E-01 
Av M213 1.3E-02 
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5.9.19 RgDAAO M213: (rac)-3-pheny1a1anine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
E05 8.OE-01 C05 6.6E-01 E03 9.7E-01 
E03 5.8E-0 E06 5.4E-01 G07 8.5E-01 
CII 5.5E-01 E07 5.OE-01 G05 8.1E-01 
C04 5.4E-01 G06 4.2E-01 G04 7.9E-0I 
C05 3.7E-01 E05 4.2E-01 Fil 7.8E-01 
D02 3.3E-0I H03 4.OE-01 E07 78E-01 
G03 3.3E-01 H08 3.7E-01 CO3 7.8E-01 
F05 3.2E-0I D02 3.6E-01 E02 7.3E-0I 
D05 3.OE-01 H07 3.5E-01 G03 7.2E-01 
H06 2.9E-01 A07 3.5E-01 D03 7.IE-01 














Av M213 O.OE+OO 
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5.9.20 RgDAAO R285: (R)-alanine 
The activity profiles relating to the variants displaying the highest activities towards 

















G12 	F06 	E12neg 	H02 	Hl0 	FOl 	F04 	H06 	F05 	G04 
The negative control well E12 contained a contamination carried from the growth 




















I 3-carboxylic acid 
Itpl-Tall  





1.0-- 	 - 41 0.0 A~. 











GOl 	G07 	G12 	B09 	G03 	H12 	B07 	Bli 	Cli 	A04 
RgDAAO R285: highest rates towards (R)-alanine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
G12 R 1.4E+00 H07 1.8E+00 D07 1.5E+00 
F06 l.2E+0O G05 1.4E+00 A08 12E+OO 
E12 neg 1.1E+00 B04 l.1E+OO F03 1.2E+OO 
F09 9.OE-01 B06 l.1E+OO D03 1.1E+00 
DOl 8.OE-Ol Gil i.OE+OO G12 R 1.1E+00 
HlO 4.9E-02 H12 R 1.OE+OO H12 R 1.OE+00 
D08 O.OE+OO G12 R i.OE+OO F08 1.OE+OO 
G06 O.OE+OO F08 2.1E-01 Cli 97E-01 
A02 O.OE+OO AOl 5.OE-04 B03 l.1E-01 
BlO O.OE+OO F06 4.8E-04 FlO LIE-02 








Eli 1.7E+00 GOl 1.4E+00 
H06 1.6E+00 G07 1.4E+00 
A05 1.5E+00 G12  1.3E+00 
GlO 1.5E+00 B09 1.3E+00 
H09 1.4E+00 G03 1.2E+00 
Fil 1.1E+00 H12  1.2E+00 
H12  7.8E-01 B07 1.1E+00 
G12  6.3E-0I Bil 5.1E-02 
B05 6.7E-03 Cli 3.9E-02 
D06 4.3E-03 A04 3.6E-02 
Av R285 7.OE-01 Av R285 1.2E+00 




(R)-Ala I 	 allo-Thr 
(-Ala teahydroisoquinoIine- 















































OO] ,  
D09 CIO CO2 H03 DOS B06 C08 G02 F07 GOl 
RgDAAO R285: highest rates towards (S)-alanine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
H12 R 6.3E-03 C04 4.2E-03 D09 1.6E+00 
CO3 5.9E-03 D12 neg 3.3E-03 A09 1.5E+00 
F06 4.8E-03 Gil 1.2E-03 D05 1.5E+00 
E02 2.8E-03 B06 1.OE-03 F03 l.OE+OO 
G12 R 2.7E-03 B04 6.OE-04 A08 l.4E-01 
CO2 2.6E-03 H12 R 3.3E-04 H12 R 1.1E-01 
E12 neg 2.OE-03 GlO 9.3E-05 E07 9.3E-02 
HOl 1.4E-03 G05 3.5E-05 FlO 9.IE-02 
FOl 6.OE-04 F12neg O.OE+OO Eli 9.1E-02 
F04 1.8E-04 H07 O.OE+OO H07 8.7E-02 
Av R285 2.1E-03 Av R285 1.7E-04 Av R285 6.OE-02 
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DOl 1.6E-02 D09 4.8E-02 
FOl 1.3E-02 CIO 3.3E-02 
D05 9.4E-03 CO2 2.9E-02 
H12 R 5.8E-03 H03 2.7E-02 
En 4.9E-03 D06 2.5E-02 
E07 4.4E-03 B06 2.4E-02 
Fl 1 3.6E-03 C08 2.OE-02 
G12 R 3.3E-03 G02 1.3E-02 
B09 2.7E-03 F07 l.2E-02 
C04 2.6E-03 GOl 1.2E-02 
Av R285 4.5E-03 Av R285 9.6E-03 
5.9.22 RgDAAO R285: (rac)-tetrahydroisoquinoline-3-carboxylic acid 
I 










































F03 	B02 	B04 	F06 	BOB 	Eli 	E10 	E06 	FlU 	dO 
RgDAAO R285:highest rates towards (rac)-tetrahydroisoquinoline-3-carboxylic acid 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
F04 1.7E-01 Gil 4.OE-02 E04 1.6E-01 
CO3 1.5E-01 Dli 1.5E-02 G06 1.5E-01 
E05 i.4E-0i G07 i.OE-02 F04 1.4E-01 
FOl 1.2E-0i B03 9.5E-03 G08 1.4E-0l 
E04 l.iE-01 G12 R 8.1E-03 COi 1.4E-01 
F06 9.3E-02 G02 8.1E-03 HOl 1.3E-01 
H02 8.8E-02 H07 8.OE-03 D06 1.3E-0I 
A02 8.4E-02 H12 R 8.OE-03 C04 1.2E-01 
G05 8.OE-02 H05 6.8E-03 D05 1.2E-01 
H04 7.8E-02 H02 6.5E-03 CH 1.2E-01 


















D07 9.1E-02 F03 1.6E-01 
H07 7.4E-02 B02 1.6E-01 
GlO 6.6E-02 B04 1.5E-01 
H06 6.1 E-02 F06 1.5E-01 
GOl 5.3E-02 B08 1.3E-01 
F07 5.3E-02 Eli i.3E-Ol 
B06 4.5E-02 ElO i.3E-Ol 
G09 4.3E-02 E06 1.2E-OI 
F03 4.3E-02 FiO l.2E-01 
A02 4.1E-02 CIO 1.2E-01 
Ày R285 9.8E-03 Av R285 3.8E-02 





















1.0 HcTh 0.0 



















H06 D03 G08 F08 H03 B02 	BOl D05 B03 B06 
RgDAAO R285: highest rates towards (R)-pipecolinic acid 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
E02 5.3E-03 E12 neg 2.8E-02 DOl 5.2E-03 
CO3 4.8E-03 D04 9.7E-04 A02 3.5E-03 
G12 R 4.1E-03 H07 9.3E-04 GO! 3.2E-03 
C04 4.IE-03 B02 8.4E-04 D08 2.6E-03 
F05 4.1E-03 B04 4.3E-04 C!! 2.3E-03 
F06 3.7E-03 E05 4.!E-04 G03 2.OE-03 
A07 2.3E-03 G05 3.8E-04 F03 1.8E-03 
El! 2.3E-03 Gil 3.5E-04 GlO 1.3E-03 
H09 2.OE-03 F06 3.3E-04 CIO l.2E-03 
A06 1.6E-03 B06 2.8E-04 Fil 1.2E-03 








H06 9.9E-03 H08 9.8E-02 
C09 77E-03 D03 2.7E-02 
CIO 6.8E-03 G08 2.2E-02 
CO2 5.4E-03 F08 1.1E-02 
G04 5.4E-03 H03 1.OE-02 
A05 4.6E-03 B02 5.8E-03 
B03 4.5E-03 BOI 5.5E-03 
D06 4.4E-03 D05 5.4E-03 
B06 3.2E-03 B03 5.IE-03 
ElO 3.OE-03 B06 5.1E-03 
Av R285 LIE-04 Av R285 1.6E-04 
5.9.24 RgDAAO R285: (rac)-al/o-threonine 
I (rac)- I 
I 	(rac)-1,2,3,4- 
I 	 allo-Thr 








































2.0 X - Ft 0.0 fltr 








B07 	G03 	G12 R 	B09 	C08 	D09 	D04 	F03 	E08 	802 
RgDAAO R285: highest rates towards (rac)-allo-threonine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
A02 2.1E-01 F12 neg 2.4E-01 D03 2.3E-01 
A08 2.1E-01 H07 1.7E-01 D07 2.1E-01 
H02 1.9E-01 G07 9.4E-02 F06 1.8E-01 
F03 19E-01 B03 8.7E-02 H08 1.7E-01 
HOl 1.9E-01 Gil 8.2E-02 G07 1.7E-01 
E05 1.8E-01 B04 6.7E-02 A08 1.6E-01 
G04 1.7E-0l A03 6.2E-02 E05 1.6E-0l 
E01 1.7E-01 G12 R 5.5E-02 F03 1.6E-01 
H03 1.6E-01 G05 3.4E-02 CH 1.3E-01 
H1O 1.6E-01 B06 3.1E-02 E07 1.3E-01 











D06 	E01 	HOl 	G03 	CO3 	001 	A04 	H04 	ElO 	G04 
R285 2.1 
















Ell 1.4E-01 B07 7.5E-02 
H07 1.1E-01 G03 5.2E-02 
H06 8.5E-02 G12 R 4.8E-02 
A05 7.7E-02 B09 4.6E-02 
H09 5.4E-02 C08 4.4E-02 
FOl 5.2E-02 D09 4.3E-02 
GlO 5.IE-02 D04 4.OE-02 
H12 R 4.5E-02 F03 4.OE-02 
G12 R 4.1E-02 E08 3.6E-02 
A07 3.2E-02 B02 3.5E-02 
Av R285 4.3E-02 Av R285 3.4E-02 
5.9.25 RgDAAO R285: (rac)--homopheny1a1anine 
I (rac)-1,2,3,4- 	I 
I 	(R)-Ala allo-Thr (S)-Ala tetrahydroisoquinoline- 




















A09 Gil A04 A08 G04 E02 BOi 
R285 6.1 
..1r.-i 




20.0 	 - 
15.0 
10.0 
:i 	 F7 	 -, 
G06 	G07 	H07 	F12 neg 	BOl 	E05 A07 	F06 	G05 	H05 
(rac) 1,2,3,4- 




RgDAAO R285: highest rates towards (rac)-f3 -homophenylalanine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
D06 3.2E-01 CO3 4.2E-01 G12 R 8.9E-02 
EOl 1.9E-OI G07 3.1E-01 G05 7.6E-02 
HOl 1.7E-01 H08 3.OE-Oi F03 7.OE-02 
G03 1.6E-01 H07 2.9E-0l F06 5.9E-02 
CO3 1.6E-0l H02 2.4E-01 G04 5.6E-02 
DOl 1.5E-01 H06 2.3E-01 HOl 5.6E-02 
A04 I.4E-Ol HOl 2.2E-01 CO3 5.6E-02 
H04 1.4E-Oi A07 2.2E-01 E07 5.3E-02 
ElO l.4E-01 EOl 2.OE-01 B02 5.3E-02 
G04 1.3E-01 E05 2.OE-01 F08 5.3E-02 






A09 1.8E-01 G06 5.2E-02 
Gil 1.3E-01 G07 5.1E-02 
A04 8.7E-02 H07 4.4E-02 
A08 7.OE-02 F12 neg 3.5E-02 
G04 7.OE-02 BOl 3.3E-02 
E02 7.OE-02 E05 3A  E-02 
BOl 6.8E-02 A07 26E-02 
B04 6.6E-02 F06 2.5E-02 
C04 6.5E-02 G05 2.1E-02 
D02 6.4E-02 H05 2.1E-02 
Av R285 1.5E-03 Av R285 O.OE+OO 
5.9.26 RgDAAO R285: (rac)- 3-aminobutyric acid 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-4.1 Normalised rate 
BlO 1.7E-02 F06 4.1E-02 F06* 2.OE-01 
E08 1.3E-02 E05 4.1E-02 H08* 1.5E-01 
G04 1.2E-02 AOl 3.7E-02 E05* 1.5E-01 
D09 1.2E-02 D04 3.3E-02 G07* 1.4E-Ol 
C08 1.2E-02 F02 3.OE-02 AO1* l.2E-01 
F05 1.2E-02 B02 3.OE-02 D04* 8.2E-02 
D06 1.1E-02 G02 2.5E-02 H04 6.6E-02 
AlO 1.1E-02 H08 2.5E-02 E07 6.4E-02 
H06 1.IE-02 Bil 2.2E-02 G06 5.9E-02 
CIO 1.IE-02 B05 2.2E-02 COI 5.7E-02 








A04 3.5E-01 A02 1.8E-01 
G04 4.7E-02 B02* 1.5E-01 
H02 4.5E-02 H06 1.1E-01 
A09 4.3E-02 F03 9.8E-02 
F04 4.IE-02 D04* 9.8E-02 
EO1 4.1E-02 F06* 9.6E-02 
A05 3.9E-02 AO1* 9.5E-02 
col 3.9E-02 A07 7.7E-02 
F05 3.7E-02 COI 7.2E-02 
A02 3.6E-02 E08 TOE-02 
Av R285 1.3E-02 Av R285 2.OE-02 
5.9.27 RgDAAO R285: (rac)--pheny1a1anine 
Plate-1.1 Normalised rate Plate-2.1 Normalised rate Plate-3.1 Normalised rate 
F04 4.OE-01 F12neg 5.7E-02 F06* 1.7E-01 
H06 3.4E-01 D04* 3.1E-02 B02* 1.4E-01 
F05 3.3E-01 B02* 3.IE-02 E05* 1.4E-01 
G04 3.3E-O! H08* 2.7E-02 D04* 1.4E-01 
A02 3.3E-0I G07* 1.8E-02 AO1* 1.3E-01 
H07 3.2E-01 F06* 1.5E-02 A04 1.3E-01 
E04 3.2E-01 H09 1.4E-02 H02 1.2E-O! 
DOl 3.OE-0I AO1* 1.4E-02 HO! 1.2E-01 
D06 3.OE-011 A03 8.3E-03 H06 1.2E-01 
H04 3.OE-01 E05* 8.2E-03 A05 1.2E-01 






H07 8.9E-02 F02 3.4E-01 
CO! 8.8E-02 F06* 2.3E-01 
G06 8.1E-02 E05* 2.2E-01 
A06 8.OE-02 F03 1.8E-01 
H09 7.7E-02 G06 1.7E-01 
H06 7.6E-02 D08 1.7E-01 
B05 7.2E-02 E04 1.7E-01 
B03 7.1E-02 D04* 1.5E-01 
E04 TOE-02 H1O 1.4E-01 
E03 6.7E-02 D09 1.4E-01 
Av R285 3.9E-03 Av R285 3.8E-02 
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5.9.28 RgDAAO Y238: Rates shown prior to normalisation 
(R)-alanine 1.1 2.1 3.1 4.1 5.1 
F3 6.OE-03 D7 4.5E-03 A5 1.7E-03 D6 5.1E-03 A6 2.2E-03 
E2 5.9E-03 E9 1.9E-03 GI 1.1E-03 DiO 4.8E-03 D6 1.6E-03 
D6 52E-03 A8 1.5E-03 G4 9.2E-04 B4 4.2E-03 G3 4.7E-04 
E8 5.OE-03 Eli l.OE-03 B3 9.OE-04 Fli 3.4E-03 H12  3.8E-04 
C5 3.5E-03 G4 l.OE-03 H12  8.4E-04 ElO 3.2E-03 G4 2.8E-04 
A5 3.5E-03 HlO 89E-04 Cl 3.9E-04 A4 3.OE-03 G12 Y 2.7E-04 
F5 2.9E-03 F7 7.9E-04 D6 3.7E-04 E4 2.4E-03 E4 1.2E-04 
F9 1.3E-03 B9 7.3E-04 G12 Y 2.6E-04 C7 2.2E-03 GI i.OE-04 
GlO l.OE-03 A7 6.1E-04 Dil 1.5E-04 H6 1.9E-03 C2 9.6E-05 
H9 6.9E-04 G9 5.OE-04 A4 1.3E-04 B9 1.9E-03 H1O 7.8E-05 
Av V 2.3E-04 Av V 1.3E-04 Av Y 5.5E-04 Av V 2.1E-04 Av V 3.3E-04 
(5)-alanine 1.1 2.1 3.1 4.1 5.1 
F 1 neg 5.2E-04 A8 3.8E-04 B3 7.4E-05 F 1 neg 2.7E-04 D6 9.9E-04 
F3 2.6E-04 D7 1.1E-04 D6 2.OE-05 D6 1.9E-04 H3 6.2E-04 
E2 1.5E-04 E9 3.2E-05 H12 Y 1.7E-05 B4 1.6E-04 A6 2.7E-04 
D6 1.IE-04 El 2.9E-05 A5 1.4E-05 DlO 1.3E-04 HlO 6.8E-05 
C5 8.7E-05 G4 2.7E-05 G3 1.2E-05 Fli 8.2E-05 DlO 9.IE-06 
E8 7.2E-05 Ell 2.OE-05 GI 1.2E-05 ElO 6.5E-05 G12  6.6E-06 
F5 5.1E-05 A7 1.4E-05 Cl 9.7E-06 C7 6.4E-05 A3 6.4E-06 
A5 4.6E-05 F7 1.3E-05 G12 Y 7.8E-06 A4 5.9E-05 G3 5.OE-06 
BI 2.IE-05 B9 l.OE-05 A4 7.6E-06 B9 5.5E-05 C2 4.7E-06 
D4 2.OE-05 C4 9.1E-06 G6 7.4E-06 B6 5.4E-05 CIO 4.5E-06 
Av V 2.8E-06 Av V 2.2E-06 Av V 1.3E-05 Av V 6.4E-06 Av Y 5.4E-06 
(R)-pipecolinic 
acid 1.1 2.1 3.1 4.1 5.1 
E2 1.3E-05 D7 7.OE-06 D12 neg 1.7E-04 DiO 9.5E-06 HlO 5.4E-06 
F3 1.2E-05 HlO 5.3E-06 E9 8.9E-06 A4 7.9E-06 B2 5.2E-06 
G7 i.OE-05 A4 4.8E-06 E5 7.7E-06 B4 7.6E-06 D4 4.9E-06 
F6 8.6E-06 E5 4.6E-06 G7 6.8E-06 G7 7.1E-06 Al 4.OE-06 
E5 8.5E-06 C4 3.7E-06 B2 6.3E-06 Fll 7.OE-06 G7 3.8E-06 
D4 8.3E-06 E9 3.6E-06 F6 5.IE-06 F6 6.3E-06 C3 3.6E-06 
B2 8.1E-06 D4 3.6E-06 D4 5.OE-06 D6 6.OE-06 DlO 3.3E-06 
C3 7.5E-06 C3 3.6E-06 Al 4.9E-06 E5 5.9E-06 E7 3.3E-06 
H8 6.9E-06 G7 3.4E-06 C3 4.8E-06 B2 5.2E-06 G3 3.1E-06 
GlO 5.8E-06 B2 3.OE-06 H8 4.7E-06 C3 4.6E-06 CIO 2.9E-06 





acid 1.1 2.1 3.1 4.1 5.1 
D4 6.3E-06 E5 6.7E-06 E9 9.OE-06 E5 6.9E-06 D4 8.OE-06 
F6 5.9E-06 D4 5.2E-06 D4 7.8E-06 D4 5.8E-06 H8 7.IE-06 
E5 5.5E-06 A4 5.1E-06 G7 7.5E-06 F6 5.8E-06 F6 6.9E-06 
0 5.4E-06 B2 4.7E-06 F6 6.2E-06 B2 5.1E-06 Al 6.OE-06 
B2 5.1E-06 G7 4.6E-06 C3 6OE-06 H8 5.OE-06 B6 5.9E-06 
Al 2.8E-06 H8 4.4E-06 B2 5.9E-06 C3 4.8E-06 B2 5.8E-06 
G7 2.4E-06 H1O 4.3E-06 Al 5.4E-06 G7 4.6E-06 0 5.6E-06 
AlO 1.3E-06 Gil 3.5E-06 E5 4.7E-06 Al 2.4E-06 H1O 4.6E-06 
GlO 1.2E-06 C4 3.4E-06 Hil 2.6E-06 GI 4.5E-07 D1O 4.6E-06 
F12 neg 1.1E-06 Al 3.2E-06 H8 2.IE-06 04 2.7E-07 E5 3.8E-06 
Av Y 1.1E-07 Av Y 7.8E-08 Av Y O.OE+OO Av Y O.OE+OO Av Y O.OE+OO 
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